<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000399.pub3" GROUP_ID="NEONATAL" ID="998699092319372088" MERGED_FROM="" MODIFIED="2017-01-03 14:40:29 +0000" MODIFIED_BY="Colleen Ovelman" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Short title (no longer in use): Nitric oxide in neonatal respiratory failure&lt;/p&gt;&lt;p&gt;sent for update Oct /03&lt;br&gt;sent 12/04&lt;br&gt;sent to Barrington May 12-05&lt;/p&gt;&lt;p&gt;CL 4/06 (substantive update) - sent to Finer for approval Aug 18-06&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2016-12-23 11:48:32 -0500" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="001" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="13.0">
<COVER_SHEET MODIFIED="2016-12-23 11:47:03 -0500" MODIFIED_BY="Colleen Ovelman">
<TITLE>Nitric oxide for respiratory failure in infants born at or near term</TITLE>
<CONTACT>
<PERSON ID="15171" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Keith</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Barrington</LAST_NAME>
<SUFFIX/>
<POSITION>Chief, Division of Neonatology</POSITION>
<EMAIL_1>keith.barrington@umontreal.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Pediatrics</DEPARTMENT>
<ORGANISATION>CHU Ste-Justine</ORGANISATION>
<ADDRESS_1>3175 Cote Ste Catherine</ADDRESS_1>
<ADDRESS_2/>
<CITY>Montreal</CITY>
<ZIP>H3T 1C5</ZIP>
<REGION>QC</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>514 345 4931 ext. 5929</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-12-23 11:47:03 -0500" MODIFIED_BY="Colleen Ovelman">
<PERSON ID="15171" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Keith</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Barrington</LAST_NAME>
<SUFFIX/>
<POSITION>Chief, Division of Neonatology</POSITION>
<EMAIL_1>keith.barrington@umontreal.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Pediatrics</DEPARTMENT>
<ORGANISATION>CHU Ste-Justine</ORGANISATION>
<ADDRESS_1>3175 Cote Ste Catherine</ADDRESS_1>
<ADDRESS_2/>
<CITY>Montreal</CITY>
<ZIP>H3T 1C5</ZIP>
<REGION>QC</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>514 345 4931 ext. 5929</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7015" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Neil</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Finer</LAST_NAME>
<SUFFIX/>
<POSITION>Director of Neonatology</POSITION>
<EMAIL_1>nfiner@ucsd.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Pediatrics</DEPARTMENT>
<ORGANISATION>University of California San Diego</ORGANISATION>
<ADDRESS_1>200 W Arbor Dr</ADDRESS_1>
<ADDRESS_2/>
<CITY>San Diego</CITY>
<ZIP>92103-8774</ZIP>
<REGION>California</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>1 619 543 3759</PHONE_1>
<PHONE_2/>
<FAX_1>1 619 543 3812</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1505261444013977529812598646318" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Thomas</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Pennaforte</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>thomas.pennaforte@umontreal.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Université de Montréal</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Montreal</CITY>
<ZIP/>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1411251826085830403361486654762" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Gabriel</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Altit</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>gabalt@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Pediatrics</DEPARTMENT>
<ORGANISATION>Universite de Montreal - CHU Sainte-Justine</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Montreal</CITY>
<ZIP/>
<REGION>QC</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2016-10-03 16:27:37 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 17/12/00&lt;/p&gt;" NOTES_MODIFIED="2016-10-03 16:27:37 -0400" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="19" MONTH="1" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="19" MONTH="1" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="3" MONTH="10" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1998"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2016-12-12 18:36:16 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;This updates the review &amp;quot;Nitric oxide for respiratory failure in infants born at or near term&amp;quot;, published in The Cochrane Library, Issue 2, 2001 (&lt;a link_type=&quot;REFERENCE&quot; href=&quot;Finer 2001&quot; protected=&quot;true&quot;&gt;Finer 2001&lt;/a&gt;).&lt;br&gt;&lt;br&gt;This update includes two additional trials (Konduri and Sadiq). Both of these trials were of intervention at moderate severity, compared to waiting until severe disease occured.&lt;/p&gt;" NOTES_MODIFIED="2016-12-12 18:36:16 -0500" NOTES_MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-12-12 18:32:55 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="19" MONTH="7" YEAR="2016"/>
<DESCRIPTION>
<P>Although new trials were added, conclusions remain unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-12-12 18:36:16 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="2" YEAR="2016"/>
<DESCRIPTION>
<P>We identified 3 new trials, added a flow chart and added GRADE Summary of findings tables.</P>
<P>Review structure has changed; several trials referred to as 'allowing back-up use of iNO in controls' are now referred to as 'comparing NO at moderate vs severe severity of illness criteria'. We entered an additional study into this group.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-12-11 17:11:59 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-12-11 17:10:07 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>We converted this review to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-12-11 17:10:56 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="5" YEAR="2006"/>
<DESCRIPTION>
<P>This updates the review, "Nitric oxide for respiratory failure in infants born at or near term", published in the Cochrane Library (2001, Issue 2) (<LINK REF="REF-Finer-2001" TYPE="REFERENCE">Finer 2001</LINK>).<BR/>
<BR/>This update includes 2 additional trials (Konduri and Sadiq). Both of these trials provided intervention at moderate disease severity rather than waiting until severe disease occurred.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2016-12-11 17:11:59 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="5" YEAR="2006"/>
<DESCRIPTION>
<P>We have made substantive amendments.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2016-12-12 18:14:01 -0500" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2016-12-12 18:14:01 -0500" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2016-12-12 18:14:01 -0500" MODIFIED_BY="[Empty name]">
<NAME>Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>Editorial support of the Cochrane Neonatal Review Group has been funded with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN275201600005C</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-12-23 11:48:32 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-12-12 19:57:56 -0500" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-08-22 12:49:06 -0400" MODIFIED_BY="[Empty name]">Nitric oxide for respiratory failure in infants born at or near term</TITLE>
<SUMMARY_BODY MODIFIED="2016-12-12 19:57:56 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>: Is inhaled nitric oxide gas, in addition to standard therapy, beneficial for babies born at full term who have lung disease leading to low levels of oxygen in the blood? Specifically, does it reduce the death rate or the number of babies who require highly invasive ECMO treatment?</P>
<P>
<B>Background</B>: Nitric oxide is a naturally occurring molecule that relaxes blood vessels and is active in the lungs when mixed with the gases that a patient is breathing.</P>
<P>
<B>Study characteristics</B>: In a search updated to February 2016, review authors identified a total of 17 studies for inclusion in the review. Most of the results reported in this review were obtained from 10 studies of moderate to high quality, which compared inhaled nitric oxide (iNO) versus standard therapy without iNO. Six studies compared iNO started when babies were less sick against waiting to see if they deteriorated, then treating them later. These studies were smaller, and only one was a high-quality trial.</P>
<P>
<B>Key results</B>: Inhaled nitric oxide is safe and can help some full-term babies with respiratory failure who have not responded to other methods of support. Inhaled nitric oxide increases levels of oxygen in babies' blood, and babies are more likely to survive without needing ECMO, a highly invasive therapy with many complications. Unfortunately, benefits of iNO are not clear in babies whose respiratory failure is due to a diaphragmatic hernia. Inhaled nitric oxide has shown no short-term or long-term adverse effects. No signs suggest that iNO given earlier is more beneficial or results in more babies treated, and the number who die or who need ECMO is not significantly reduced.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-12-12 19:57:36 -0500" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2016-12-11 17:12:20 -0500" MODIFIED_BY="[Empty name]">
<P>Nitric oxide (NO) is a major endogenous regulator of vascular tone. Inhaled nitric oxide (iNO) gas has been investigated as treatment for persistent pulmonary hypertension of the newborn.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-12-11 17:13:08 -0500" MODIFIED_BY="[Empty name]">
<P>To determine whether treatment of hypoxaemic term and near-term newborn infants with iNO improves oxygenation and reduces rate of death and use of extracorporeal membrane oxygenation (ECMO), or affects long-term neurodevelopmental outcomes.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-12-12 18:34:11 -0500" MODIFIED_BY="[Empty name]">
<P>We used the standard search strategy of the Cochrane Neonatal Review Group to search the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 1), MEDLINE via PubMed (1966 to January 2016), Embase (1980 to January 2016) and the Cumulative Index to Nursing and Allied Health Literature (CINAHL; 1982 to January 2016). We searched clinical trials databases, conference proceedings and reference lists of retrieved articles for randomised controlled trials and quasi-randomised trials. We contacted the principal investigators of studies published as abstracts to ascertain the necessary information.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-12-12 18:34:22 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised studies of iNO in term and near-term infants with hypoxic respiratory failure, with clinically relevant outcomes, including death, use of ECMO and oxygenation.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-12-11 17:18:11 -0500" MODIFIED_BY="[Empty name]">
<P>We analysed trial reports to assess methodological quality using the criteria of the Cochrane Neonatal Review Group. We tabulated mortality, oxygenation, short-term clinical outcomes (particularly use of ECMO) and long-term developmental outcomes.</P>
<P>Statistics: For categorical outcomes, we calculated typical estimates for risk ratios and risk differences. For continuous variables, we calculated typical estimates for weighted mean differences. We used 95% confidence intervals and assumed a fixed-effect model for meta-analysis.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-12-12 19:57:36 -0500" MODIFIED_BY="[Empty name]">
<P>We found 17 eligible randomised controlled studies that included term and near-term infants with hypoxia.</P>
<P>Ten trials compared iNO versus control (placebo or standard care without iNO) in infants with moderate or severe severity of illness scores (<A HREF="Ninos 1996">Ninos 1996</A>; <A HREF="Roberts 1996">Roberts 1996</A>; <A HREF="Wessel 1996">Wessel 1996</A>; <A HREF="Davidson 1997">Davidson 1997</A>; <A HREF="Ninos 1997">Ninos 1997</A>; <A HREF="Mercier 1998">Mercier 1998</A>; <A HREF="Christou 2000">Christou 2000</A>; <A HREF="Clark 2000">Clark 2000</A>; <A HREF="INNOVO 2007">INNOVO 2007</A>; <A HREF="Liu 2008">Liu 2008</A>). <A HREF="Mercier 1998">Mercier 1998</A> compared iNO versus control but allowed back-up treatment with iNO for infants who continued to satisfy the same criteria for severity of illness after two hours. This trial enrolled both preterm and term infants but reported most results separately for the two groups. <A HREF="Ninos 1997">Ninos 1997</A> studied only infants with congenital diaphragmatic hernia.</P>
<P>One trial compared iNO versus high-frequency ventilation (<A HREF="Kinsella 1997">Kinsella 1997</A>).</P>
<P>Six trials enrolled infants with moderate severity of illness scores (oxygenation index (OI) or alveolar-arterial oxygen difference (A-aDO<SUB>2</SUB>)) and randomised them to immediate iNO treatment or iNO treatment only after deterioration to more severe criteria (<A HREF="Barefield 1996">Barefield 1996</A>; <A HREF="Day 1996">Day 1996</A>; <A HREF="Sadiq 1998">Sadiq 1998</A>; <A HREF="Cornfield 1999">Cornfield 1999</A>; <A HREF="Konduri 2004">Konduri 2004</A>; <A HREF="Gonzalez 2010">Gonzalez 2010</A>).</P>
<P>Inhaled nitric oxide appears to have improved outcomes in hypoxaemic term and near-term infants by reducing the incidence of the combined endpoint of death or use of ECMO (high-quality evidence). This reduction was due to a reduction in use of ECMO (with number needed to treat for an additional beneficial outcome (NNTB) of 5.3); mortality was not affected. Oxygenation was improved in approximately 50% of infants receiving iNO. The OI was decreased by a (weighted) mean of 15.1 within 30 to 60 minutes after the start of therapy, and partial pressure of arterial oxygen (PaO<SUB>2</SUB>) was increased by a mean of 53 mmHg. Whether infants had clear echocardiographic evidence of persistent pulmonary hypertension of the newborn (PPHN) did not appear to affect response to iNO. Outcomes of infants with diaphragmatic hernia were not improved; outcomes were slightly, but not significantly, worse with iNO (moderate-quality evidence).</P>
<P>Infants who received iNO at less severe criteria did not have better clinical outcomes than those who were enrolled but received treatment only if their condition deteriorated. Fewer of the babies who received iNO early satisfied late treatment criteria, showing that earlier iNO reduced progression of the disease but did not further decrease mortality nor the need for ECMO (moderate-quality evidence). Incidence of disability, incidence of deafness and infant development scores were all similar between tested survivors who received iNO and those who did not.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-12-11 17:31:31 -0500" MODIFIED_BY="[Empty name]">
<P>Inhaled nitric oxide is effective at an initial concentration of 20 ppm for term and near-term infants with hypoxic respiratory failure who do not have a diaphragmatic hernia.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-12-23 11:48:32 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-12-12 18:49:47 -0500" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2016-12-12 18:46:18 -0500" MODIFIED_BY="[Empty name]">
<P>Persistent pulmonary hypertension of the newborn (PPHN) is an important cause of cardiorespiratory failure in the near-term neonate (&gt; 34 weeks), as a primary condition of neonatal maladaptation or secondary to other diseases such as hyaline membrane disease (HMD), meconium aspiration, infection and congenital diaphragmatic hernia (CDH). A review of the Oxford Database of Perinatal Trials performed in 1996, which included PPHN as an outcome, showed that at that time, no single randomised controlled trial (RCT) had demonstrated that PPHN could be prevented by any perinatal intervention. PPHN is a common underlying factor among infants who qualify for treatment with extracorporeal membrane oxygenation (ECMO).</P>
<P>Before inhaled nitric oxide (iNO) was available, conventional therapy involved paralysis, sedation and induction of alkalosis by hyperventilation and bicarbonate. None of these therapies were proven by prospective randomised trials to reduce mortality nor the need for ECMO. In addition, no clinically evaluated selective pulmonary vasodilator was free of systemic side effects.</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-12-11 17:51:16 -0500" MODIFIED_BY="[Empty name]">
<P>Addition of low concentrations of nitric oxide gas to the inhaled gas mixture.</P>
</INTERVENTION>
<THEORY MODIFIED="2016-12-12 18:48:08 -0500" MODIFIED_BY="[Empty name]">
<P>Regulation of vascular muscle tone at the cellular level occurs, in part, via nitric oxide (NO). Nitric oxide is generated enzymatically by one of three NO synthases from L-arginine. NO activates guanyl cyclase by binding to its heme component, leading to the production of cyclic guanosine monophosphate (cGMP), which leads to relaxation of vascular smooth muscle.</P>
<P>Abman and coworkers (<LINK REF="REF-Abman-1990" TYPE="REFERENCE">Abman 1990</LINK>) showed, in the late gestation ovine fetus, that inhibition of NO production caused foetal pulmonary and systemic hypertension with attenuation of the rise in pulmonary blood flow at delivery. They also demonstrated that inhibition of NO formation impeded the pulmonary vasodilation produced by ventilation, increasing oxygen tension and shear stress (<LINK REF="REF-Cornfield-1992" TYPE="REFERENCE">Cornfield 1992</LINK>), and that inhalation of NO by the ovine foetus caused sustained and selective pulmonary vasodilation (<LINK REF="REF-Kinsella-1992a" TYPE="REFERENCE">Kinsella 1992a</LINK>).</P>
<P>In newborn mammals, several models of pulmonary hypertension are reversed by iNO (<LINK REF="REF-Fratacci-1991" TYPE="REFERENCE">Fratacci 1991</LINK>; <LINK REF="REF-Frostell-1991" TYPE="REFERENCE">Frostell 1991</LINK>; <LINK REF="REF-Roberts-1993" TYPE="REFERENCE">Roberts 1993</LINK>; <LINK REF="REF-Etches-1994" TYPE="REFERENCE">Etches 1994</LINK>). None of these studies reported an effect on systemic vascular resistance.</P>
<P>In adults with pulmonary hypertension, the initial observation by Higenbottam and coworkers (<LINK REF="REF-Higenbottam-1988" TYPE="REFERENCE">Higenbottam 1988</LINK>) that iNO decreases pulmonary vascular resistance was confirmed by Pepke-Zaba and coworkers (<LINK REF="REF-Pepke_x002d_Zaba-1991" TYPE="REFERENCE">Pepke-Zaba 1991</LINK>), who showed that iNO (40 ppm) reduced pulmonary hypertension with no change in systemic vascular resistance. In adults with acute respiratory distress syndrome, Rossaint and coworkers (<LINK REF="REF-Rossaint-1993" TYPE="REFERENCE">Rossaint 1993</LINK>) showed a reduction in pulmonary arterial pressure and a decrease in intrapulmonary shunting within 40 minutes of inhalation of NO. In these patients, improvement in oxygenation was due largely to improved ventilation/perfusion matching.</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-12-12 18:49:47 -0500" MODIFIED_BY="[Empty name]">
<P>Two uncontrolled reports in neonates with PPHN from separate groups working in Denver (<LINK REF="REF-Kinsella-1992b" TYPE="REFERENCE">Kinsella 1992b</LINK>) and Boston (<LINK REF="REF-Roberts-1992" TYPE="REFERENCE">Roberts 1992</LINK>) indicated that iNO rapidly produced a significant improvement in preductal oxygen saturation, with no detectable toxicity. The Boston group (<LINK REF="REF-Roberts-1992" TYPE="REFERENCE">Roberts 1992</LINK>) revealed that concentrations of 80 ppm of iNO were required to achieve a response, whereas the Denver group (<LINK REF="REF-Kinsella-1992b" TYPE="REFERENCE">Kinsella 1992b</LINK>) observed beneficial effects with only 10 to 20 ppm. This latter group reported on nine additional infants treated with iNO, eight of whom showed a sustained beneficial response (<LINK REF="REF-Kinsella-1993" TYPE="REFERENCE">Kinsella 1993</LINK>). Finer and coworkers conducted a prospective evaluation of the dose response to iNO in infants referred for possible ECMO therapy (<LINK REF="REF-Finer-1994" TYPE="REFERENCE">Finer 1994</LINK>). Inhalation of NO was associated with significant improvements in partial pressure of arterial oxygen (PaO<SUB>2</SUB>) and decreases in alveolar-arterial oxygen difference (A-aDO<SUB>2</SUB>) and oxygenation index (OI) among 14 of 21 studied infants. Investigators noted no difference in response between 5 ppm and higher concentrations.</P>
<P>Preliminary evidence led to prospective randomised controlled clinical trials conducted to evaluate the role of iNO in infants with respiratory failure.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-12-11 17:13:53 -0500" MODIFIED_BY="[Empty name]">
<P>To determine whether treatment of hypoxaemic term and near-term newborn infants with iNO improves oxygenation and reduces rate of death and use of extracorporeal membrane oxygenation (ECMO), or affects long-term neurodevelopmental outcomes.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-12-18 20:21:33 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2016-12-18 20:19:27 -0500" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2016-12-11 18:04:34 -0500" MODIFIED_BY="[Empty name]">
<P>We included only randomised prospective clinical trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-12-12 18:50:17 -0500" MODIFIED_BY="[Empty name]">
<P>Participants were newborn infants (&lt; 1 month of age) with hypoxaemia suspected to be due to lung disease, pulmonary hypertension with right-to-left shunting or both. We included only studies in term and near-term infants (&gt; 34 weeks' gestation). In all studies, investigators made an effort to exclude infants with intracardiac shunting due to structural congenital heart disease. As infants with congenital diaphragmatic hernia (CDH) may respond differently from other near-term infants (from preliminary data), as far as possible results for these infants were evaluated separately.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-12-12 18:50:38 -0500" MODIFIED_BY="[Empty name]">
<P>Studies compared administration of iNO gas versus control - no gas or placebo gas.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-12-18 20:19:27 -0500" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-12-11 18:06:59 -0500" MODIFIED_BY="[Empty name]">
<OL>
<LI>Death or use of ECMO</LI>
<LI>Death before hospital discharge</LI>
<LI>Use of ECMO before hospital discharge</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-12-18 20:19:27 -0500" MODIFIED_BY="[Empty name]">
<OL>
<LI>Improvement in oxygenation (as a dichotomous variable) within 30 to 60 minutes</LI>
<LI>Effects on oxygenation index after 30 to 60 minutes of therapy (both absolute values and change from baseline)</LI>
<LI>Effects on partial pressure of arterial oxygen (PaO<SUB>2</SUB>) after 30 to 60 minutes of therapy (both absolute values and change from baseline)</LI>
<LI>Neurodevelopmental disability at 18 to 24 months</LI>
<LI>Cerebral palsy</LI>
<LI>Cognitive impairment at 18 to 24 months</LI>
<LI>Deafness</LI>
</OL>
<SUBSECTION>
<HEADING LEVEL="5">Outcomes added post hoc</HEADING>
<OL>
<LI>Change in oxygenation index after treatment</LI>
<LI>Change in PaO<SUB>2</SUB> after treatment</LI>
<LI>Chronic lung disease</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-12-16 17:22:17 -0500" MODIFIED_BY="[Empty name]">
<P>We used Cochrane criteria and standard methods and those of the Cochrane Neonatal Review Group (see <A HREF="http://neonatal.cochrane.org/resources-review-authors">the Cochrane Neonatal Group search strategy for specialized register</A>).</P>
<ELECTRONIC_SEARCHES MODIFIED="2016-12-16 17:22:17 -0500" MODIFIED_BY="[Empty name]">
<P>For the 1998 review, we used standard methods of the Neonatal Collaborative Review Group. We performed the first MEDLINE search in March 1997, using the search engine 'Melvyl medline plus' and the following search terms: 'key word=nitric', and 'subject heading = infant, newborn'.</P>
<P>For the 2016 update, we conducted a comprehensive search that included the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 1) in the Cochrane Library; MEDLINE via PubMed (1966 to January 2016); Embase (1980 to January 2016); and the Cumulative Index to Nursing and Allied Health Literature (CINAHL; 1982 to January 2016), using the following search terms: (Nitric OR Nitrix Oxide), plus database-specific limiters for RCTs and neonates (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the full search strategies for each database). We applied no language restrictions.<BR/>
</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-12-11 18:14:53 -0500" MODIFIED_BY="[Empty name]">
<P>For the 1998 review, we searched Society for Pediatric Research meeting abstracts on diskette for 1995, 1996 and 1997, using the terms 'control, controls or controlled' and 'nitric or NO'.</P>
<P>For the 2016 update, we searched clinical trials registries for ongoing and recently completed trials (<A HREF="https://www.clinicaltrials.gov/">clinicaltrials.gov</A>; the World Health Organization International Trials Registry and Platform (<A HREF="http://www.whoint/ictrp/search/en/">www.whoint/ictrp/search/en/</A>); and <A HREF="http://www.isrctn.com/">the ISRCTN Registry</A>). We also searched conference abstracts from the Pediatric Academic Societies (PAS) and the European Society for Paediatric Research (ESPR). We carried out searches in Abstracts 2 View (2000 to 2014) and <I>Pediatric Research</I>.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-12-18 20:21:33 -0500" MODIFIED_BY="[Empty name]">
<P>For each included study, we collected information regarding method of randomisation, blinding, drug intervention, stratification and whether the trial was a single-centre or multi-centre study. We noted information regarding trial participants, including gestational age criteria, birth weight criteria and other inclusion or exclusion criteria. We analysed information on clinical outcomes, including death or use of ECMO, death before hospital discharge, use of ECMO before hospital discharge, improvement in oxygenation (as a dichotomous variable) within 30 to 60 minutes, effects on OI after 30 to 60 minutes of therapy (both absolute values and changes from baseline), effects on PaO<SUB>2</SUB> after 30 to 60 minutes of therapy (both absolute values and changes from baseline), neurodevelopmental disability at 18 to 24 months, cerebral palsy, cognitive impairment at 18 to 24 months and deafness.</P>
<STUDY_SELECTION MODIFIED="2016-12-12 18:57:07 -0500" MODIFIED_BY="[Empty name]">
<P>We included all randomised and quasi-randomised controlled trials fulfilling the selection criteria described in the previous section. All review authors reviewed results of the search, separately selected studies for inclusion and resolved disagreements by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-12-12 18:57:30 -0500" MODIFIED_BY="[Empty name]">
<P>KB, TP and GA extracted, assessed and coded all data for each study, for studies newly added to this version of the review, using the same categories as were used in the previous version. We replaced any standard error of the mean reported with the corresponding standard deviation and resolved disagreements by discussion. For each study, one review author (KB) entered final data into Review Manager (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>), and the other review authors (NF, TP, GA) checked the data. All review authors reviewed the protocol, analysis and draft manuscript.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-12-12 19:00:15 -0500" MODIFIED_BY="[Empty name]">
<P>We employed standard methods of the <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/NEONATAL/sect0-meta.html">Cochrane Neonatal Group</A>. We assessed methodological quality of studies by using the following key criteria: allocation concealment (blinding of randomisation), blinding of intervention, completeness of follow-up and blinding of outcome measurement/assessment. We assessed each criterion as introducing high, low or unclear risk. We included this information in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>In addition, review authors independently assessed risk of bias for each study by using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>We assessed methodological quality of studies by using the following criteria.</P>
<OL>
<LI>Sequence generation (evaluating possible selection bias). For each included study, we described the method used to generate the allocation sequence as adequate (any truly random process, e.g. random number table; computer random number generator), inadequate (any non-random process, e.g. odd or even date of birth; hospital or clinic record number; or an unverifiable process, e.g. coin toss) or unclear.</LI>
<LI>Allocation concealment (evaluating possible selection bias). For each included study, we described the method used to conceal the allocation sequence as adequate (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes), inadequate (open random allocation; unsealed or non-opaque envelopes; alternation; date of birth) or unclear.</LI>
<LI>Blinding (evaluating possible performance bias). For each included study, we described methods used to blind study participants and personnel from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes, and we assessed methods as adequate, inadequate or unclear for participants; adequate, inadequate or unclear for study personnel; and adequate, inadequate or unclear for outcome assessors.</LI>
<LI>Incomplete outcome data (evaluating possible attrition bias through withdrawals, drop-outs, protocol deviations). For each included study and for each outcome, we described the completeness of data including attrition and exclusions from analysis. We stated whether attrition and exclusions were reported, numbers included in the analysis at each stage (compared with total randomised participants) and reasons for attrition or exclusion when reported, and whether missing data were balanced across groups or were related to outcomes. We assessed methods as adequate (&lt; 20% missing data), inadequate (&#8805; 20% missing data) or unclear.</LI>
<LI>Selective reporting bias. For each included study for which the protocol was available (through trials registers), we investigated the possibility of selective outcome reporting bias and reported what we found. We assessed methods as adequate (when it was clear that all of the study's prespecified outcomes and all expected outcomes of interest to the review had been reported), inadequate (when not all of the study's prespecified outcomes had been reported; one or more reported primary outcomes were not prespecified; outcomes of interest were reported incompletely and so could not be used; or study failed to include results of a key outcome that would have been expected to have been reported) or unclear.</LI>
<LI>Other sources of bias. We noted other possible sources of bias (e.g. whether a potential source of bias was related to the specific study design, whether the trial was stopped early owing to some data-dependent process). We assessed whether each study was free of other problems that could put it at risk of bias as yes, no or unclear.</LI>
<LI>Funding sources. For each study, we attempted to determine the nature and, if possible, the role of the funding source. Using published or registered protocols and the final publication of the main trial results, we determined whether funds for the trial were obtained from local agencies (e.g. research groups, hospital foundations, university funds), charitable sources (local, national or international foundations), government agencies or industry sources. If potential funding conflicts of interest were evident (particularly with industry funding), we evaluated the role of the funding source. We determined that when funding was received entirely from industry, studies were at high risk of bias. In cases of funding received in part from industry sources, we evaluated risk of bias according to the apparent role of the funding source.</LI>
</OL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-12-11 18:31:26 -0500" MODIFIED_BY="[Empty name]">
<P>We performed statistical analyses using Review Manager 5 software (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We analysed categorical data using risk ratio (RR) and risk difference (RD). For statistically significant outcomes, we calculated the number needed to treat for an additional beneficial outcome (NNTB) or the number needed to treat for an additional harmful outcome (NNTH). We analysed continuous data by using weighted mean difference (WMD) and standardised mean difference (SMD). We reported 95% confidence intervals (CIs) for all estimates.</P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-12-12 19:00:49 -0500" MODIFIED_BY="[Empty name]">
<P>We estimated treatment effects reported by individual trials and examined heterogeneity among trials by inspecting forest plots and quantifying the impact of heterogeneity using the I² statistic. We graded the degree of heterogeneity as less than 25% (no heterogeneity), 25% to 49% (low heterogeneity), 50% to 75% (moderate heterogeneity) or greater than 75% (substantial heterogeneity). If we noted statistical heterogeneity (I² &gt; 50%), we explored possible causes (e.g. differences in study quality, participants, intervention regimens or outcome assessments).</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-12-12 19:02:29 -0500" MODIFIED_BY="[Empty name]">
<P>If we identified multiple studies and thought they were sufficiently similar, we performed meta-analysis by using RevMan version 5.3, as supplied by Cochrane. For categorical outcomes, we calculated typical estimates of RR and RD, each with its 95% CI, and for continuous outcomes, WMD or a summary estimate for SMD, each with its 95% CI. We used a fixed-effect model for meta-analysis. When we judged meta-analysis to be inappropriate, we analysed and interpreted separately subgroups of individual trials that were very similar.</P>
<SUBSECTION>
<HEADING LEVEL="3">Quality of evidence</HEADING>
<P>We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, as outlined in the <I>GRADE Handbook</I> (<LINK REF="REF-Sch_x00fc_nemann-2013" TYPE="REFERENCE">Schünemann 2013</LINK>), to assess the quality of evidence for the following (clinically relevant) outcomes: survival without the need for ECMO (or its converse - death or use of ECMO) and the two components of that outcome - death (before hospital discharge) and use of ECMO. The long-term outcome that we considered important was evaluation of neurodevelopmental disability at 18 to 24 months (components of which were cerebral palsy, cognitive impairment and deafness).</P>
<P>Two review authors (KB and TP) independently assessed the quality of the evidence for each of the outcomes above. We considered evidence from RCTs as high quality but downgraded evidence one level for serious (or two levels for very serious) limitations on the basis of the following: design (risk of bias), consistency across studies, directness of evidence, precision of estimates and presence of publication bias. We used the <LINK REF="REF-GRADEpro" TYPE="REFERENCE">GRADEpro</LINK> Guideline Development Tool to create a &#8216;Summary of findings&#8217; table to report the quality of the evidence.</P>
<P>The GRADE approach results in an assessment of the quality of a body of evidence according to one of four grades.</P>
<OL>
<LI>High: We are very confident that the true effect lies close to the estimate of effect.</LI>
<LI>Moderate: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of effect but may be substantially different.</LI>
<LI>Low: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of effect.</LI>
<LI>Very low: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.</LI>
</OL>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-12-12 19:03:12 -0500" MODIFIED_BY="[Empty name]">
<P>The major subgroups that we analysed included trials that compared iNO versus no iNO and trials that compared immediate nitric oxide treatment upon enrolment in the trial versus selective treatment only when the infant's condition deteriorated, to satisfy rescue treatment criteria. We considered separately the unique study comparing high-frequency ventilation versus iNO (<LINK REF="STD-Kinsella-1997" TYPE="STUDY">Kinsella 1997</LINK>) and did not include this study in the meta-analysis.</P>
<P>Among studies that compared iNO versus control, we examined three subgroups: trials that did not allow iNO in the control group; the one study (<LINK REF="STD-Mercier-1998" TYPE="STUDY">Mercier 1998</LINK>) that allowed iNO at the physician's discretion (with no specific criteria) after a relatively brief two-hour period; and trials that enrolled participants with diaphragmatic hernia.</P>
<P>We used the I<SUP>2 </SUP>statistic for investigation of heterogeneity in each subgroup.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-12-18 20:21:33 -0500" MODIFIED_BY="[Empty name]">
<P>For major outcomes, we performed sensitivity analysis by running the meta-analysis both while including and while excluding studies at higher risk of bias.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-12-23 11:48:32 -0500" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2016-12-16 17:45:31 -0500" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2016-12-16 17:26:28 -0500" MODIFIED_BY="[Empty name]">
<P>The previous version of this review identified 14 randomised controlled trials. Updated searches revealed 652 records after duplicates were removed; after screening, review authors identified three new RCTs for inclusion in the review (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-12-16 17:45:31 -0500" MODIFIED_BY="[Empty name]">
<P>In all, we identified 17 RCTs including term and near-term infants with hypoxaemic respiratory failure (<LINK REF="STD-Barefield-1996" TYPE="STUDY">Barefield 1996</LINK>; <LINK REF="STD-Day-1996" TYPE="STUDY">Day 1996</LINK>; <LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996</LINK>; <LINK REF="STD-Roberts-1996" TYPE="STUDY">Roberts 1996</LINK>; <LINK REF="STD-Wessel-1996" TYPE="STUDY">Wessel 1996</LINK>; <LINK REF="STD-Davidson-1997" TYPE="STUDY">Davidson 1997</LINK>; <LINK REF="STD-Kinsella-1997" TYPE="STUDY">Kinsella 1997</LINK>; <LINK REF="STD-Ninos-1997" TYPE="STUDY">Ninos 1997</LINK>; <LINK REF="STD-Mercier-1998" TYPE="STUDY">Mercier 1998</LINK>; <LINK REF="STD-Sadiq-1998" TYPE="STUDY">Sadiq 1998</LINK>; <LINK REF="STD-Cornfield-1999" TYPE="STUDY">Cornfield 1999</LINK>; <LINK REF="STD-Christou-2000" TYPE="STUDY">Christou 2000</LINK>; <LINK REF="STD-Clark-2000" TYPE="STUDY">Clark 2000</LINK>; <LINK REF="STD-Konduri-2004" TYPE="STUDY">Konduri 2004</LINK>; <LINK REF="STD-INNOVO-2007" TYPE="STUDY">INNOVO 2007</LINK>; <LINK REF="STD-Liu-2008" TYPE="STUDY">Liu 2008</LINK>; <LINK REF="STD-Gonzalez-2010" TYPE="STUDY">Gonzalez 2010</LINK>).<BR/>
</P>
<P>Ten of these trials (<LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996</LINK>; <LINK REF="STD-Roberts-1996" TYPE="STUDY">Roberts 1996</LINK>; <LINK REF="STD-Wessel-1996" TYPE="STUDY">Wessel 1996</LINK>; <LINK REF="STD-Davidson-1997" TYPE="STUDY">Davidson 1997</LINK>; <LINK REF="STD-Ninos-1997" TYPE="STUDY">Ninos 1997</LINK>; <LINK REF="STD-Mercier-1998" TYPE="STUDY">Mercier 1998</LINK>; <LINK REF="STD-Christou-2000" TYPE="STUDY">Christou 2000</LINK>; <LINK REF="STD-Clark-2000" TYPE="STUDY">Clark 2000</LINK>; <LINK REF="STD-INNOVO-2007" TYPE="STUDY">INNOVO 2007</LINK>; <LINK REF="STD-Liu-2008" TYPE="STUDY">Liu 2008</LINK>) compared iNO versus control (placebo or standard care without iNO in infants with moderate or severe severity of illness scores), and 10 did not allow use of iNO in control groups. One trial (<LINK REF="STD-Mercier-1998" TYPE="STUDY">Mercier 1998</LINK>) allowed treatment of both control and intervention participants after 2 hours of iNO at the physician's discretion, without clear criteria for treatment initiation in the control group. We therefore included this trial in group 1 but as a separate subgroup. Two trials applied other restrictions to eligibility criteria: One study enrolled only infants with diaphragmatic hernia (<LINK REF="STD-Ninos-1997" TYPE="STUDY">Ninos 1997</LINK>) and compared iNO versus placebo, while not allowing open-label iNO. The other study (<LINK REF="STD-Liu-2008" TYPE="STUDY">Liu 2008</LINK>) included only infants with meconium aspiration and compared iNO versus no iNO (for this trial, no back-up ECMO was available).</P>
<P>One trial randomised infants to iNO or high-frequency ventilation (<LINK REF="STD-Kinsella-1997" TYPE="STUDY">Kinsella 1997</LINK>), crossed participants over to the other treatment in case of failure, then combined treatments if the cross-over was not successful.</P>
<P>Six of these trials (<LINK REF="STD-Barefield-1996" TYPE="STUDY">Barefield 1996</LINK>; <LINK REF="STD-Day-1996" TYPE="STUDY">Day 1996</LINK>; <LINK REF="STD-Sadiq-1998" TYPE="STUDY">Sadiq 1998</LINK>; <LINK REF="STD-Cornfield-1999" TYPE="STUDY">Cornfield 1999</LINK>; <LINK REF="STD-Konduri-2004" TYPE="STUDY">Konduri 2004</LINK>; <LINK REF="STD-Gonzalez-2010" TYPE="STUDY">Gonzalez 2010</LINK>) randomised infants with moderate severity of illness scores (defined by OI or A-aDO<SUB>2</SUB>) to an intervention group that received immediate iNO and compared them with controls who were treated without iNO unless they deteriorated to more serious severity scores, in which case iNO was used.</P>
<P>These three groups of trials are investigating different questions: 'Is iNO preferable to no treatment?' 'Is iNO preferable to high-frequency ventilation, or is the combination better?' 'Is early iNO preferable to later iNO?' Therefore, we divided the trials post hoc into the three groups.</P>
<P>One of the above studies enrolled infants of any gestational age but reported most descriptive and outcome data separately for preterm (&lt; 33 weeks' gestation) and near-term (&#8805; 33 weeks') babies (<LINK REF="STD-Mercier-1998" TYPE="STUDY">Mercier 1998</LINK>). These studies varied in size from n = 17 (<LINK REF="STD-Barefield-1996" TYPE="STUDY">Barefield 1996</LINK>) to n = 235 (<LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996</LINK>). Eligibility criteria have been reasonably homogeneous; some studies excluded infants with pulmonary hypoplasia, some excluded infants with pulmonary hypoplasia of any cause and others specifically excluded only those with congenital diaphragmatic hernia (<LINK REF="STD-Barefield-1996" TYPE="STUDY">Barefield 1996</LINK>; <LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996</LINK>; <LINK REF="STD-Roberts-1996" TYPE="STUDY">Roberts 1996</LINK>; <LINK REF="STD-Wessel-1996" TYPE="STUDY">Wessel 1996</LINK>; <LINK REF="STD-Davidson-1997" TYPE="STUDY">Davidson 1997</LINK>; <LINK REF="STD-Mercier-1998" TYPE="STUDY">Mercier 1998</LINK>; <LINK REF="STD-Christou-2000" TYPE="STUDY">Christou 2000</LINK>; <LINK REF="STD-Konduri-2004" TYPE="STUDY">Konduri 2004</LINK>), whereas the remaining studies included infants with these conditions (<LINK REF="STD-Day-1996" TYPE="STUDY">Day 1996</LINK>; <LINK REF="STD-Kinsella-1997" TYPE="STUDY">Kinsella 1997</LINK>; <LINK REF="STD-Sadiq-1998" TYPE="STUDY">Sadiq 1998</LINK>; <LINK REF="STD-Cornfield-1999" TYPE="STUDY">Cornfield 1999</LINK>; <LINK REF="STD-Clark-2000" TYPE="STUDY">Clark 2000</LINK>). The Ninos group ran a parallel RCT of infants with congenital diaphragmatic hernia (<LINK REF="STD-Ninos-1997" TYPE="STUDY">Ninos 1997</LINK>). Most studies limited participants to near-term infants (&#8805; 34 weeks: <LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996</LINK>; <LINK REF="STD-Kinsella-1997" TYPE="STUDY">Kinsella 1997</LINK>; <LINK REF="STD-Wessel-1996" TYPE="STUDY">Wessel 1996</LINK>; <LINK REF="STD-Cornfield-1999" TYPE="STUDY">Cornfield 1999</LINK>; <LINK REF="STD-Christou-2000" TYPE="STUDY">Christou 2000</LINK>; <LINK REF="STD-Clark-2000" TYPE="STUDY">Clark 2000</LINK>; &#8805; 35 weeks: <LINK REF="STD-Barefield-1996" TYPE="STUDY">Barefield 1996</LINK>; 'full term': <LINK REF="STD-Roberts-1996" TYPE="STUDY">Roberts 1996</LINK>; <LINK REF="STD-Davidson-1997" TYPE="STUDY">Davidson 1997</LINK>), but <LINK REF="STD-Day-1996" TYPE="STUDY">Day 1996</LINK> included preterm infants (five of 50 participants).</P>
<P>Hypoxaemic respiratory failure was required for entry into each of these studies, but exact criteria differed and are noted in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>Many, but not all, of the studies (<LINK REF="STD-Day-1996" TYPE="STUDY">Day 1996</LINK>; <LINK REF="STD-Roberts-1996" TYPE="STUDY">Roberts 1996</LINK>; <LINK REF="STD-Wessel-1996" TYPE="STUDY">Wessel 1996</LINK>; <LINK REF="STD-Davidson-1997" TYPE="STUDY">Davidson 1997</LINK>; <LINK REF="STD-Kinsella-1997" TYPE="STUDY">Kinsella 1997</LINK>; <LINK REF="STD-Sadiq-1998" TYPE="STUDY">Sadiq 1998</LINK>; <LINK REF="STD-Cornfield-1999" TYPE="STUDY">Cornfield 1999</LINK>; <LINK REF="STD-Christou-2000" TYPE="STUDY">Christou 2000</LINK>) also required echocardiographic evidence of PPHN. <LINK REF="STD-Clark-2000" TYPE="STUDY">Clark 2000</LINK> required clinical or echocardiographic evidence of PPHN, and <LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996</LINK> required no evidence of PPHN.</P>
<P>Many studies reported data regarding short-term effects on oxygenation as percentage or absolute change in PaO<SUB>2</SUB> and OI. Data for all percentages, absolute changes and absolute values were available to us only for the <LINK REF="STD-Mercier-1998" TYPE="STUDY">Mercier 1998</LINK> study. Other studies provided results in one way or another.</P>
<SUBSECTION>
<HEADING LEVEL="4">Trials comparing iNO versus control (no iNO)</HEADING>
<P>
<LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996</LINK> was a multi-centre trial that included participants 14 days of age or younger without congenital structural heart disease. Although all infants in this trial received an echocardiogram before randomisation, an echocardiographic diagnosis of PPHN was not an inclusion criterion for this trial, as it was for many of the other trials herein reported. Infants were randomly assigned to receive 20 ppm of iNO or placebo; in this study, the placebo gas was 100% oxygen. The primary hypothesis was that administration of iNO to such infants would reduce the risk of death or the need for ECMO by 120 days from 50% in control infants to 30% in infants receiving iNO. This study encouraged full aggressive conventional therapy including high-frequency ventilation provided by centres experienced in its use, use of a bovine surfactant as well as maintenance of arterial blood pressure above 45 mmHg, induction of alkalosis (target pH 7.45 to 7.60) with encouragement for use of sedation and/or paralysis and vasopressors and volume expansion as necessary to maintain blood pressure. The external data safety monitoring committee recommended termination of the trial after the second planned review of data revealed that the trial had reached the predetermined boundary of statistical significance, at which time 235 infants (121 controls and 114 infants in the iNO group) had been enrolled. These two groups were well matched for their clinical characteristics and blood gas values and were nearly identical in the use of support treatments at the time of randomisation. Approximately 55% of infants were receiving high-frequency ventilation at the time of randomisation, and approximately 72% had received surfactant before randomisation. More than 90% of all infants had received volume and vasopressor support, neuromuscular blockade and sedation before randomisation.</P>
<P>The <LINK REF="REF-Ninos-2000" TYPE="REFERENCE">Ninos 2000</LINK> publication presents follow-up of survivors of the two Ninos studies who underwent comprehensive neurodevelopmental assessment at 18 to 24 months of age. A secondary hypothesis of the original study was that administration of iNO would lead to no increase in neurodevelopmental disability at 18 to 24 months. Of 235 infants enrolled, 36 died, and 176 of the 199 survivors were assessed at follow-up: 88 control infants and 85 iNO infants. In addition, this study included survivors of the parallel trial of infants with congenital diaphragmatic hernia (<LINK REF="STD-Ninos-1997" TYPE="STUDY">Ninos 1997</LINK>). Among the original 53 enrolled infants, 29 were survivors and follow-up was available for eight of 13 iNO survivors and for 14 of 16 control infants. Survivors were well matched for their neonatal characteristics. Investigators performed structured neurological examinations and hearing tests, and blinded assessors most often assigned Bayley Scales of Infant Development (BSID) scores.</P>
<P>
<LINK REF="STD-Roberts-1996" TYPE="STUDY">Roberts 1996</LINK> conducted a multi-centre trial including infants who had fraction of inspired oxygen (FiO<SUB>2</SUB>) of 1.0 and postductal PaO<SUB>2</SUB> of 55 mmHg or less on two consecutive determinations 30 minutes apart. Researchers excluded infants who had polycythaemia (hematocrit &#8805; 70%) or uncorrected hypotension (defined as mean aortic blood pressure &lt; 40 mmHg) or an unevacuated pneumothorax. They also excluded infants who had received treatment with high-frequency oscillatory ventilation or jet ventilation and included infants who had previously received surfactant without sustained improvement in oxygenation. All infants had FiO<SUB>2</SUB> reduced to 0.9 and were enrolled if they maintained PaO<SUB>2</SUB> greater than 85% of their previous baseline. An interim analysis after 50 participants were enrolled demonstrated that iNO increased systemic oxygenation significantly compared with the control gas. A total of 28 control group infants and 30 iNO infants appeared well matched in terms of diagnoses, blood gases, oxygen indices and ventilator settings.</P>
<P>
<LINK REF="STD-Wessel-1996" TYPE="STUDY">Wessel 1996</LINK> was a single-centre, open-label trial in which treatment of participants included sedation and neuromuscular blockade. Infants in this trial were permitted to have previously received surfactant therapy or high-frequency ventilation. Investigators initiated iNO therapy at 80 ppm after FiO<SUB>2</SUB> was reduced to 0.97, with a protocol that lowered the iNO dose to 40 ppm after one hour and with continued weaning if tolerated. Researchers discontinued iNO when a participant was cannulated for ECMO, or when the clinician chose to initiate high-frequency ventilation. They evaluated the effectiveness of iNO by assessing alterations in oxygenation, mortality and use of ECMO. Investigators enrolled 51 participants, of whom they excluded two. Researchers randomised 23 included infants to receive conventional treatment and 26 to receive iNO. Only four participants in this study actually received surfactant treatment, and, as in previous studies, the most common diagnosis was meconium aspiration (in 45% of enrolled participants). This group has published follow-up data, including neurodevelopmental outcomes that were obtained by telephone interview from 60 of 83 survivors of the original trial. They conducted the interview when participants were between one and four years of age.</P>
<P>
<LINK REF="STD-Davidson-1997" TYPE="STUDY">Davidson 1997</LINK> performed a multi-centre study (funded by manufacturers) that compared three different doses of iNO (5 ppm, 20 ppm and 80 ppm) versus nitrogen placebo. Researchers hypothesised that iNO would reduce the incidence of a sequela included in the PPHN Major Sequelae Index (MSI), which they constructed. This index included death, ECMO, neurological sequelae and chronic lung disease. Investigators enrolled 155 infants with echocardiographic evidence of PPHN and PaO<SUB>2</SUB> between 40 and 100 mmHg in 100% oxygen, with a wide range of illness severity at enrolment. They excluded infants who received surfactant therapy and did not allow concurrent high-frequency ventilation. They defined failure as PaO<SUB>2</SUB> less than 40 mmHg for longer than 30 minutes. This study was terminated early owing to poor enrolment. Researchers enrolled 155 infants; they entered 41 into the control group and 114 into one of the three iNO groups, with 41 receiving 5 ppm, 36 receiving 20 ppm and 37 receiving 80 ppm.</P>
<P>
<LINK REF="STD-Mercier-1998" TYPE="STUDY">Mercier 1998</LINK> was a randomised multi-centre trial conducted at 33 French and Belgian neonatal units. Investigators enrolled 204 infants into the trial, 107 of whom were near-term infants. Near-term infants were entered at an OI between 15 and 40, which was confirmed on two blood gases taken one hour apart, and were treated with iNO at 10 ppm or with no iNO. Researchers excluded infants with pulmonary hypoplasia, including congenital diaphragmatic hernia. The primary outcome measure was OI at two hours. If an infant exceeded OI of 40 during the two-hour period, iNO therapy was allowed. After the two-hour assessment, further therapy was provided at the discretion of the physician, and it is not reported how many infants received iNO at this time. The randomisation procedure stratified infants according to gestation, mode of ventilation and pulmonary diagnosis. Two-thirds of the infants had received surfactant, and just over half (57%) were given high-frequency oscillatory ventilation. Thirty percent of the infants had meconium aspiration syndrome, 25% idiopathic PPHN and 45% RDS. Enrolment into the study was terminated because of slowing recruitment after 204 of the originally planned 360 infants had been entered. ECMO was not available as back-up therapy; therefore, the number of infants dying was the same as the number of infants dying or requiring ECMO.</P>
<P>
<LINK REF="STD-Christou-2000" TYPE="STUDY">Christou 2000</LINK> randomised 42 infants of at least 34 weeks' gestation with respiratory failure and PaO<SUB>2</SUB> less than 100 mmHg on 100% oxygen, one of whom proved to have congenital heart disease and was removed from the study, leaving 41 study infants. Researchers compared iNO at 40 ppm versus standard therapy, without placebo gas. After one hour, they decreased the dose to 20 ppm if tolerated and made daily attempts at weaning iNO. The study was terminated early after an ad hoc committee reviewed the data.</P>
<P>
<LINK REF="STD-Clark-2000" TYPE="STUDY">Clark 2000</LINK> randomised 248 near-term infants who were four days of age or younger with OI greater than 25, to 20 ppm of iNO or nitrogen placebo. Infants were not eligible if their PaO<SUB>2</SUB> was less than 30 mmHg and they were considered to be in urgent need of ECMO for refractory hypotension (mean blood pressure &lt; 35 mmHg). Investigators did not exclude infants with congenital diaphragmatic hernia, and these data are available as a separate stratum, allowing comparison of results with those of <LINK REF="STD-Ninos-1997" TYPE="STUDY">Ninos 1997</LINK>. Researchers stratified infants by one of five diagnostic categories and then randomised them within that stratum. These strata included meconium aspiration, pneumonia, respiratory distress syndrome, lung hypoplasia syndromes including congenital diaphragmatic hernia and idiopathic persistent pulmonary hypertension. Echocardiographic or clinical confirmation of pulmonary hypertension was required. The primary outcome variable was the need for ECMO. After 24 hours of treatment with 20 ppm, investigators reduced the dose to 5 ppm for up to another 96 hours. Researchers evaluated secondary outcome variables of oxygen dependence at 30 days and neurological abnormality defined clinically or on ultrasonography.</P>
<P>
<LINK REF="STD-INNOVO-2007" TYPE="STUDY">INNOVO 2007</LINK> randomised infants with more than 33 weeks' gestation if they had severe respiratory failure in the first 28 days of life, and 'if the responsible clinician was uncertain about whether an infant might benefit from iNO'. Researchers initiated iNO at 20 ppm or provided control intervention (without placebo gas). No cross-over was allowed. Investigators enrolled 60 infants at European centres. Six of 31 controls received iNO; four iNO babies did not receive the gas, three improved and one died before the gas could be started. The primary outcome was death or severe disability at one year of age. Sample size was determined by a time limit for study duration.</P>
<P>
<LINK REF="STD-Liu-2008" TYPE="STUDY">Liu 2008</LINK>, which was conducted in China, limited participants to infants with meconium aspiration syndrome. Investigators required that infants have gestational age greater than 36 weeks and birth weight of at least 2.5 kg, and that intubated infants have an OI greater than 15. Infants did not receive surfactant; all underwent echocardiography during the initial workup but were not required to have pulmonary hypertension to be eligible. The primary outcome variable is not clear; iNO at 15 ppm or no additional gas was given, and iNO could be increased to 20 ppm in cases of poor response.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Trials comparing iNO at moderate compared with severe criteria for illness severity</HEADING>
<P>
<LINK REF="STD-Barefield-1996" TYPE="STUDY">Barefield 1996</LINK> compared iNO versus 'conventional treatment'. Infants had been treated with induction of alkalosis, both metabolic and respiratory, to obtain a pH of 7.65 or greater with partial pressure of carbon dioxide (PCO<SUB>2</SUB>) of 25 to 35 mmHg, and all infants were paralysed with vecuronium and sedated. Infants were not allowed to receive other vasodilators during the trial and were initially randomised to receive no iNO, iNO at a dose of 20 ppm for PaO<SUB>2</SUB> of 40 to 99 mmHg and iNO at 40 ppm for PaO<SUB>2</SUB> less than 40 mmHg; increases were allowed up to 80 ppm. Treatment failure occurred if PaO<SUB>2</SUB> was less than 80 mmHg for one hour "despite alkalosis", less than 40 mmHg for longer than one hour or less than 30 mmHg for 30 minutes. When control infants met treatment failure criteria, they were treated with iNO. The primary outcome of this trial was the need for ECMO or treatment failure.</P>
<P>
<LINK REF="STD-Day-1996" TYPE="STUDY">Day 1996</LINK> was a single-centre study in which investigators randomised infants with OI between 25 and 40 to receive conventional therapy or 20 ppm of iNO, then treated control infants whose OI increased to greater than 40 with open-label iNO. As a result, 22 infants treated in the randomised portion of the trial presented with OI between 25 and 40; 11 received iNO, and 11 conventional therapy. Much of this report combines infants randomised to iNO and some non-randomised infants who received iNO as well as control infants who crossed over to iNO. We have included data only when they were clearly derived from the initially randomised comparison.</P>
<P>
<LINK REF="STD-Sadiq-1998" TYPE="STUDY">Sadiq 1998</LINK> randomised infants with birth weight &gt; 2 kg on assisted ventilation with 100% oxygen and an A-aDO<SUB>2</SUB> between 500 and 599 mmHg on two blood gases at least one hour apart to iNO (10 to 80 ppm) or standard medical management. Echocardiographic evidence of pulmonary hypertension was required, and infants must have received at least one dose of surfactant before enrolment. The primary outcome criterion was "severe pulmonary hypertension", which was defined as A-aDO<SUB>2</SUB> greater than 600 mmHg. If infants satisfied this definition, then iNO and other therapies including ECMO were allowed. Infants with congenital diaphragmatic hernia were enrolled, and only those with "lethal anomalies" were excluded.</P>
<P>
<LINK REF="STD-Cornfield-1999" TYPE="STUDY">Cornfield 1999</LINK> was a randomised study conducted at three centres that compared 2 ppm of iNO versus control. The hypothesis of this study was that low-dose iNO would acutely improve oxygenation. The study was unblinded. Investigators enrolled 38 full-term infants with OI over 25, nine of whom had a congenital diaphragmatic hernia. After the initial one-hour period, if infants in either group had OI greater than 35, they were considered treatment failures and received 20 ppm of iNO. Thus the trial could be considered a trial of moderate (OI &gt; 25) compared with severe (OI &gt; 35) criteria for iNO, even though investigators used different concentrations for those criteria.</P>
<P>
<LINK REF="STD-Konduri-2004" TYPE="STUDY">Konduri 2004</LINK> randomised infants at &#8805; 34 weeks' gestation on assisted ventilation with OI between 15 and 25 and with FiO<SUB>2</SUB> of 0.80 on any two arterial blood gases, at least 15 minutes and not more than 12 hours apart, to iNO at 5 to 20 ppm or placebo (nitrogen gas). Investigators started iNO at 5 ppm and increased the dose to a maximum of 20 ppm when they noted a partial response (adjustments were made by a single unmasked therapist, and the remainder of the team were masked). Researchers excluded infants with congenital diaphragmatic hernia or cardiac malformation and those older than 14 days. The primary outcome was death or the need for ECMO. The control group received iNO if OI exceeded 25.</P>
<P>
<LINK REF="STD-Gonzalez-2010" TYPE="STUDY">Gonzalez 2010</LINK>, a two-centre study conducted in Chile, randomised near-term and term infants with OI between 10 and 30 to receive iNO at 20 ppm or control; if within 48 hours, OI worsened to 40 or more, then controls received iNO. Infants who remained with OI greater than 40 were treated with high-frequency ventilation. All infants had echocardiographic evidence of PPHN, but investigators did not state whether they received surfactant. The primary outcome variable was progression to OI over 40.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Trials comparing iNO versus high-frequency ventilation</HEADING>
<P>
<LINK REF="STD-Kinsella-1997" TYPE="STUDY">Kinsella 1997</LINK> compared iNO versus high-frequency ventilation rather than against 'standard therapy'; if infants failed the first therapy, they were crossed over to the alternate therapy, then to combined treatment. Data from this study included in this review relate only to the first comparison between initially randomised groups. This multi-centre study excluded infants with lethal abnormalities and proscribed the use of surfactant after enrolment. The definition of success in this trial was achievement of a PaO<SUB>2</SUB> greater than 60 mmHg with assigned therapy. Initial randomisation was to iNO 20 to 40 ppm or to high-frequency ventilation with the SensorMedics oscillator (SensorMedics Corporation, Yorba Linda, California, USA). The trial had enrolled 205 infants when it was terminated as the result of an interim analysis that demonstrated lack of efficacy. Thirty-one percent of the infants included in this trial had received surfactant before enrolment. As this is the only trial included in this group, we did not perform a meta-analysis, and all infants had the possibility of receiving iNO at some point in the trial. Therefore, we included data on short-term oxygenation changes after iNO but did not analyse clinical outcome data.</P>
<P>All of the studies described above, with the exception of <LINK REF="STD-Kinsella-1997" TYPE="STUDY">Kinsella 1997</LINK>, <LINK REF="STD-Day-1996" TYPE="STUDY">Day 1996</LINK> and <LINK REF="STD-Clark-2000" TYPE="STUDY">Clark 2000</LINK>, excluded infants with congenital diaphragmatic hernia (CDH). This patient population is unique in presentation and pathophysiology. As a result, NINOS investigators performed a parallel study of infants with CDH using an identical study protocol to the main NINOS study (<LINK REF="STD-Ninos-1997" TYPE="STUDY">Ninos 1997</LINK>). They enrolled 53 infants (28 control, 25 iNO treated), and their primary hypothesis was that iNO would reduce the occurrence of death or the need for ECMO at 120 days. Treated and control groups were well matched, with baseline OI of 45.8 ± 16.3 in controls and 44.5 ± 14.5 in iNO-treated infants.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-12-11 20:37:14 -0500" MODIFIED_BY="[Empty name]">
<P>See the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-12-12 19:58:30 -0500" MODIFIED_BY="[Empty name]">
<P>The overall quality of these studies is highly variable. The highest-quality studies were fully blinded, adequately powered, multi-centre RCTs with external data monitoring groups that examined clinically important outcomes (<LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996;</LINK> <LINK REF="STD-Ninos-1997" TYPE="STUDY">Ninos 1997;</LINK> <LINK REF="STD-Clark-2000" TYPE="STUDY">Clark 2000</LINK>; <LINK REF="STD-Konduri-2004" TYPE="STUDY">Konduri 2004</LINK>). Another group of studies of intermediate quality used variable degrees of blinding or examined primarily oxygenation outcomes (<LINK REF="STD-Roberts-1996" TYPE="STUDY">Roberts 1996</LINK>; <LINK REF="STD-Davidson-1997" TYPE="STUDY">Davidson 1997</LINK>; <LINK REF="STD-Mercier-1998" TYPE="STUDY">Mercier 1998;</LINK> <LINK REF="STD-Sadiq-1998" TYPE="STUDY">Sadiq 1998</LINK>; <LINK REF="STD-INNOVO-2007" TYPE="STUDY">INNOVO 2007</LINK>). A third group of studies consisted of single (or few)-centre studies that were unblinded and included very small sample sizes (<LINK REF="STD-Barefield-1996" TYPE="STUDY">Barefield 1996</LINK>; <LINK REF="STD-Day-1996" TYPE="STUDY">Day 1996</LINK>; <LINK REF="STD-Wessel-1996" TYPE="STUDY">Wessel 1996;</LINK> <LINK REF="STD-Cornfield-1999" TYPE="STUDY">Cornfield 1999</LINK>; <LINK REF="STD-Christou-2000" TYPE="STUDY">Christou 2000</LINK>; <LINK REF="STD-Liu-2008" TYPE="STUDY">Liu 2008;</LINK> <LINK REF="STD-Gonzalez-2010" TYPE="STUDY">Gonzalez 2010</LINK>).</P>
<P>
<LINK REF="STD-Kinsella-1997" TYPE="STUDY">Kinsella 1997</LINK> is a unique study of high quality that had a rather complex protocol and cannot be directly compared with the remaining studies, as investigators compared iNO versus high-frequency ventilation. Several studies were terminated early. In the case of <LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996</LINK>, this occurred because predetermined stopping rules were satisfied. In other cases (<LINK REF="STD-Davidson-1997" TYPE="STUDY">Davidson 1997</LINK>; <LINK REF="STD-Mercier-1998" TYPE="STUDY">Mercier 1998</LINK>; <LINK REF="STD-Sadiq-1998" TYPE="STUDY">Sadiq 1998</LINK>; <LINK REF="STD-Konduri-2004" TYPE="STUDY">Konduri 2004</LINK>), it occurred because of slowing enrolment; in <LINK REF="STD-Christou-2000" TYPE="STUDY">Christou 2000</LINK>, it followed examination of data.</P>
<P>Risk of bias summaries are shown in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Studies at low risk of bias</HEADING>
<P>
<LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996</LINK>: In this masked multi-centre trial, investigators masked allocation, intervention and outcome assessment. Investigators performed preplanned interim analyses and used standard stopping rules. They noted the significance of the primary outcome variable after performing the second analysis.</P>
<P>
<LINK REF="STD-Ninos-1997" TYPE="STUDY">Ninos 1997</LINK>: This trial was designed in an unusual and pragmatic fashion to run simultaneously at the same centres as the main study (<LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996</LINK>), with a sample size that was planned by terminating enrolment when the main Ninos study was complete. Investigators performed allocation, intervention and outcome analysis in a masked fashion. Investigators reported long-term neurodevelopmental follow-up of infants in <LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996,</LINK> and in <LINK REF="STD-Ninos-1997" TYPE="STUDY">Ninos 1997</LINK>, they reported survival of 87% for <LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996</LINK> (n = 173) and 76% for <LINK REF="STD-Ninos-1997" TYPE="STUDY">Ninos 1997</LINK> (n = 53). All but seven assessments were blinded to original treatment. Non-blinded BSID administrators assessed control infants and six iNO-treated infants.</P>
<P>
<LINK REF="STD-Clark-2000" TYPE="STUDY">Clark 2000</LINK>: This multi-centre trial reported masked allocation and intervention and complete follow-up. The published manuscript does not mention a prespecified sample size.</P>
<P>
<LINK REF="STD-Konduri-2004" TYPE="STUDY">Konduri 2004</LINK>: This multi-centre study used central randomisation allocation and masking of the intervention. Researchers compared thresholds of OI 15 to 25 versus OI &gt; 25. Unfortunately, slow enrolment led to early termination of the study and a reduction in power. This was done without review of results and should not affect the validity of study conclusions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Studies at intermediate risk of bias</HEADING>
<P>
<LINK REF="STD-Roberts-1996" TYPE="STUDY">Roberts 1996</LINK>: Sample size determination leaves this study open to the criticism of little protection against type 1 error, in that study authors reported that they planned to stop after enrolling 50 participants if results showed significant improvement in oxygenation. Review authors made no adjustments to the critical P value for multiple looks at the data. Researchers did not report the study hypothesis.</P>
<P>
<LINK REF="STD-Davidson-1997" TYPE="STUDY">Davidson 1997</LINK>: A three-to-one randomisation scheme enabled the provision of dose-response oxygenation information but limited the number of controls. This study was terminated early and was therefore underpowered to detect clinical benefit.</P>
<P>
<LINK REF="STD-Mercier-1998" TYPE="STUDY">Mercier 1998</LINK>: This multi-centre trial reported masked allocation and complete follow-up but no masking of the intervention. Many protocol violations were noted (44 of the 54 assigned to control therapy received iNO, and only 55 of the 62 assigned to iNO received this treatment).</P>
<P>
<LINK REF="STD-Sadiq-1998" TYPE="STUDY">Sadiq 1998</LINK>: This multi-centre study included a relatively small sample and was terminated owing to slowing enrolment. The intervention was not masked. Review authors requested data on death and ECMO, and the principal investigator provided them.</P>
<P>
<LINK REF="STD-INNOVO-2007" TYPE="STUDY">INNOVO 2007</LINK>: The term section of the INNOVO study enrolled only 60 participants from 27 participating hospitals over four years (15 hospitals actually contributed patients). Recruitment ended when the preterm portion of the trial ended. The entry criteria made it difficult to extrapolate study results to other populations, but infants were very sick with 25% mortality, and almost half had OI over 40 at enrolment.</P>
<P>
<LINK REF="STD-Gonzalez-2010" TYPE="STUDY">Gonzalez 2010</LINK>: This two-centre trial randomised near-term infants with OI between 10 and 30 to iNO at 20 ppm or to no iNO. All infants whose condition deteriorated to reach OI of 40 received iNO and could receive high-frequency ventilation; if already receiving iNO, investigators added high-frequency ventilation. ECMO in case of failure was not available. Randomisation was described only as sequenced sealed envelopes and may have been masked, but this is not certain. Investigators calculated the sample size on the basis of a very large predicted effect and achieved this goal. They did not mask the intervention.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Studies at higher risk of bias</HEADING>
<P>
<LINK REF="STD-Barefield-1996" TYPE="STUDY">Barefield 1996:</LINK> This very small study included somewhat unbalanced groups at enrolment; the mean OI at entry was 26 in the control group and 38 in the treatment group. Infants receiving iNO also appeared to have a lower pH (7.46 ± 0.06 vs 7.61 ± 0.07), higher partial pressure of arterial carbon dioxide (PaCO<SUB>2</SUB>) (40 ± 7 vs 28 ± 4 mmHg) and lower PaO<SUB>2</SUB> (49 ± 7 vs 63 ± 7 mmHg). Study authors did not clearly describe the study hypothesis. The sample size calculation required 24 participants per group, but the basis for this calculated sample size is not clear. Study authors did not explain why the study was discontinued before the calculated sample size was enrolled.</P>
<P>
<LINK REF="STD-Day-1996" TYPE="STUDY">Day 1996</LINK>: Study authors did not state how the sample size was calculated and reported no study hypothesis. The method of randomisation is unclear and was described as a 'blind draw'. Researchers reported the study objective as to "review the acute effects" of iNO.</P>
<P>
<LINK REF="STD-Wessel-1996" TYPE="STUDY">Wessel 1996</LINK>: This small single-centre study provided unmasked intervention and did not adequately describe allocation; review authors could not ascertain whether it was masked.</P>
<P>
<LINK REF="STD-Cornfield-1999" TYPE="STUDY">Cornfield 1999</LINK>: Study authors did not clearly describe the randomisation procedure, and masking of allocation is unclear. Study authors planned to enrol 60 participants. They planned an interim analysis at two-thirds of full enrolment to be performed blind. The study was terminated after this interim analysis (n = 38) because a secondary analysis (i.e. response to 20 ppm after failure of initial therapy) differed between groups. Early termination of this trial was the result of an unexpected finding with limited clinical significance, and no difference in clinically important outcomes seriously limited the power of this study.</P>
<P>
<LINK REF="STD-Christou-2000" TYPE="STUDY">Christou 2000</LINK>: This study included a limited sample size, as the study was terminated after <LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996</LINK> and <LINK REF="STD-Roberts-1996" TYPE="STUDY">Roberts 1996</LINK> reported results. Study authors did not explicitly state the hypothesis, and they listed study objectives as determining whether iNO improves oxygenation in infants given high-frequency ventilation; however, not all infants received this mode of ventilation.</P>
<P>
<LINK REF="STD-Liu-2008" TYPE="STUDY">Liu 2008</LINK>: This single-centre trial noted no prespecified sample size and is the only trial that restricted enrolment to infants with meconium aspiration syndrome; ECMO was not available as rescue therapy. The intervention was unmasked, and researchers provided little detail about the mechanics of randomisation.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-12-23 11:48:32 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1: iNO versus control (no iNO) in infants with hypoxic respiratory failure</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Outcome 1.1: Death or use of ECMO</HEADING>
<P>This outcome was reported by 10 trials (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Nine studies (<LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996</LINK>; <LINK REF="STD-Roberts-1996" TYPE="STUDY">Roberts 1996</LINK>; <LINK REF="STD-Wessel-1996" TYPE="STUDY">Wessel 1996</LINK>; <LINK REF="STD-Davidson-1997" TYPE="STUDY">Davidson 1997</LINK>; <LINK REF="STD-Ninos-1997" TYPE="STUDY">Ninos 1997</LINK>; <LINK REF="STD-Mercier-1998" TYPE="STUDY">Mercier 1998</LINK>; <LINK REF="STD-Christou-2000" TYPE="STUDY">Christou 2000</LINK>; <LINK REF="STD-Clark-2000" TYPE="STUDY">Clark 2000</LINK>; <LINK REF="STD-INNOVO-2007" TYPE="STUDY">INNOVO 2007</LINK>; <LINK REF="STD-Liu-2008" TYPE="STUDY">Liu 2008</LINK>) did not allow use of iNO in controls who did not respond. One of these trials (<LINK REF="STD-Liu-2008" TYPE="STUDY">Liu 2008</LINK>) did not have ECMO available; therefore, the frequency of death reported is equal to death or requirement for ECMO. One study gave the randomised intervention for only two hours before allowing iNO among controls (<LINK REF="STD-Mercier-1998" TYPE="STUDY">Mercier 1998</LINK>).</P>
<P>One study (<LINK REF="STD-Ninos-1997" TYPE="STUDY">Ninos 1997)</LINK> included infants with CDH and reported the CDH stratum of <LINK REF="STD-Roberts-1996" TYPE="STUDY">Roberts 1996</LINK> as a separate subgroup. Investigators reported all outcomes of this subgroup separately (see below).</P>
<P>Four studies (<LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996</LINK>; <LINK REF="STD-Christou-2000" TYPE="STUDY">Christou 2000</LINK>; <LINK REF="STD-Clark-2000" TYPE="STUDY">Clark 2000</LINK> and the non-CDH stratum of <LINK REF="STD-Roberts-1996" TYPE="STUDY">Roberts 1996</LINK>) found a statistically significant reduction in the combined outcome of death or requirement for ECMO. Meta-analysis of the eight trials in the subgroup without back-up iNO treatment and without participants with CDH revealed that iNO treatment resulted in a reduction in the incidence of death or requirement for ECMO (typical RR 0.66, 95% CI 0.57 to 0.77; eight studies, 859 infants; typical RD -0.18, 95% CI -0.25 to -0.12) (high-quality evidence) and showed little heterogeneity (I<SUP>2</SUP> = 21%). Sensitivity analysis revealed that exclusion of studies at higher risk of bias (<LINK REF="STD-Wessel-1996" TYPE="STUDY">Wessel 1996</LINK>; <LINK REF="STD-Liu-2008" TYPE="STUDY">Liu 2008</LINK>) had no effect on the risk ratio of this outcome but reduced heterogeneity (I<SUP>2</SUP>) to zero.</P>
<P>The study that allowed back-up iNO among controls (<LINK REF="STD-Mercier-1998" TYPE="STUDY">Mercier 1998</LINK>) did not report a significant effect for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome 1.2: Death before hospital discharge</HEADING>
<P>The same studies also reported death (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). None of the individual studies found a significant effect. Likewise, meta-analysis revealed no evidence of effect (typical RR 0.89, 95% CI 0.60 to 1.31; eight studies, 860 infants; typical RD -0.01, 95% CI -0.05 to 0.03) (high-quality evidence). On sensitivity analysis, after trials at high risk of bias were excluded, the RR was 0.93 and confidence intervals were wide.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome 1.3: Use of ECMO before hospital discharge</HEADING>
<P>Seven studies reported this outcome (<LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996</LINK>; <LINK REF="STD-Roberts-1996" TYPE="STUDY">Roberts 1996</LINK>; <LINK REF="STD-Wessel-1996" TYPE="STUDY">Wessel 1996</LINK>; <LINK REF="STD-Davidson-1997" TYPE="STUDY">Davidson 1997</LINK>; <LINK REF="STD-Christou-2000" TYPE="STUDY">Christou 2000</LINK>; <LINK REF="STD-Clark-2000" TYPE="STUDY">Clark 2000</LINK>; <LINK REF="STD-INNOVO-2007" TYPE="STUDY">INNOVO 2007</LINK>). Meta-analysis of results of these studies in this subgroup supported a significant effect (typical RR 0.60, 95% CI 0.50 to 0.71; seven studies, 815 infants; typical RD -0.20, 95% CI -0.27 to -0.14) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). Thus, the number needed to treat with iNO for an additional beneficial outcome (NNTB) to prevent one infant from requiring ECMO was 5 (95% CI 3.7 to 7.1) (high-quality evidence). On sensitivity analysis, exclusion of <LINK REF="STD-Wessel-1996" TYPE="STUDY">Wessel 1996</LINK> had no effect (<LINK REF="STD-Liu-2008" TYPE="STUDY">Liu 2008</LINK> did not have ECMO available).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome 1.4: Failure to improve oxygenation (PaO<SUB>2</SUB>)</HEADING>
<P>Two studies in this group reported this outcome (<LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996</LINK>; <LINK REF="STD-Roberts-1996" TYPE="STUDY">Roberts 1996</LINK>). Both trials reported a statistically significant benefit of iNO, with fewer infants failing to have improved oxygenation (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome 1.5: OI 30 to 60 minutes after the start of treatment</HEADING>
<P>Five studies reported this outcome (<LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996</LINK>; <LINK REF="STD-Roberts-1996" TYPE="STUDY">Roberts 1996</LINK>; <LINK REF="STD-Davidson-1997" TYPE="STUDY">Davidson 1997</LINK>; <LINK REF="STD-Clark-2000" TYPE="STUDY">Clark 2000</LINK>; <LINK REF="STD-Liu-2008" TYPE="STUDY">Liu 2008</LINK>) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) and found a statistically significant benefit of iNO. The results are remarkably homogeneous across studies. Meta-analysis shows that OI 30 to 60 minutes after therapy commenced was significantly lower in the iNO group (weighted mean difference -8.45, 95% CI -11.42 to -5.48; five studies, 709 infants). <LINK REF="STD-Christou-2000" TYPE="STUDY">Christou 2000</LINK> reported median changes in OI after 60 minutes of -18 in the iNO group and 0 in the control group. <LINK REF="STD-Mercier-1998" TYPE="STUDY">Mercier 1998</LINK> reported OI results at two hours after the start of treatment as median and interquartile ranges. Therefore, we cannot currently add these data to our analysis. However, the direction and magnitude of the effect of iNO were very similar: Among controls, median OI at baseline was 21.7 with little change at two hours (median 19.4), whereas in those given iNO, median OI at baseline was 25.9 and fell to 15.8 at two hours. The two-hour OI was significantly different between groups, as was the absolute change in OI (median -2.7 in the control group vs -7.8 in the iNO group).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome 1.6: PaO<SUB>2</SUB> 30 to 60 minutes after treatment</HEADING>
<P>Four studies reported this outcome (<LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996</LINK>; <LINK REF="STD-Roberts-1996" TYPE="STUDY">Roberts 1996</LINK>; <LINK REF="STD-Davidson-1997" TYPE="STUDY">Davidson 1997</LINK>; <LINK REF="STD-Clark-2000" TYPE="STUDY">Clark 2000</LINK>) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). All found statistically significant benefit of iNO. Study results are remarkably homogeneous. Meta-analysis shows that PaO<SUB>2</SUB> 30 to 60 minutes after treatment was statistically significantly higher in the iNO group (weighted mean difference 32.62 mmHg, 95% CI 23.56 to 41.67; five studies, 707 infants). <LINK REF="STD-Christou-2000" TYPE="STUDY">Christou 2000</LINK> reported median changes in PaO<SUB>2</SUB> of 53 mmHg in the iNO group and 2 mmHg in the control group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes 1.7: Change in OI after treatment; and 1.8: Change in PaO<SUB>2</SUB> after treatment</HEADING>
<P>Only the Ninos trials reported these outcomes; both showed substantial improvement in PaO<SUB>2</SUB> and decreased OI (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). For both outcomes, the change was statistically significant only among infants in the main trial who did not have congenital diaphragmatic hernia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes 1.9 to 1.13: Neurodevelopmental and other late outcomes</HEADING>
<P>Four studies reported these outcomes (<LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996</LINK>; <LINK REF="STD-Wessel-1996" TYPE="STUDY">Wessel 1996</LINK>; <LINK REF="STD-Davidson-1997" TYPE="STUDY">Davidson 1997</LINK>; <LINK REF="STD-Ninos-1997" TYPE="STUDY">Ninos 1997</LINK>) (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>; <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>; <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>; <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>). The <LINK REF="REF-Ninos-2000" TYPE="REFERENCE">Ninos 2000</LINK> publication reported neurodevelopmental outcomes from both <LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996</LINK> and <LINK REF="STD-Ninos-1997" TYPE="STUDY">Ninos 1997</LINK>, and <LINK REF="REF-Lipkin-2002" TYPE="REFERENCE">Lipkin 2002</LINK> reported outcomes of <LINK REF="STD-Davidson-1997" TYPE="STUDY">Davidson 1997</LINK>. <LINK REF="STD-Wessel-1996" TYPE="STUDY">Wessel 1996</LINK> reported neurodevelopmental outcomes obtained by telephone interview.</P>
<P>For survivors of <LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996</LINK>, investigators performed BSID II testing (n = 154), a neurological examination (n = 172) and hearing tests (n = 157). Results showed no significant differences in the occurrence of neurodevelopmental sequelae between iNO and control infants: 18/87 control infants and 19/85 iNO infants did not have normal neurological examination findings, and 9/87 controls compared with 10/85 iNO infants had cerebral palsy (CP). Investigators observed no differences in the occurrence of hearing impairment (defined as a threshold &gt; 40 db; 23/82 evaluated controls vs 24/75 evaluated iNO infants) nor in scores on the BSID (Mental Development Index (MDI) 87 ± 18.7 for control infants vs 85 ± 21.7 for iNO infants; Physical Development Index (PDI) 93.6 ± 17.5 for control infants vs 85.7 ± 21.2 for iNO infants). One or more neurodevelopmental disabilities occurred in 26/87 control infants compared with 29/85 iNO infants. The occurrence of seizures was less among iNO infants (13/87 control infants vs 4/85 iNO infants; P = 0.046). In addition, investigators reported no differences in requirements for later hospital readmission, use of home medications, apnoea monitors, home oxygen, use of gastrostomy tubes or requirement for speech therapy. Researchers did not report outcomes of all infant testing conducted in <LINK REF="STD-Ninos-1997" TYPE="STUDY">Ninos 1997 </LINK>and stated that they found no differences in the mean results of BSID examinations, and proportions with scores lower than 70 were similar.</P>
<P>Investigators from <LINK REF="STD-Davidson-1997" TYPE="STUDY">Davidson 1997</LINK> examined 35 control infants and 94 iNO-treated infants at an average of 13 months of age by performing a neurological examination - Bayley Scales of Infant Development (BSID) - and audiological assessment. The prevalence of CP, developmental delay (BSID scores &gt; 2 SD below the mean) and hearing impairment (defined as mild 25 to 50 db threshold, or severe &gt; 50 db) was not different between groups. The general health of infants in terms of hospitalisation and growth was not different between groups.</P>
<P>
<LINK REF="STD-Wessel-1996" TYPE="STUDY">Wessel 1996</LINK> used different scales and relied on a telephone interview to record outcome data. Researchers observed no differences in the developmental quotient calculated from the Motor and Social Development Scale of the 1981 Child Health Supplement to the National Health Interview Survey. The reliability, reproducibility and validity of this scale have received little attention. The number of infants with a quotient less than 70 was greater among the control group (4/25) than among the iNO group (0/35). Although cerebral palsy, visual disability and hearing and speech disabilities were reported, it is unclear how these terms were defined, and the incidence of overall neurological disability included seizures. Therefore, it is not possible for review authors to add any of these data to the meta-analysis, but they do appear to show no evidence of neurodevelopmental impairment due to iNO therapy. The study included an assessment of general and pulmonary health; 31% of iNO participants (n = 35) and 20% of control participants (n = 20) had required hospital readmission, and 14% of iNO participants and 24% of control participants were found to have reactive airways disease; neither of these events was statistically significant.</P>
<P>Definitions used by the Ninos group and by Lipkin and coworkers for the overall incidence of neurodevelopmental disability were dissimilar. The Ninos group reported the incidence of having one or more disabilities (CP, BSID MDI or PDI &lt; 2 SD, blindness or hearing impairment). <LINK REF="REF-Lipkin-2002" TYPE="REFERENCE">Lipkin 2002</LINK> reported the incidence of mild (one or two mild impairments, including mild neurological abnormalities and mild reduction in scores on the BSID - between 1 and 2 SDs below the mean) and severe impairments (CP, more than two mild impairments, or at least one severe impairment). If we proceed on the assumption that the definition of severe impairment in <LINK REF="REF-Lipkin-2002" TYPE="REFERENCE">Lipkin 2002</LINK> is similar enough to the Ninos definition of one or more neurodevelopmental disabilities for a combined analysis, we find no effect of iNO (typical RR of adverse outcomes 0.97, 95% CI 0.66 to 1.44) (low-quality evidence).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1, subgroup analysis: iNO versus control (no iNO) in infants with hypoxic respiratory failure (subgroup of infants with CDH)</HEADING>
<P>Infants with CDH do not appear to share the benefits of iNO; indeed it has been suggested that outcomes could be worse in infants with CDH who receive iNO compared with control infants. We have combined the results of <LINK REF="STD-Ninos-1997" TYPE="STUDY">Ninos 1997</LINK> with the diaphragmatic hernia stratum of <LINK REF="STD-Clark-2000" TYPE="STUDY">Clark 2000</LINK> - the only other study from which such information can be extrapolated.</P>
<SUBSECTION>
<HEADING LEVEL="4">Outcome 1.1.3: Death or requirement for ECMO in infants with CDH</HEADING>
<P>The incidence of death or requirement for ECMO was 40/46 control infants and 36/38 infants with iNO (RR 1.09, 95% CI 0.95 to 1.26; two studies, 84 infants; RD 0.08, 95% CI -0.04 to 0.20) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.3).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome 1.2.3: Death in infants with CDH</HEADING>
<P>Mortality rate was not changed: 18/46 control infants compared with 18/38 infants with iNO (RR 1.20, 95% CI 0.74 to 1.96; two studies, 84 infants; RD 0.08, 95% CI -0.13 to 0.29) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.3).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome 1.3.2: Requirement for ECMO in infants with CDH</HEADING>
<P>Results showed a barely significant increase in the requirement for ECMO: 31/46 control infants compared with 32/38 infants with iNO (RR 1.27, 95% CI 1.00 to 1.62; two studies, 84 infants; RD 0.18, 95% CI 0.01 to 0.35) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>.2). This occurred despite the fact that infants with CDH who received iNO were more likely to improve their oxygenation (data from <LINK REF="STD-Ninos-1997" TYPE="STUDY">Ninos 1997</LINK> only; all control infants failed to improve oxygenation compared with 20/24 iNO infants; RR of failure to improve oxygenation 0.83, 95% CI, 0.70 to 1.00). The mean difference in PaO<SUB>2</SUB>, however, was small and was not statistically significant. PaO<SUB>2</SUB> 30 minutes after treatment increased by 7.8 mmHg in iNO infants compared with 1.1 mmHg in control infants (MD 6.7, 95% CI 15.7 to -2.3), and OI decreased by 2.7 in iNO infants compared with an increase of 4.0 among control infants (MD -6.70, 95% CI -18.39 to +4.99).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes 1.10.2 and 1.11.2: Neurodevelopmental outcomes in infants with CDH</HEADING>
<P>Survivors with CDH (from the <LINK REF="STD-Ninos-1997" TYPE="STUDY">Ninos 1997</LINK> study) had comparable neurodevelopmental outcomes at follow-up. Mean BSID MDI among controls was 73.6 (SD 18) and PDI was 77.2 (SD 14.4); among iNO-treated infants, mean MDI was 69.1 (SD 17) and PDI was 75.8 (SD 25.8). Both control infants and iNO infants had a high rate of sensorineural hearing loss (4/14 control infants vs 3/8 iNO infants) (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>.2).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 2. iNO started for moderate compared with severe disease criteria</HEADING>
<P>All five trials included in this group all showed no incremental benefit for death or requirement for ECMO when iNO was started earlier.</P>
<SUBSECTION>
<HEADING LEVEL="4">Outcome 2.1: Death or use of ECMO</HEADING>
<P>The RR of death or ECMO was 0.88 (95% CI 0.62 to 1.27; five studies, 495 infants; RD -0.02, 95% CI -0.09 to 0.04). On sensitivity analysis, when data from Barefield and Cornfield were excluded, leaving only the results of Konduri, Gonzalez and Sadiq, review authors found no effect on the conclusion of effect (RR 0.83, 95% CI 0.54 to 1.2) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome 2.2: Death before hospital discharge</HEADING>
<P>The RR of death with earlier treatment was 0.69 (95% CI 0.38 to 1.26; five studies, 495 infants; RD -0.03, 95% CI -0.08 to 0.02). On sensitivity analysis, we found no impact on the conclusion of no effect (RR 0.70, 95% CI 0.34 to 1.43) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome 2.3: Use of ECMO before hospital discharge</HEADING>
<P>Four studies reported the requirement for ECMO (ECMO was not available for infants during <LINK REF="STD-Gonzalez-2010" TYPE="STUDY">Gonzalez 2010</LINK>). The RR for needing ECMO was 1.01 (95% CI 0.66 to 1.54; four studies, 439 infants; RD 0.00, 95% CI -0.06 to 0.06). On sensitivity analysis, we found that the RR for needing ECMO, after studies at higher risk of bias were excluded, was 0.90 (95% CI 0.52 to 1.58) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome 2.4: Progression to severe disease criteria</HEADING>
<P>Treatment at lower disease severity appears to prevent progression to severe disease (i.e. fewer iNO participants progressed to satisfying rescue or severe disease criteria compared with control infants; RR 0.66, 95% CI 0.55 to 0.79; six studies, 512 infants; RD -0.20, 95% CI -0.28 to -0.12). On sensitivity analysis, we found that the RR was 0.59 (95% CI 0.48 to 0.74) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome 2.5: Chronic lung disease</HEADING>
<P>
<LINK REF="STD-Gonzalez-2010" TYPE="STUDY">Gonzalez 2010</LINK>, <LINK REF="STD-Konduri-2004" TYPE="STUDY">Konduri 2004</LINK> and <LINK REF="STD-Sadiq-1998" TYPE="STUDY">Sadiq 1998</LINK> reported frequency of requiring oxygen at 28 days of age. Early iNO confers no advantage over late iNO for this outcome (RR 0.91, 95% CI 0.54 to 1.53; three studies, 437 infants; RD -0.01, 95% CI -0.07 to 0.05).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes 2.6 to 2.8: Neurodevelopmental outcomes</HEADING>
<P>One study reported longer-term neurodevelopmental outcomes (<LINK REF="STD-Konduri-2004" TYPE="STUDY">Konduri 2004</LINK>). Analysis revealed no difference in frequency of neurological impairment or developmental delay at 18 to 24 months of age (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>), hearing loss requiring amplification (<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>), nor grades of cerebral palsy (<LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>). Investigators showed no difference in severe CP but a lower BSID PDI score at 18 months among infants who received iNO early.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other possibly important outcomes</HEADING>
<P>
<LINK REF="STD-Gonzalez-2010" TYPE="STUDY">Gonzalez 2010</LINK>, <LINK REF="STD-Konduri-2004" TYPE="STUDY">Konduri 2004</LINK> and <LINK REF="STD-Sadiq-1998" TYPE="STUDY">Sadiq 1998</LINK> reported duration of mechanical ventilation and duration of oxygen therapy in the two groups. Konduri and Sadiq also reported duration of hospitalisation. Gonzalez reported outcomes as median and range, Konduri as median and interquartile range and Sadiq as mean and standard deviation. Therefore, meta-analysis cannot be performed, but we have tabulated the results (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 3. iNO versus high-frequency ventilation in infants with hypoxic respiratory failure</HEADING>
<P>Only one study compared iNO versus high-frequency ventilation. <LINK REF="STD-Kinsella-1997" TYPE="STUDY">Kinsella 1997</LINK> found that 23% of infants treated with high-frequency ventilation compared with 28% treated with iNO had a successful response, defined as PaO<SUB>2</SUB> greater than 60 mmHg. After cross-over, 21% of 75 infants with high-frequency ventilation failure responded to iNO, whereas 14% of 77 infants with iNO failure responded to high-frequency ventilation (not significant). This study demonstrated that response to iNO was equivalent to response to high-frequency ventilation among near-term infants with hypoxic respiratory failure. Study authors evaluated infants who failed to respond to either therapy singly (n = 125) and found that 32% responded to the combination. Study authors concluded that the combination of high-frequency ventilation and iNO was the most effective therapy for infants who failed to respond to either treatment alone. This study suggests that use of high-frequency ventilation may be valuable in establishing adequate lung volumes in such a way that iNO therapy may then be efficacious.</P>
<P>As all infants were eligible to receive iNO during preparation of the protocol, this study is not informative for the outcome of death or ECMO. As this is the only study included in this group, we have not performed any meta-analysis.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-12-12 19:59:33 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Main results</HEADING>
<P>First, use of inhaled nitric oxide (iNO) at doses of 10 to 80 ppm is supported by studies that enrolled near-term, hypoxic, mechanically ventilated neonates with an oxygenation index (OI) of 25 or greater, or partial pressure of arterial oxygen (PaO<SUB>2</SUB>) less than 100 mmHg in 100% oxygen. Use of iNO in these circumstances decreases the need for extracorporeal membrane oxygenation (ECMO). All but one of the trials that compared iNO versus no iNO had ECMO available for participants who were failing, and no effect on mortality was evident. One very small trial from China (<LINK REF="STD-Liu-2008" TYPE="STUDY">Liu 2008</LINK>), which had no ECMO available, showed a small reduction in mortality, which may have been due to chance. ECMO is invasive and expensive and is associated with clinically important complications. Therefore, a reduction in ECMO requirement with less invasive and safer treatment provides benefit for patients. However, reviewed trials showed significant differences with respect to the use of other therapies, such as high-frequency ventilation or surfactant. <LINK REF="STD-Ninos-1996" TYPE="STUDY">Ninos 1996,</LINK> <LINK REF="STD-Ninos-1997" TYPE="STUDY">Ninos 1997,</LINK> <LINK REF="STD-Day-1996" TYPE="STUDY">Day 1996</LINK> and <LINK REF="STD-Wessel-1996" TYPE="STUDY">Wessel 1996</LINK> allowed both treatments, <LINK REF="STD-Clark-2000" TYPE="STUDY">Clark 2000</LINK> "encouraged" both treatments, whereas others proscribed such management or excluded infants who received such treatments (<LINK REF="STD-Barefield-1996" TYPE="STUDY">Barefield 1996</LINK> proscribed both; <LINK REF="STD-Roberts-1996" TYPE="STUDY">Roberts 1996</LINK> disallowed high-frequency ventilation; <LINK REF="STD-Davidson-1997" TYPE="STUDY">Davidson 1997</LINK> excluded infants who received surfactant therapy and did not allow concurrent high-frequency ventilation).</P>
<P>Second, studies that enrolled infants at moderate disease severity and randomised them to immediate iNO, or to iNO only if their condition deteriorated, showed no incremental benefit of giving iNO earlier, even if infants receiving earlier iNO were less likely to experience a deterioration in their oxygenation.</P>
<P>Third, the <LINK REF="REF-Ninos-2000" TYPE="REFERENCE">Ninos 2000</LINK> publication provides reassuring information regarding long-term neurodevelopmental outcomes and demonstrates that infants who receive iNO are not at increased risk of neurodevelopmental sequelae, consistent with the observations of Rosenberg and coworkers (<LINK REF="REF-Rosenberg-1997" TYPE="REFERENCE">Rosenberg 1997</LINK>), and did not experience increased postdischarge pulmonary complications, consistent with the report of Dobyns and coworkers (<LINK REF="REF-Dobyns-1999" TYPE="REFERENCE">Dobyns 1999</LINK>).</P>
<P>Fourth, clinical or echocardiographic evidence of pulmonary hypertension was not universally present in all reported trials; therefore, use of iNO should be considered for near-term infants with hypoxic respiratory failure, with or without clear evidence of pulmonary hypertension. Inhaled NO can improve ventilation/perfusion mismatching and may improve oxygenation by this mechanism in infants without documented pulmonary hypertension.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Limits/toxicity issues</HEADING>
<P>Nitric oxide reacts with oxygen to form nitrogen dioxide (NO<SUB>2</SUB>). Both NO and NO<SUB>2</SUB> are toxic, causing death in dogs at concentrations between 0.1% and 2% due to methaemoglobinaemia, hypoxaemia and pulmonary edema (<LINK REF="REF-Greenbaum-1967" TYPE="REFERENCE">Greenbaum 1967</LINK>). In humans, exposure to 2.3 ppm NO<SUB>2</SUB> for five hours produced a 14% decrease in serum glutathione peroxidase activity and a 22% decrease in alveolar permeability 11 hours after the start of exposure, suggesting that even very low concentrations of NO<SUB>2</SUB> may produce a delayed response (<LINK REF="REF-Rasmussen-1992" TYPE="REFERENCE">Rasmussen 1992</LINK>). Occupational health guidelines set 25 ppm as the limit for eight hours/day NO exposure in the workplace, and 3 ppm (measured as the time-weighted average) as the limit for NO<SUB>2</SUB> (<LINK REF="REF-MMWR-1988" TYPE="REFERENCE">MMWR 1988</LINK>). It has been demonstrated that using 80 ppm iNO in a neonatal ventilator with fraction of inspired oxygen (FiO<SUB>2</SUB>) of 0.9 could produce 5 ppm NO<SUB>2</SUB> in less than 20 seconds (<LINK REF="REF-Bouchet-1993" TYPE="REFERENCE">Bouchet 1993</LINK>). Ongoing monitoring of inhaled gas for NO<SUB>2</SUB> is therefore mandatory.</P>
<P>The condition of infants receiving iNO, even those who have not demonstrated a positive response, may deteriorate when iNO is discontinued. Davidson and coworkers (<LINK REF="REF-Davidson-1999" TYPE="REFERENCE">Davidson 1999</LINK>) reviewed the results of their previous trial (<LINK REF="STD-Davidson-1997" TYPE="STUDY">Davidson 1997</LINK>) and reported a 42 ± 101% increase in OI when iNO was withdrawn from participants who did not demonstrate a positive response to iNO. They reported that minimising the iNO dose to 1 ppm before discontinuation was associated with the least deterioration, so it appears that this practice should be followed for infants who are being weaned from iNO, regardless of their initial response.</P>
<P>Methaemoglobin levels must also be carefully monitored, and significant methaemoglobinaemia has been reported after accidental overdose of a neonate with &gt; 135 ppm of iNO (<LINK REF="REF-Heal-1995" TYPE="REFERENCE">Heal 1995</LINK>). Long-term treatment (up to 23 days for a newborn, 53 days for an adult) has not been shown to increase toxicity. When NO reacts with superoxide, peroxynitrite is rapidly formed, and this can result in membrane lipid peroxidation (<LINK REF="REF-Beckman-1990" TYPE="REFERENCE">Beckman 1990</LINK>). No information is available to date with respect to the actual formation of such peroxynitrites in human patients receiving iNO, but the potential remains for resultant tissue injury, especially in the lung, with damage to surfactant and its related proteins (<LINK REF="REF-Haddad-1993" TYPE="REFERENCE">Haddad 1993</LINK>). NO inhibits platelet aggregation and adhesion and in this way plays an important role in vascular homeostasis (<LINK REF="REF-Radomski-1993" TYPE="REFERENCE">Radomski 1993</LINK>). Although it is believed that iNO does not exert systemic effects because of the previously mentioned interaction with haemoglobin, Hogman and coworkers have reported increased bleeding times in rabbits and humans exposed to 30 ppm of iNO (<LINK REF="REF-Hogman-1993" TYPE="REFERENCE">Hogman 1993</LINK>; <LINK REF="REF-Hogman-1994" TYPE="REFERENCE">Hogman 1994</LINK>).</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-12-12 19:54:07 -0500" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-12-12 19:54:07 -0500" MODIFIED_BY="[Empty name]">
<P>On the basis of currently available information, iNO has been established as effective therapy for near-term and term infants with hypoxic respiratory failure unresponsive to other therapy, with the possible exclusion of infants with congenital diaphragmatic hernia. Its use reduces the need for ECMO (with number needed to treat for an additional beneficial outcome (NNTB) of 5.3), and it appears to be the only selective pulmonary vasodilator for which proof of efficacy is available.</P>
<P>Lack of effect on systemic haemodynamics, coupled with relative safety of administration when appropriately monitored, and lack of significant longer-term neurodevelopmental sequelae support the use of iNO in preference to other vasodilators.</P>
<P>It appears to be appropriate to institute therapy for those who are severely ill (with OI &#8805; 25, or PaO<SUB>2</SUB> &lt; 100 mmHg in 100% oxygen); commencing therapy earlier does not appear to further reduce ECMO requirements or mortality (however, some uncertainty surrounds this, as confidence intervals of the RR are very wide (0.61 to 1.24)). Instituting therapy at lower severity of illness criteria may prevent progression to higher disease severity.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-12-12 07:08:59 -0500" MODIFIED_BY="[Empty name]">
<P>Additional studies with untreated control groups in term and near-term infants with hypoxic respiratory failure would not be ethically acceptable.</P>
<P>Comparative trials with other active agents, or with different doses of iNO, may be valuable. Indeed, the minimal effective dose remains unclear. <LINK REF="REF-Finer-2001" TYPE="REFERENCE">Finer 2001</LINK> suggested that starting treatment at 2 ppm was as effective as starting treatment at higher concentrations, whereas <LINK REF="STD-Cornfield-1999" TYPE="STUDY">Cornfield 1999</LINK> suggested that starting treatment at 2 ppm was not effective in preventing deterioration. This discrepancy warrants further investigation by an adequately powered study.</P>
<P>Moreover, treating at less severe criteria for poor oxygenation has not been shown to improve mortality or ECMO requirements, or other reported clinical outcomes, compared with waiting to see whether the patient's condition deteriorates. However, substantial uncertainty remains regarding effects on death or ECMO, with 95% confidence intervals including the possibility of a 40% reduction in death or ECMO, or a 25% increase. Also, earlier treatment may prevent disease progression, and long-term outcomes could be affected by preventing more severe illness. This should be further investigated.</P>
<P>Finally, other unanswered questions include the following: Does pretreatment with surfactant improve response to iNO in humans (as it appears to in some animal models)? Is iNO safer and more effective than other vasodilators delivered by inhalation such as inhaled prostacyclin?</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-07-19 14:17:27 -0400" MODIFIED_BY="[Empty name]">
<P>We are very grateful for the translation from Chinese of the article by <LINK REF="STD-Liu-2008" TYPE="STUDY">Liu 2008</LINK>, provided by Dr David Corpman.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-12-12 07:12:08 -0500" MODIFIED_BY="[Empty name]">
<P>Dr Barrington was chair of the iNO Therapeutics Canadian Medical Advisory Committee for a single meeting, for which he received expenses and an honorarium.<BR/>Dr Finer previously served as a member of the iNO Therapeutics Advisory Committee.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-12-12 07:11:43 -0500" MODIFIED_BY="[Empty name]">
<P>The original protocol was written by Drs Finer and Barrington, and both review authors equally completed each revision of the review. All four review authors have edited the latest revision of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-12-12 07:12:47 -0500" MODIFIED_BY="[Empty name]">
<P>The original protocol did not divide trials into the three groups now presented in the review. The original protocol and review did not include GRADE recommendations and Summary of findings tables.</P>
<P>Review authors added the following outcomes post hoc (reported in trials but not prespecified): change in oxygenation index after treatment, change in PaO<SUB>2</SUB> after treatment, chronic lung disease.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-01-03 14:40:29 +0000" MODIFIED_BY="Colleen Ovelman">
<STUDIES MODIFIED="2016-12-18 20:56:13 -0500" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2016-12-18 20:56:13 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Barefield-1996" NAME="Barefield 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Barefield ES, Karke VA, Phillips JB, Carlo WA. Inhaled nitric oxide in term infants with hypoxemic respiratory failure. J Pediatr 1996;129:279-86.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Barefield ES, Karke VA, Phillips JB, Carlo WA</AU>
<TI>Inhaled nitric oxide in term infants with hypoxemic respiratory failure</TI>
<SO>Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>129</VL>
<PG>279-86</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359203"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Barefield ES, Karke VA, Phillips JB, Carlo WA. Randomized, controlled trial of inhaled NO in ECMO candidates. Pediatr Res 1995;37:195A.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barefield ES, Karke VA, Phillips JB, Carlo WA</AU>
<TI>Randomized, controlled trial of inhaled NO in ECMO candidates</TI>
<SO>Pediatric Research</SO>
<YR>1995</YR>
<VL>37</VL>
<PG>195A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359204"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3359202"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christou-2000" MODIFIED="2016-12-12 18:15:20 -0500" MODIFIED_BY="[Empty name]" NAME="Christou 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-12-12 18:15:20 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christou H, Van Marter LJ, Wessel DL, Allred EN, Kane JW, Thompson JE et al</AU>
<TI>Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn</TI>
<SO>Critical Care Medicine</SO>
<YR>2000</YR>
<VL>28</VL>
<PG>3722-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359206"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3359205"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clark-2000" MODIFIED="2016-12-12 18:15:38 -0500" MODIFIED_BY="[Empty name]" NAME="Clark 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-12-12 18:15:38 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clark RH, Keuser TJ, Walker MW, Southgate MS, Huckaby JL, Perez JA et al; for the Clinical Inhaled Nitric Oxide Research Group</AU>
<TI>Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>342</VL>
<PG>469-74</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359208"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3359207"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cornfield-1999" NAME="Cornfield 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cornfield DN, Maynard RC, deRegnier RA, Guiang SF 3rd, Barbato JE, Milla CE</AU>
<TI>Randomized, controlled trial of low-dose inhaled nitric oxide in the treatment of term and near-term infants with respiratory failure and pulmonary hypertension</TI>
<SO>Pediatrics</SO>
<YR>1999</YR>
<VL>104</VL>
<PG>1089-94</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359210"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3359209"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-1997" MODIFIED="2016-12-12 18:16:49 -0500" MODIFIED_BY="[Empty name]" NAME="Davidson 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-12-12 18:16:49 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask, M, Straube R, Rhines J, Chang CT.Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. Pediatrics 1998;101:325-334.&lt;/p&gt;" NOTES_MODIFIED="2016-12-12 18:16:49 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R et al</AU>
<TI>Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study</TI>
<SO>Pediatrics</SO>
<YR>1998</YR>
<VL>101</VL>
<PG>325-34</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359213"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-12 18:16:25 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R, Rhines J, and I-NO/PPHN study group. A double masked, randomized, placebo controlled, dose response study of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn. Pediatr Res 1997;41:144A(abstract).&lt;/p&gt;" NOTES_MODIFIED="2016-12-12 18:16:25 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R et al; I-NO/PPHN Study Group</AU>
<TI>A double masked, randomized, placebo controlled, dose response study of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn</TI>
<SO>Pediatric Research</SO>
<YR>1997</YR>
<VL>41</VL>
<PG>144A (abstract)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359212"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3359211"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Day-1996" NAME="Day 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Day RW, Lynch JM, White KS, Ward RM</AU>
<TI>Acute response to inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension</TI>
<SO>Pediatrics</SO>
<YR>1996</YR>
<VL>98</VL>
<PG>698-705</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359215"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Day RW, Lynch JM. Acute hemodynamic and blood gas effects of Inhaled Nitric Oxide in newborns with lung disease and pulmonary hypertension. Pediatr Res 1996;39:330A.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Day RW, Lynch JM</AU>
<TI>Acute hemodynamic and blood gas effects of inhaled nitric oxide in newborns with lung disease and pulmonary hypertension</TI>
<SO>Pediatric Research</SO>
<YR>1996</YR>
<VL>39</VL>
<PG>330A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359216"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3359214"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonzalez-2010" MODIFIED="2016-12-12 18:17:18 -0500" MODIFIED_BY="[Empty name]" NAME="Gonzalez 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-12-12 18:17:18 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez A, Fabres J, D'Apremont I, Urcelay G, Avaca M, Gandolfi C et al</AU>
<TI>Randomized controlled trial of early compared with delayed use of inhaled nitric oxide in newborns with a moderate respiratory failure and pulmonary hypertension</TI>
<SO>Journal of Perinatology</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>6</NO>
<PG>420-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359218"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3359217"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-INNOVO-2007" MODIFIED="2016-12-12 18:17:39 -0500" MODIFIED_BY="[Empty name]" NAME="INNOVO 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-12-12 18:17:39 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Field D, Elbourne D, Hardy P, Fenton AC, Ahluwalia J, Halliday HL et al; INNOVO Trial Collaborating Group</AU>
<TI>Neonatal ventilation with inhaled nitric oxide vs. ventilatory support without inhaled nitric oxide for infants with severe respiratory failure born at or near term: the INNOVO multicentre randomised controlled trial</TI>
<SO>Neonatology</SO>
<YR>2007</YR>
<VL>91</VL>
<NO>2</NO>
<PG>73-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359220"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3359219"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinsella-1997" MODIFIED="2016-12-12 18:18:22 -0500" MODIFIED_BY="[Empty name]" NAME="Kinsella 1997" YEAR="1996">
<REFERENCE MODIFIED="2016-12-12 18:18:07 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Kinsella JP, Truog WE, Walsh WF, Goldberg RN, Bancalari E, Clark RH, Mayock DE, Redding GJ, deLemos RA, Sardesai S, McCurnin DC, Yoder BA, Moreland SG, Cutter GR, Abman SH. Randomized, multicenter trial of inhaled nitric oxide and high frequency ventilation in severe persistent pulmonary hypertension of the newborn. Pediatr Res 1996;39:222A.&lt;/p&gt;" NOTES_MODIFIED="2016-12-12 18:18:07 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinsella JP, Truog WE, Walsh WF, Goldberg RN, Bancalari E, Clark RH et al</AU>
<TI>Randomized, multicenter trial of inhaled nitric oxide and high frequency ventilation in severe persistent pulmonary hypertension of the newborn</TI>
<SO>Pediatric Research</SO>
<YR>1996</YR>
<VL>39</VL>
<PG>222A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359222"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-12 18:18:22 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Kinsella JP, Truog WE, Walsh WF, Goldberg RN, Bancalari EE, Mayock DE, et al. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr 1997;131:55-62.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2016-12-12 18:18:22 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kinsella JP, Truog WE, Walsh WF, Goldberg RN, Bancalari EE, Mayock DE et al</AU>
<TI>Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn</TI>
<SO>Journal of Pediatrics</SO>
<YR>1997</YR>
<VL>131</VL>
<PG>55-62</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359223"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3359221"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Konduri-2004" MODIFIED="2016-12-12 18:19:03 -0500" MODIFIED_BY="[Empty name]" NAME="Konduri 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-12-12 18:18:36 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Konduri GG, Solimano A, Sokol GM, Singer J, Ehrenkranz RA, Singhal N et al; Neonatal Inhaled Nitric Oxide Study Group</AU>
<TI>A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure</TI>
<SO>Pediatrics</SO>
<YR>2004</YR>
<VL>113</VL>
<NO>3 Pt 1</NO>
<PG>559-64</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359225"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-12 18:19:03 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Konduri GG, Vohr B, Robertson C, Sokol GM, Solimano A, Singer J et al</AU>
<TI>Early inhaled nitric oxide therapy for term and near-term newborn infants with hypoxic respiratory failure: neurodevelopmental follow-up</TI>
<SO>Journal of Pediatrics</SO>
<YR>2007</YR>
<VL>150</VL>
<NO>3</NO>
<PG>235-40.e1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359226"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3359224"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2008" MODIFIED="2016-12-12 18:19:32 -0500" MODIFIED_BY="[Empty name]" NAME="Liu 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-12-12 18:19:32 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu CQ, Ma L, Tang LM, He XJ, Wei SF, Wang SX et al</AU>
<TI>A randomized controlled study on the efficacy of inhaled nitric oxide in treatment of neonates with meconium aspiration syndrome</TI>
<SO>Zhonghua Er Ke za Zhi [Chinese Journal of Pediatrics]</SO>
<YR>2008</YR>
<VL>46</VL>
<NO>3</NO>
<PG>224-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359228"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3359227"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mercier-1998" MODIFIED="2016-12-12 18:19:48 -0500" MODIFIED_BY="[Empty name]" NAME="Mercier 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-12-12 18:19:48 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Franco-Belgium Collaborative NO Trial Group</AU>
<TI>Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<PG>1066-71</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359230"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Mercier JC, Dehan M, Breart G, Clement S, O'Nody P. Inhaled nitric oxide in neonatal respiratory failure. Pediatr Res 1998;43:290A.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mercier JC, Dehan M, Breart G, Clement S, O'Nody P</AU>
<TI>Inhaled nitric oxide in neonatal respiratory failure</TI>
<SO>Pediatric Research</SO>
<YR>1998</YR>
<VL>43</VL>
<PG>290A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359231"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3359229"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Ninos-1996" MODIFIED="2016-12-12 18:20:17 -0500" MODIFIED_BY="[Empty name]" NAME="Ninos 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-08-22 13:19:06 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;The Neonatal inhaled nitric oxide Study Group: Inhaled nitric oxide in full-term and nearly full term infants with hypoxic respiratory failure. N Engl J Med 1997;336:597-604.&lt;/p&gt;" NOTES_MODIFIED="2008-08-22 13:19:06 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>The Neonatal Inhaled Nitric Oxide Study Group</AU>
<TI>Inhaled nitric oxide in full-term and nearly full term infants with hypoxic respiratory failure</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>336</VL>
<PG>597-604</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359233"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-12 18:20:17 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Neonatal Inhaled Nitric Oxide Study Group</AU>
<TI>Inhaled nitric oxide in term and near-term infants: neurodevelopmental follow-up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS)</TI>
<SO>Journal of Pediatrics</SO>
<YR>2000</YR>
<VL>136</VL>
<PG>611-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359234"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3359232"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Ninos-1997" MODIFIED="2016-12-12 18:20:39 -0500" MODIFIED_BY="[Empty name]" NAME="Ninos 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics 1997;99:838-845.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>The Neonatal Inhaled Nitric Oxide Study Group</AU>
<TI>Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia</TI>
<SO>Pediatrics</SO>
<YR>1997</YR>
<VL>99</VL>
<PG>838-45</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359236"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-12 18:20:39 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Neonatal Inhaled Nitric Oxide Study Group</AU>
<TI>Inhaled nitric oxide in term and near-term infants: neurodevelopmental follow-up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS)</TI>
<SO>Journal of Pediatrics</SO>
<YR>2000</YR>
<VL>136</VL>
<PG>611-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359237"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3359235"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roberts-1996" MODIFIED="2016-12-12 18:21:43 -0500" MODIFIED_BY="[Empty name]" NAME="Roberts 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-12-12 18:21:43 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Roberts JD Jr., Fineman J, Morin FC III, Shaul PW, Rimar S, Schreiber MD, Polin RA, Zwass MS, Zayek MM, Gross I, Heymann MA, Zapol WM. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med 1997;336:605-610.&lt;/p&gt;" NOTES_MODIFIED="2016-12-12 18:21:43 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Roberts JD Jr, Fineman J, Morin FC III, Shaul PW, Rimar S, Schreiber MD et al</AU>
<TI>Inhaled nitric oxide and persistent pulmonary hypertension of the newborn</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>336</VL>
<PG>605-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359240"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-12 18:21:23 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Roberts JD Jr., Fineman J, Morin FC III, Shaul PW, Rimar S, Schreiber MD, Polin RA, Thusu KG, Zayek M, Zwass MS, Zellers TM, Wylam ME, Gross I, Zapol WM, Heymann MA. Inhaled nitric oxide gas improves oxygenation in PPHN. Pediatr Res 1996;39:241A.&lt;/p&gt;" NOTES_MODIFIED="2016-12-12 18:21:23 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roberts JD Jr, Fineman J, Morin FC III, Shaul PW, Rimar S, Schreiber MD et al</AU>
<TI>Inhaled nitric oxide gas improves oxygenation in PPHN</TI>
<SO>Pediatric Research</SO>
<YR>1996</YR>
<VL>39</VL>
<PG>241A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359239"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3359238"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sadiq-1998" MODIFIED="2016-12-12 18:22:08 -0500" MODIFIED_BY="[Empty name]" NAME="Sadiq 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-12-12 18:22:08 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Sadiq FH, Illinois multicenter trial. Treatment of persistent pulmonary hypertension of the newborn with nitric oxide: a randomized trial. Pediatr Res 1998;43:192A.&lt;/p&gt;" NOTES_MODIFIED="2016-12-12 18:22:08 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sadiq FH; Illinois Multicenter Trial</AU>
<TI>Treatment of persistent pulmonary hypertension of the newborn with nitric oxide: a randomized trial</TI>
<SO>Pediatric Research</SO>
<YR>1998</YR>
<VL>43</VL>
<PG>192A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359242"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sadiq HF, Mantych G, Benawra RS, Devaskar UP, Hocker JR</AU>
<TI>Inhaled nitric oxide in the treatment of moderate persistent pulmonary hypertension of the newborn: a randomized controlled, multicenter trial</TI>
<SO>Journal of Perinatology</SO>
<YR>2003</YR>
<VL>23</VL>
<PG>98-103</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359243"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3359241"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wessel-1996" MODIFIED="2016-12-18 20:56:13 -0500" MODIFIED_BY="[Empty name]" NAME="Wessel 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-12-12 18:23:08 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ellington M, O'Reilly D, Allred EN, McCormick MC, Wessel DL, Kourembanas S</AU>
<TI>Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn</TI>
<SO>Pediatrics</SO>
<YR>2001</YR>
<VL>107</VL>
<PG>1351-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359245"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-12 18:23:27 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Wessel D, Adatia I, Thompson J, Kane J, Van Marter L, Stark A, Kourembanas S. Improved oxygenation in a randomized trial of inhaled nitric oxide for PPHN. Pediatr Res 1996;39:252A.&lt;/p&gt;" NOTES_MODIFIED="2016-12-12 18:23:27 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wessel D, Adatia I, Thompson J, Kane J, Van Marter L, Stark A et al</AU>
<TI>Improved oxygenation in a randomized trial of inhaled nitric oxide for PPHN</TI>
<SO>Pediatric Research</SO>
<YR>1996</YR>
<VL>39</VL>
<PG>252A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359246"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-18 20:56:13 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Wessel DL, Adatia I, Van Marter LJ, Thompson JE, Kane JW, Stark AR, Kourembanas S. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics 1997;100. URL http://www.pediatrics.org/cgi/content/full/100/5/e7&lt;/p&gt;" NOTES_MODIFIED="2016-12-18 20:56:13 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wessel DL, Adatia I, Van Marter LJ, Thompson JE, Kane JW, Stark AR et al</AU>
<TI>Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn</TI>
<SO>Pediatrics</SO>
<YR>1997</YR>
<VL>100</VL>
<NO>5</NO>
<PG>e7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359247"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3359244"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-10-17 14:34:21 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Hoffman-1997" MODIFIED="2014-10-17 14:34:21 -0400" MODIFIED_BY="[Empty name]" NAME="Hoffman 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-10-17 14:34:21 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Hoffman GM, Ross GA, Day SE, Rice TB, Nelin LD. Inhaled nitric oxide reduces the utilization of extracoropreal membrane oxygenation in persistent pulmonary hypertension of the newborn. Crit Care Med 1997;25:352-359.&lt;/p&gt;" NOTES_MODIFIED="2014-10-17 14:34:21 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoffman GM, Ross GA, Day SE, Rice TB, Nelin LD</AU>
<TI>Inhaled nitric oxide reduces the utilization of extracorporeal membrane oxygenation in persistent pulmonary hypertension of the newborn</TI>
<SO>Critical Care Medicine</SO>
<YR>1997</YR>
<VL>25</VL>
<PG>352-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359249"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3359248"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pinheiro-1998" NAME="Pinheiro 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Pinheiro JMB, Carey T. Inhaled NO vs. intravenous nitroprusside in neonatal pulmonary hypertension: randomized trial at a center without ECMO. Pediatr Res 1998;43:294A.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pinheiro JMB, Carey T</AU>
<TI>Inhaled NO vs. intravenous nitroprusside in neonatal pulmonary hypertension: randomized trial at a center without ECMO</TI>
<SO>Pediatric Research</SO>
<YR>1998</YR>
<VL>43</VL>
<PG>294A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3359251"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3359250"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-12-12 18:31:12 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2016-12-12 18:31:12 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abman-1990" NAME="Abman 1990" NOTES="&lt;p&gt;Abman SH, Chatfield BA, Hall SL, McMurtry IF. Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. Am J Physiol 1990;259:H1921-H1927.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Abman SH, Chatfield BA, Hall SL, McMurtry IF</AU>
<TI>Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth</TI>
<SO>American Journal of Physiology</SO>
<YR>1990</YR>
<VL>259</VL>
<PG>H1921-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beckman-1990" MODIFIED="2016-12-12 18:25:59 -0500" MODIFIED_BY="[Empty name]" NAME="Beckman 1990" NOTES="&lt;p&gt;Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxides. Proc Natl Acad Sci USA Med Sci 1990;87:1620-1624.&lt;/p&gt;" NOTES_MODIFIED="2016-12-12 18:25:59 -0500" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA</AU>
<TI>Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxides</TI>
<SO>Proceedings of the National Academy of Sciences of the United States of America</SO>
<YR>1990</YR>
<VL>87</VL>
<PG>1620-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bouchet-1993" NAME="Bouchet 1993" NOTES="&lt;p&gt;Bouchet M, Renaudin MH, Raveau C, Mercier JC Dehan M, Zupan V. Safety requirement for use of inhaled nitric oxide in neonates. Lancet 1993;341:968-969.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Bouchet M, Renaudin MH, Raveau C, Mercier JC Dehan M, Zupan V</AU>
<TI>Safety requirement for use of inhaled nitric oxide in neonates</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>341</VL>
<PG>968-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cornfield-1992" NAME="Cornfield 1992" NOTES="&lt;p&gt;Cornfield DN, Chatfield BA, McQueston JA, McMurtry IF, Abman SH. Effects of birth-related stimuli on L-arginine-dependent pulmonary vasodilation in ovine fetus. Am J Physiol 1992;262:H1474-H1481.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Cornfield DN, Chatfield BA, McQueston JA, McMurtry IF, Abman SH</AU>
<TI>Effects of birth-related stimuli on L-arginine-dependent pulmonary vasodilation in ovine fetus</TI>
<SO>American Journal of Physiology</SO>
<YR>1992</YR>
<VL>262</VL>
<PG>H1474-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davidson-1999" MODIFIED="2016-12-12 18:26:29 -0500" MODIFIED_BY="[Empty name]" NAME="Davidson 1999" TYPE="JOURNAL_ARTICLE">
<AU>Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R et al</AU>
<TI>Safety of withdrawing inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn</TI>
<SO>Pediatrics</SO>
<YR>1999</YR>
<VL>104</VL>
<PG>231-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dobyns-1999" NAME="Dobyns 1999" TYPE="JOURNAL_ARTICLE">
<AU>Dobyns EL, Griebel J, Kinsella JP, Abman SH, Accurso FJ</AU>
<TI>Infant lung function after inhaled nitric oxide therapy for persistent pulmonary hypertension of the newborn</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1999</YR>
<VL>28</VL>
<PG>24-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Etches-1994" NAME="Etches 1994" NOTES="&lt;p&gt;Etches PC, Finer NN, Barrington KJ, Graham AJ, Chan WKY. Nitric oxide reverses pulmonary hypertension in the newborn piglet. Pediatr Res 35:15-19, 1994.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Etches PC, Finer NN, Barrington KJ, Graham AJ, Chan WKY</AU>
<TI>Nitric oxide reverses pulmonary hypertension in the newborn piglet</TI>
<SO>Pediatric Research</SO>
<YR>1994</YR>
<VL>35</VL>
<PG>15-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Finer-1994" MODIFIED="2016-12-12 18:26:55 -0500" MODIFIED_BY="[Empty name]" NAME="Finer 1994" NOTES="&lt;p&gt;Finer NN, Etches PC, Kamstra B, Tierney AJ, Peliowski A, Ryan CA. Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: Dose response. J Pediatr 1994;124:302-308.&lt;/p&gt;" NOTES_MODIFIED="2016-12-12 18:26:55 -0500" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Finer NN, Etches PC, Kamstra B, Tierney AJ, Peliowski A, Ryan CA</AU>
<TI>Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: dose response</TI>
<SO>Journal of Pediatrics</SO>
<YR>1994</YR>
<VL>124</VL>
<PG>302-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fratacci-1991" NAME="Fratacci 1991" NOTES="&lt;p&gt;Fratacci MD, Frostell CG, Chen TY, Wain JC, Robinson DR, Zapol WM. Inhaled nitric oxide - A selective pulmonary vasodilator of heparin-protamine vasoconstriction in sheep. Anesthesiology 1991;75:990-999.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Fratacci MD, Frostell CG, Chen TY, Wain JC, Robinson DR, Zapol WM</AU>
<TI>Inhaled nitric oxide - A selective pulmonary vasodilator of heparin-protamine vasoconstriction in sheep</TI>
<SO>Anesthesiology</SO>
<YR>1991</YR>
<VL>75</VL>
<PG>990-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frostell-1991" NAME="Frostell 1991" NOTES="&lt;p&gt;Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide - A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991;83:2038-2047.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM</AU>
<TI>Inhaled nitric oxide - A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction</TI>
<SO>Circulation</SO>
<YR>1991</YR>
<VL>83</VL>
<PG>2038-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro" MODIFIED="2016-12-12 18:27:23 -0500" MODIFIED_BY="[Empty name]" NAME="GRADEpro" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro</TI>
<TO>www.gradepro.org</TO>
<YR>2014</YR>
<PB>McMaster University</PB>
<CY>Ontario</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenbaum-1967" MODIFIED="2016-12-12 18:27:49 -0500" MODIFIED_BY="[Empty name]" NAME="Greenbaum 1967" NOTES="&lt;p&gt;Greenbaum R, Bay J, Hargreaves MD, Kain ML, Kelman GR, Nunn JF, Prys-Roberts C, Siebold K. Effects of higher oxides of nitrogen on the anaesthetized dog. Brit J Anaesth 1967;39:393-404.&lt;/p&gt;" NOTES_MODIFIED="2016-12-12 18:27:49 -0500" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Greenbaum R, Bay J, Hargreaves MD, Kain ML, Kelman GR, Nunn JF et al</AU>
<TI>Effects of higher oxides of nitrogen on the anaesthetized dog</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1967</YR>
<VL>39</VL>
<PG>393-404</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haddad-1993" MODIFIED="2016-12-12 18:28:24 -0500" MODIFIED_BY="[Empty name]" NAME="Haddad 1993" NOTES="&lt;p&gt;Haddad IY, Ischiropoulos H, Holm B.A, Beckman JS, Baker JR, Matalon S. Mechanisms of peroxynitrite-induced injury to pulmonary surfactants. Am J Physiol 1993;265:L555-64.&lt;/p&gt;" NOTES_MODIFIED="2016-12-12 18:28:24 -0500" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Haddad IY, Ischiropoulos H, Holm BA, Beckman JS, Baker JR, Matalon S</AU>
<TI>Mechanisms of peroxynitrite-induced injury to pulmonary surfactants</TI>
<SO>American Journal of Physiology</SO>
<YR>1993</YR>
<VL>265</VL>
<PG>L555-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heal-1995" NAME="Heal 1995" NOTES="&lt;p&gt;Heal CA, Spencer SA. Methaemoglobinaemia with high-dose nitric oxide administration. Acta Paediatr 1995;84:1318-9.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Heal CA, Spencer SA</AU>
<TI>Methaemoglobinaemia with high-dose nitric oxide administration</TI>
<SO>Acta Paediatrica</SO>
<YR>1995</YR>
<VL>84</VL>
<PG>1318-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higenbottam-1988" NAME="Higenbottam 1988" NOTES="&lt;p&gt;Higenbottam T, Pepke-Zaba J, Scott J, Wollman P, Coutts C, Wallwork J. Inhaled &amp;quot;endothelium-derived relaxing factor&amp;quot; (EDRF) in primary hypertension (PPH). Am Rev Respir Dis 1988;137:A107.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Higenbottam T, Pepke-Zaba J, Scott J, Wollman P, Coutts C, Wallwork J</AU>
<TI>Inhaled "endothelium-derived relaxing factor" (EDRF) in primary hypertension (PPH)</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1988</YR>
<VL>137</VL>
<PG>A107</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-12-12 18:28:54 -0500" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hogman-1993" NAME="Hogman 1993" NOTES="&lt;p&gt;Hogman M, Frostell C, Arnberg H, Hedenstierma G. Bleeding time prolongation and NO inhalation. Lancet 1993;341:1664-1665.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Hogman M, Frostell C, Arnberg H, Hedenstierma G</AU>
<TI>Bleeding time prolongation and NO inhalation</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>341</VL>
<PG>1664-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hogman-1994" NAME="Hogman 1994" TYPE="JOURNAL_ARTICLE">
<AU>Hogman M, Frostell C, Arnberg H, Sandhagen B, Hedenstierna G</AU>
<TI>Prolonged bleeding time during nitric oxide inhalation in the rabbit</TI>
<SO>Acta Physiologica Scandinavica</SO>
<YR>1994</YR>
<VL>151</VL>
<PG>125</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kinsella-1992a" NAME="Kinsella 1992a" NOTES="&lt;p&gt;Kinsella JP, McQueston JA, Rosenberg AA, Abman SH. Hemodynamic effects of exogenous nitric oxide in ovine transitional pulmonary circulation. Am J Physiol 1992;263:H875-H880.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kinsella JP, McQueston JA, Rosenberg AA, Abman SH</AU>
<TI>Hemodynamic effects of exogenous nitric oxide in ovine transitional pulmonary circulation</TI>
<SO>American Journal of Physiology</SO>
<YR>1992</YR>
<VL>263</VL>
<PG>H875-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kinsella-1992b" NAME="Kinsella 1992b" NOTES="&lt;p&gt;Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340:819-820.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kinsella JP, Neish SR, Shaffer E, Abman SH</AU>
<TI>Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>340</VL>
<PG>819-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kinsella-1993" NAME="Kinsella 1993" NOTES="&lt;p&gt;Kinsella JP, Neish SR, Ivy DD, Shaffer E, Abman SH. Clinical Responses to Prolonged Treatment of Persistent Pulmonary Hypertension of the Newborn with Low Doses of Inhaled Nitric Oxide. J Pediatr 1993; 123(1):103-8.&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kinsella JP, Neish SR, Ivy DD, Shaffer E, Abman SH</AU>
<TI>Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxide</TI>
<SO>Journal of Pediatrics</SO>
<YR>1993</YR>
<VL>123</VL>
<PG>103-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lipkin-2002" NAME="Lipkin 2002" TYPE="JOURNAL_ARTICLE">
<AU>Lipkin PH, Davidson D, Spivak L, Straube R, Rhines J, Chang CT</AU>
<TI>Neurodevelopmental and medical outcomes of persistent pulmonary hypertension in term newborns treated with nitric oxide</TI>
<SO>Journal of Pediatrics</SO>
<YR>2002</YR>
<VL>140</VL>
<PG>306-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MMWR-1988" NAME="MMWR 1988" TYPE="JOURNAL_ARTICLE">
<AU>National Institute for Occupational Safety and Health</AU>
<TI>NIOSH recommendations for occupational safety and health standards</TI>
<SO>MMWR</SO>
<YR>1988</YR>
<VL>37</VL>
<PG>21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ninos-2000" NAME="Ninos 2000" TYPE="JOURNAL_ARTICLE">
<AU>Neonatal Inhaled Nitric Oxide Study Group</AU>
<TI>Inhaled nitric oxide in term and near-term infants: neurodevelopmental follow-up of the neonatal inhaled nitric oxide study group (NINOS)</TI>
<SO>Journal of Pediatrics</SO>
<YR>2000</YR>
<VL>136</VL>
<PG>611-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pepke_x002d_Zaba-1991" NAME="Pepke-Zaba 1991" NOTES="&lt;p&gt;Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet 1991;338:1173-1174.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J</AU>
<TI>Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>338</VL>
<PG>1173-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Radomski-1993" NAME="Radomski 1993" NOTES="&lt;p&gt;Radomski MW, Moncada S. Regulation of vascular homeostasis by nitric oxide. Thromb Haemo 1993;70:36-41.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Radomski MW, Moncada S</AU>
<TI>Regulation of vascular homeostasis by nitric oxide</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1993</YR>
<VL>70</VL>
<PG>36-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rasmussen-1992" NAME="Rasmussen 1992" NOTES="&lt;p&gt;Rasmussen TR, Kjaergaard SK, Tarp U, Pedersen OF. Delayed effects of NO2 exposure on alveolar permeability and glutathione peroxidase in healthy humans. Am Rev Respir Dis 1992;146:654-659.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Rasmussen TR, Kjaergaard SK, Tarp U, Pedersen OF</AU>
<TI>Delayed effects of NO2 exposure on alveolar permeability and glutathione peroxidase in healthy humans</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1992</YR>
<VL>146</VL>
<PG>654-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2016-07-19 14:14:15 -0400" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roberts-1992" NAME="Roberts 1992" NOTES="&lt;p&gt;Roberts JD, Polaner DM, Lang P, Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340:818-819.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Roberts JD, Polaner DM, Lang P, Zapol WM</AU>
<TI>Inhaled nitric oxide in persistent pulmonary hypertension of the newborn</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>340</VL>
<PG>818-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roberts-1993" NAME="Roberts 1993" NOTES="&lt;p&gt;Roberts JD Jr, Chen T-Y. Inhaled Nitric Oxide Reverses Pulmonary Vasoconstriction in the Hypoxic and Acidotic Newborn Lamb. Circ Res 1993; 72:246.&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Roberts JD Jr, Chen T-Y</AU>
<TI>Inhaled nitric oxide reverses pulmonary vasoconstriction in the hypoxic and acidotic newborn lamb</TI>
<SO>Circulation Research</SO>
<YR>1993</YR>
<VL>72</VL>
<PG>246</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosenberg-1997" MODIFIED="2016-12-12 18:30:33 -0500" MODIFIED_BY="[Empty name]" NAME="Rosenberg 1997" TYPE="JOURNAL_ARTICLE">
<AU>Rosenberg AA, Kennaugh JM, Moreland SG, Fashaw LM, Hale KA, Torielli FM et al</AU>
<TI>Longitudinal follow-up of a cohort of newborn infants treated with inhaled nitric oxide for persistent pulmonary hypertension</TI>
<SO>Journal of Pediatrics</SO>
<YR>1997</YR>
<VL>131</VL>
<PG>70-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rossaint-1993" NAME="Rossaint 1993" NOTES="&lt;p&gt;Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993;328:399-405.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM</AU>
<TI>Inhaled nitric oxide for the adult respiratory distress syndrome</TI>
<SO>New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>328</VL>
<PG>399-405</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2013" MODIFIED="2016-12-12 18:31:12 -0500" MODIFIED_BY="[Empty name]" NAME="Schünemann 2013" TYPE="OTHER">
<AU>Schünemann H, Bro&#380;ek J, Guyatt G, Oxman A, editors; GWG</AU>
<TI>GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations</TI>
<SO>www.guidelinedevelopment.org/handbook</SO>
<YR>Updated October 2013</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-08-22 13:23:17 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Finer-1997" MODIFIED="2008-08-22 13:23:17 -0400" MODIFIED_BY="[Empty name]" NAME="Finer 1997" NOTES="&lt;p&gt;Finer NN, Barrington KJ. Nitric oxide in respiratory failure in full-term and nearly full-term newborn infants (Cochrane Review). In: The Cochrane Library, Issue 4, 1997. Oxford: Update Software.&lt;/p&gt;" NOTES_MODIFIED="2008-08-22 13:23:17 -0400" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Finer NN, Barrington KJ</AU>
<TI>Nitric oxide in respiratory failure in full-term and nearly full-term newborn infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1997</YR>
<NO>4</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-08-22 13:22:59 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-08-22 13:22:59 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000399"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Finer-1999" MODIFIED="2008-08-22 13:22:42 -0400" MODIFIED_BY="[Empty name]" NAME="Finer 1999" TYPE="COCHRANE_REVIEW">
<AU>Finer NN, Barrington KJ</AU>
<TI>Nitric oxide in respiratory failure in full-term and nearly full-term newborn infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-08-22 13:22:21 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-08-22 13:22:21 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000399"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Finer-2001" MODIFIED="2008-08-22 13:22:12 -0400" MODIFIED_BY="[Empty name]" NAME="Finer 2001" TYPE="COCHRANE_REVIEW">
<AU>Finer NN, Barrington KJ</AU>
<TI>Nitric oxide in respiratory failure in full-term and nearly full-term newborn infants (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-08-22 13:22:12 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-08-22 13:22:12 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000399.pub2"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-12-16 17:50:31 -0500" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-12-16 17:50:31 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-12-12 14:02:00 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barefield-1996">
<CHAR_METHODS MODIFIED="2016-12-12 13:57:58 -0500" MODIFIED_BY="[Empty name]">
<P>Single-centre randomised study. Masking of allocation: yes. Masking of intervention: no. Completeness of follow-up: yes. Masking of outcome measurement: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-12 13:58:20 -0500" MODIFIED_BY="[Empty name]">
<P>17 near-term infants &#8805; 35 weeks with PaO<SUB>2</SUB> &lt; 100 mmHg on 100% oxygen on ventilator<BR/>Patients with congenital diaphragmatic hernia were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-12 14:00:04 -0500" MODIFIED_BY="[Empty name]">
<P>iNO at 20 to 40 ppm increased to 80 if PaO<SUB>2</SUB> stayed &lt; 100 mmHg. Use of iNO allowed in case of failure of control treatment, if PaO<SUB>2</SUB> was (1) &lt; 80 mmHg (10.7 kPa) for longer than 1 hour, (2) &lt; 40 mmHg (5.3 kPa) beyond 1 hour or (3) &lt; 30 mmHg (4 kPa) beyond 30 minutes<BR/>High-frequency ventilation not allowed during study</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-12 14:01:18 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome: 'treatment failure' or meeting ECMO criteria (defined as PaO<SUB>2</SUB> &lt; 80 mmHg for &gt; 1 hour, &lt; 40 mmHg after 1 hour or &lt; 30 mmHg after 30 minutes)<BR/>Secondary outcomes: oxygenation index, PaO<SUB>2</SUB>, alveolar arterial oxygen gradient, after 30 and 60 minutes; death and ultimate use of high-frequency ventilation or ECMO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-12 14:02:00 -0500" MODIFIED_BY="[Empty name]">
<P>Admission OI in control group averaged 26, in treatment group 38</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-12 14:04:15 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Christou-2000">
<CHAR_METHODS MODIFIED="2016-12-12 14:02:42 -0500" MODIFIED_BY="[Empty name]">
<P>Single-centre randomised study. Masking of allocation: yes. Masking of intervention: no. Completeness of follow-up: yes. Masking of outcome: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-12 14:03:50 -0500" MODIFIED_BY="[Empty name]">
<P>42 near-term infants &#8805; 34 weeks with PaO<SUB>2</SUB> &lt; 100 mmHg on 100%oxygen on ventilator. 41 infants after exclusion of 1 case of congenital heart disease. Patients with diaphragmatic hernia were excluded. Some evidence showing increased pulmonary artery pressure on echocardiography required</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-12 14:04:10 -0500" MODIFIED_BY="[Empty name]">
<P>40 ppm iNO reduced to 20 ppm after 1 hour. Combined therapy with high-frequency ventilation and iNO allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-12 14:04:15 -0500" MODIFIED_BY="[Empty name]">
<P>Death before discharge or requirement for ECMO. Secondary outcomes included changes in oxygenation and duration of ventilation and oxygen therapy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-12 14:07:44 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clark-2000">
<CHAR_METHODS MODIFIED="2016-12-12 14:05:17 -0500" MODIFIED_BY="[Empty name]">
<P>Multi-centre randomised trial. Masking of allocation: yes. Masking of intervention: yes. Completeness of follow-up: yes. Masking of outcome: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-12 14:06:22 -0500" MODIFIED_BY="[Empty name]">
<P>248 near-term infants, &#8805; 34 weeks, &#8804; 4 days of age, with OI &#8805; 25</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-12 14:06:29 -0500" MODIFIED_BY="[Empty name]">
<P>20 ppm iNO or nitrogen placebo. Inhaled NO gas weaned to 5 ppm after 24 hours for a maximum of 96 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-12 14:07:44 -0500" MODIFIED_BY="[Empty name]">
<P>Death before discharge, need for ECMO, chronic lung disease, neurological injury</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-01-07 22:21:07 -0500" MODIFIED_BY="[Empty name]">
<P>No calculation of sample size for the trial is described.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-12 14:09:44 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cornfield-1999">
<CHAR_METHODS MODIFIED="2016-12-12 14:08:42 -0500" MODIFIED_BY="[Empty name]">
<P>Three-centre randomised trial. Masking of allocation: cannot tell. Masking of intervention: no. Completeness of follow-up: yes. Masking of outcome: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-12 14:09:21 -0500" MODIFIED_BY="[Empty name]">
<P>38 near-term infants with OI &#8805; 25, &lt; 1 week old, with echocardiographically proven pulmonary hypertension</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-12 14:09:24 -0500" MODIFIED_BY="[Empty name]">
<P>Inhaled NO at 2 ppm or no therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-12 14:09:44 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome: failure, defined as OI &gt; 35 after 1 hour of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-12 15:32:51 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davidson-1997">
<CHAR_METHODS MODIFIED="2016-12-12 15:32:51 -0500" MODIFIED_BY="[Empty name]">
<P>Multi-centre randomised trial, with nitrogen used as placebo gas<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-12 14:10:36 -0500" MODIFIED_BY="[Empty name]">
<P>155 term infants with echocardiographic evidence of pulmonary hypertension. PaO<SUB>2</SUB> between 40 and 100 mmHg in 100% oxygen. Randomised equally to each of the 4 groups<BR/>Excluded infants with congenital diaphragmatic hernia or other causes of pulmonary hypoplasia<BR/>Did not allow surfactant therapy or concurrent high-frequency ventilation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-12 14:10:58 -0500" MODIFIED_BY="[Empty name]">
<P>Inhaled nitric oxide at 5, 20 or 80 ppm or control, gas stopped upon 'failure', defined as PaO<SUB>2</SUB> &lt; 40 mmHg for longer than 30 minutes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-12 14:11:27 -0500" MODIFIED_BY="[Empty name]">
<P>Major sequelae index: composite index of death, ECMO, neurological sequelae or bronchopulmonary dysplasia<BR/>Oxygenation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-01-07 22:23:32 -0500" MODIFIED_BY="[Empty name]">
<P>Terminated early because of poor enrolment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-12 19:59:57 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Day-1996">
<CHAR_METHODS MODIFIED="2016-12-12 14:14:38 -0500" MODIFIED_BY="[Empty name]">
<P>Single-centre randomised parallel-group study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-12 14:15:18 -0500" MODIFIED_BY="[Empty name]">
<P>22 term or premature infants with OI &gt; 25 and &lt; 40, plus right-to-left ductal shunting or estimated peak right ventricular pressure &gt; 75% of systemic systolic pressure</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-12 19:59:57 -0500" MODIFIED_BY="[Empty name]">
<P>20 ppm iNO. High-frequency jet ventilation allowed concurrently. Back-up use of iNO allowed in case of failure of control treatment. Few details of other therapy given</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-12 14:15:50 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: oxygenation index, PaO<SUB>2</SUB>, echocardiographic Doppler changes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-12 14:16:16 -0500" MODIFIED_BY="[Empty name]">
<P>If the condition of infants in the controlled trial deteriorated to an OI &gt; 40, iNO was given.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-12 14:17:54 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gonzalez-2010">
<CHAR_METHODS MODIFIED="2016-12-12 14:16:40 -0500" MODIFIED_BY="[Empty name]">
<P>Two-centre randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-12 14:17:06 -0500" MODIFIED_BY="[Empty name]">
<P>56 infants &gt; 34 weeks, &lt; 48 hours old, with OI between 10 and 30</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-12 14:17:20 -0500" MODIFIED_BY="[Empty name]">
<P>Immediate iNO at 20 ppm, or no iNO unless OI increases to &gt; 40</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-12 14:17:54 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome was the proportion with OI increasing to &gt; 40. Secondary outcomes were death, days of ventilation and chronic lung disease.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-12 14:19:42 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-INNOVO-2007">
<CHAR_METHODS MODIFIED="2016-12-12 14:19:14 -0500" MODIFIED_BY="[Empty name]">
<P>Multi-centre parallel-group randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-12 14:19:33 -0500" MODIFIED_BY="[Empty name]">
<P>60 full-term infants &#8805; 34 weeks with severe hypoxic respiratory failure for whom attending physician was unsure whether iNO was indicated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-12 14:19:36 -0500" MODIFIED_BY="[Empty name]">
<P>iNO at 20 ppm or no iNO</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-12 14:19:39 -0500" MODIFIED_BY="[Empty name]">
<P>Survival without severe disability to 1 year of age</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-12 14:19:42 -0500" MODIFIED_BY="[Empty name]">
<P>Sample size determined by limit to trial duration</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-12 20:00:06 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinsella-1997">
<CHAR_METHODS MODIFIED="2016-12-12 20:00:06 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised multi-centre controlled parallel-group trial of iNO compared with high-frequency ventilation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-12 14:21:00 -0500" MODIFIED_BY="[Empty name]">
<P>205 near-term infants, OI &gt; 40. Stratified by disease process; infants with diaphragmatic hernia (n = 34) were included as a separate stratum</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-12 18:36:40 -0500" MODIFIED_BY="[Empty name]">
<P>iNO at 40 ppm was compared with high-frequency ventilation with the SensorMedics oscillator. Initial randomisation was followed by back-up treatment with alternate therapy in cases of failure. This was followed by further cross-over to combination treatment with high-frequency ventilation and iNO if alternate therapy failed.<BR/>iNO therapy was administered via a standard time-cycled pressure-limited ventilator. High-frequency ventilation was aimed at a lung recruitment strategy. Surfactant treatment after enrolment was prohibited. iNO dose was increased to 40 ppm in case of failure to maintain PaO<SUB>2</SUB> &gt; 60 mmHg.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-12 14:22:25 -0500" MODIFIED_BY="[Empty name]">
<P>Sustained PaO<SUB>2</SUB> &#8805; 60 mmHg. Failure defined as PaO<SUB>2</SUB> &lt; 60 mmHg after 2 hours of therapy or lack of improvement in PaO<SUB>2</SUB> before 2 hours. Some data on infants with diaphragmatic hernia were presented separately.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-12 14:23:02 -0500" MODIFIED_BY="[Empty name]">
<P>Complex study design; we abstracted only results from the initial randomisation. All infants who failed were exposed to iNO at some stage in the protocol. Study was stopped after interim analysis, suggesting no difference between initial treatment limbs.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-12 15:11:24 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Konduri-2004">
<CHAR_METHODS MODIFIED="2016-12-12 15:08:47 -0500" MODIFIED_BY="[Empty name]">
<P>Multi-centre randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-12 15:09:58 -0500" MODIFIED_BY="[Empty name]">
<P>All 302 enrolled (3 excluded, as they turned out to have congential heart disease) infants were &#8805; 34 weeks' gestation, with hypoxic respiratory failure and OI between 15 and 25, while receiving &#8805; 80% oxygen, on 2 blood gases between 15 minutes and 12 hours apart</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-12 15:10:28 -0500" MODIFIED_BY="[Empty name]">
<P>iNO at 5 ppm; iNO could be increased to 20 ppm in the case of partial response; treated up to 14 days. Controls received nitrogen, or iNO if OI increased to &gt; 25.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-12 15:11:04 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome: occurrence or death or requirement for ECMO<BR/>Secondary hypotheses were that early iNO therapy would (1) reduce the probability of using standard iNO therapy; (2) decrease progression to severe respiratory failure, defined as OI &gt; 40; and (3) would not increase neurodevelopmental impairment among surviving infants at 18 to 24 months of age.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-12 15:11:24 -0500" MODIFIED_BY="[Empty name]">
<P>Study terminated early because of slowing enrolment; 75% of anticipated sample enrolled; study terminated without knowledge of results at that point</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-12 15:21:08 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2008">
<CHAR_METHODS MODIFIED="2016-12-12 15:20:40 -0500" MODIFIED_BY="[Empty name]">
<P>Single-centre randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-12 15:20:51 -0500" MODIFIED_BY="[Empty name]">
<P>46 infants with meconium aspiration syndrome, over 36 weeks, &gt; 2.5 kg, OI &gt; 15</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-17 13:37:08 -0400" MODIFIED_BY="[Empty name]">
<P>iNO at 15 ppm or no additional gas</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-12 15:21:08 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome variable unclear; outcomes reported include changes in OI and in echocardiography, survival, certain medical complications and duration of assisted ventilation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-12 20:00:12 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mercier-1998">
<CHAR_METHODS MODIFIED="2016-12-12 20:00:12 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised multi-centre trial of iNO</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-12 15:22:34 -0500" MODIFIED_BY="[Empty name]">
<P>204 infants; 107 near term, &#8805; 33 weeks' gestation. OI 15 to 40, on 2 blood gases 1 hour apart. Congenital diaphragmatic hernia excluded, congenital heart disease excluded, &lt; 7 days of age only</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>iNO at 10 ppm for 2 hours, continued if response. Controls could be treated after 2 hours.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-12 15:22:56 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome: change in OI at 2 hours after initiation of treatment. Secondary outcomes: death, brain injury, long-term oxygen therapy, duration of hospitalisation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-12 18:36:45 -0500" MODIFIED_BY="[Empty name]">
<P>ECMO not available as back-up therapy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-12 15:32:21 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ninos-1996">
<CHAR_METHODS MODIFIED="2016-12-12 15:32:21 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised multi-centre study, with oxygen used as placebo gas</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-12 15:24:03 -0500" MODIFIED_BY="[Empty name]">
<P>235 near-term infants, &#8805; 34 weeks' gestation, OI &gt; 25 on 2 blood gases, 15 minutes apart. Congenital diaphragmatic hernia excluded, congenital heart disease excluded, &lt; 14 days of age only</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-12 15:30:45 -0500" MODIFIED_BY="[Empty name]">
<P>iNO at 20 ppm, trial at 80 ppm if no response to 20 ppm (in treatment group). Comparison with control. Both groups received 'maximal therapy' before study entry, including surfactant in the majority, high-frequency ventilation at experienced centres, muscle relaxation and inotropes. Induction of alkalosis with target pH of 7.45-7.60 was also used as a guideline. All of these treatment strategies were continued in controls. Investigators were not allowed to start high-frequency ventilation or to administer surfactant after study entry.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-12 15:26:36 -0500" MODIFIED_BY="[Empty name]">
<P>Survival to 120 days or discharge home, without requiring ECMO. Secondary outcomes were oxygenation (OI and PaO<SUB>2</SUB>) after 30 minutes, length of hospital stay, days of assisted ventilation and incidence of air leak or bronchopulmonary dysplasia. Neurodevelopment at 18-24 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-12 20:00:18 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ninos-1997">
<CHAR_METHODS MODIFIED="2016-12-12 20:00:18 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised multi-centre trial of iNO in infants with diaphragmatic hernia, with oxygen used as placebo gas</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-12 15:28:47 -0500" MODIFIED_BY="[Empty name]">
<P>53 near-term infants with diaphragmatic hernia, &#8805; 34 weeks' gestation, &lt; 14 days of age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-12 15:31:03 -0500" MODIFIED_BY="[Empty name]">
<P>iNO at 20 ppm, trial at 80 ppm if no response to 20 ppm (in treatment group). Comparison with control. Both groups received 'maximal therapy' before study entry, including surfactant in the majority, high-frequency ventilation at experienced centres, muscle relaxation and inotropes. Induction of alkalosis with target pH of 7.45-7.60 was also used as a guideline. All of these treatment strategies were continued in controls. Investigators were not allowed to start high-frequency ventilation or to administer surfactant after study entry.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-12 15:29:44 -0500" MODIFIED_BY="[Empty name]">
<P>Survival to 120 days or discharge home, without requiring ECMO. Secondary outcomes were oxygenation (OI and PaO<SUB>2</SUB>) after 30 minutes, length of hospital stay, days of assisted ventilation and incidence of air leak or bronchopulmonary dysplasia. Neurodevelopment at 18-24 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-12 15:35:15 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roberts-1996">
<CHAR_METHODS MODIFIED="2016-12-12 15:31:58 -0500" MODIFIED_BY="[Empty name]">
<P>Multi-centre randomised study, with nitrogen used for placebo gas</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-12 15:34:31 -0500" MODIFIED_BY="[Empty name]">
<P>58 'full-term infants' on FiO<SUB>2</SUB> 1.0 with PaO<SUB>2</SUB> &lt; 55 mmHg. All had echocardiographic signs of pulmonary hypertension.<BR/>Patients excluded if they had received high-frequency ventilation<BR/>Patients with diaphragmatic hernia excluded, or other causes of pulmonary hypoplasia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-12 15:34:38 -0500" MODIFIED_BY="[Empty name]">
<P>iNO at 80 ppm or control. Control patients received conventional ventilation. Surfactant was not allowed during the study.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-12 15:34:58 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome was 'success', defined as improved OI to &lt; 40, without a fall in PaO<SUB>2</SUB> or hypotension.<BR/>Secondary outcomes were oxygenation, both OI and PaO<SUB>2</SUB>, after 30 minutes of therapy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-12 15:35:15 -0500" MODIFIED_BY="[Empty name]">
<P>Study was terminated after an interim analysis showed an effect at P &lt; 0.05. Original sample size was not described.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-12 17:19:31 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sadiq-1998">
<CHAR_METHODS MODIFIED="2016-12-12 17:17:39 -0500" MODIFIED_BY="[Empty name]">
<P>Multi-centre randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-12 17:18:00 -0500" MODIFIED_BY="[Empty name]">
<P>87 infants &gt; 2 kg birth weight, with A-aDO<SUB>2</SUB> 500-599 after surfactant on 2 gases 1 hour apart, on 100% oxygen with echocardiographic evidence of PPHN</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-12 17:18:53 -0500" MODIFIED_BY="[Empty name]">
<P>iNO at 10 ppm or control; iNO increased up to 80 ppm until no further increases in arterial PaO<SUB>2</SUB> occurred</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-12 17:19:21 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome variable was progression to severe PPHN, defined as an A-aDO<SUB>2</SUB> persistently &gt; 600. Secondary outcome variables included death, ECMO rate, length of hospitalisation, amount and duration of mechanical ventilation, number of days of oxygen use and need for supplemental oxygen at 28 days of life.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-12 17:19:31 -0500" MODIFIED_BY="[Empty name]">
<P>Study was terminated early after approval of iNO by the Federal Drug Administration, as this impaired recruitment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-12 17:21:17 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wessel-1996">
<CHAR_METHODS MODIFIED="2016-12-12 17:20:37 -0500" MODIFIED_BY="[Empty name]">
<P>Single-centre randomised trial. Masking of allocation: not clear. Masking of intervention: no. Completeness of follow-up: yes. Masking of outcome: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-12 17:20:53 -0500" MODIFIED_BY="[Empty name]">
<P>49 near-term infants &#8805; 34 weeks, PaO<SUB>2</SUB> &lt; 100 mmHg on 100% oxygen; all had evidence of PPHN on echocardiography</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-12 17:21:00 -0500" MODIFIED_BY="[Empty name]">
<P>iNO at 80 ppm, reduced to 40 ppm after 1 hour. All received muscle relaxants and sedation and conventional ventilation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-12 17:21:17 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcomes were oxygenation as well as death and need for ECMO.<BR/>Secondary outcomes were duration of mechanical ventilation, duration of hospitalisation and need for oxygen after hospital discharge.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>A-aDO2: alveolar-arterial oxygen difference.<BR/>ECMO: extracorporeal membrane oxygenation.<BR/>FiO2: fraction of inspired oxygen.<BR/>iNO: inhaled nitric oxide.<BR/>NO: nitric oxide.<BR/>OI: oxygenation index.<BR/>PaO2: partial pressure of arterial oxygen.<BR/>PPHN: persistent pulmonary hypertension of the newborn<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-12-12 17:23:08 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-12-12 17:22:40 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hoffman-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-12-12 17:22:40 -0500" MODIFIED_BY="[Empty name]">
<P>Non-randomised retrospective study; infants were treated or were not treated according to availability of inhaled nitric oxide. The time period over which infants were studied was different between control and inhaled nitric oxide groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-12-12 17:23:08 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pinheiro-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-12-12 17:23:08 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised comparison of inhaled nitric oxide with intravenous nitroprusside. Study was stopped after enrolment of 25 participants owing to decreasing enrolment. Inhaled nitric oxide produced much greater improvements in oxygenation than were produced by nitroprusside.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-12-12 17:21:28 -0500" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-12-12 17:19:45 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-22 22:02:54 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barefield-1996">
<DESCRIPTION>
<P>Method of sequence generation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-17 15:10:06 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Christou-2000">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 14:08:01 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clark-2000">
<DESCRIPTION>
<P>Cards on which treatment assignments were written were randomly ordered (shuffled by hand 3 times) and placed in sequentially numbered opaque envelopes in blocks of 8.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 14:09:52 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cornfield-1999">
<DESCRIPTION>
<P>Computer-generated random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 14:11:37 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Davidson-1997">
<DESCRIPTION>
<P>Randomised by a "scratch-off card"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-15 20:08:44 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Day-1996">
<DESCRIPTION>
<P>Randomised by "blind draw"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-07 21:59:55 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gonzalez-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 14:19:53 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-INNOVO-2007">
<DESCRIPTION>
<P>Central randomisation by random number generator with minimisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-23 14:55:12 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 15:11:27 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Konduri-2004">
<DESCRIPTION>
<P>Central computerised randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 15:21:15 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2008">
<DESCRIPTION>
<P>Method not clearly reported but may be acceptable; 'random number method'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-23 14:54:26 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mercier-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 11:05:39 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ninos-1996">
<DESCRIPTION>
<P>Prepared by study centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 15:29:47 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ninos-1997">
<DESCRIPTION>
<P>Centralised blocked randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 17:17:20 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roberts-1996">
<DESCRIPTION>
<P>Not described in the publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 17:19:45 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sadiq-1998">
<DESCRIPTION>
<P>Randomisation order was determined a priori, in blocks of 10, by coin toss with folded group assignment cards.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-07 22:41:42 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wessel-1996">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-12-12 17:19:57 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 14:02:09 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barefield-1996">
<DESCRIPTION>
<P>Sequentially numbered, opaque, sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-12 17:03:57 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Christou-2000">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-12 17:03:51 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clark-2000">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-12 17:05:56 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cornfield-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-07 22:26:15 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davidson-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-18 15:34:34 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Day-1996">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-15 22:22:49 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gonzalez-2010">
<DESCRIPTION>
<P>Opaque sealed sequential envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 14:19:59 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-INNOVO-2007">
<DESCRIPTION>
<P>Enrolled before allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-15 22:30:02 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 15:11:30 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Konduri-2004">
<DESCRIPTION>
<P>Randomised by telephone after enrolment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-17 13:41:16 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2008">
<DESCRIPTION>
<P>No relevant information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-07 22:35:34 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mercier-1998">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 11:06:01 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ninos-1996">
<DESCRIPTION>
<P>Telephone randomisation system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 15:29:52 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ninos-1997">
<DESCRIPTION>
<P>Telephone randomisation system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-07 22:36:01 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roberts-1996">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 17:19:57 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sadiq-1998">
<DESCRIPTION>
<P>Cards were placed in sequentially numbered opaque envelopes for each centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-07 22:41:01 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wessel-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-12-12 15:29:54 -0500" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-10-22 22:03:07 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barefield-1996">
<DESCRIPTION>
<P>Unmasked trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-23 14:56:03 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Christou-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-03-23 18:47:45 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clark-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-10-17 15:10:30 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cornfield-1999">
<DESCRIPTION>
<P>Unmasked trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-12-12 14:11:40 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davidson-1997">
<DESCRIPTION>
<P>Placebo-controlled masked trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-01-07 22:26:38 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Day-1996">
<DESCRIPTION>
<P>Unmasked trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-10-15 22:23:08 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gonzalez-2010">
<DESCRIPTION>
<P>Unmasked trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-10-15 22:29:29 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-INNOVO-2007">
<DESCRIPTION>
<P>Unmasked study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-10-15 22:30:39 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kinsella-1997">
<DESCRIPTION>
<P>Unmasked trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-03-23 19:19:21 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Konduri-2004">
<DESCRIPTION>
<P>Masked gas administration</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-10-17 13:41:36 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liu-2008">
<DESCRIPTION>
<P>Unmasked study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-10-17 15:14:48 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mercier-1998">
<DESCRIPTION>
<P>Unmasked study gas administration</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-03-24 11:06:17 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ninos-1996">
<DESCRIPTION>
<P>Masked gas administration</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-12-12 15:29:54 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ninos-1997">
<DESCRIPTION>
<P>Masked gas administration</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-03-24 11:09:53 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roberts-1996">
<DESCRIPTION>
<P>Masked gas administration</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-10-17 15:16:57 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sadiq-1998">
<DESCRIPTION>
<P>Unmasked trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-10-17 15:17:26 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wessel-1996">
<DESCRIPTION>
<P>Unmasked trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-12-12 15:30:02 -0500" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-23 18:47:10 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barefield-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-23 14:56:00 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Christou-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-23 18:47:45 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clark-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-22 20:40:52 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cornfield-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-22 20:40:35 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davidson-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-10-17 15:11:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Day-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-12 14:18:04 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gonzalez-2010">
<DESCRIPTION>
<P>All participants accounted for</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-10-17 15:12:13 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-INNOVO-2007">
<DESCRIPTION>
<P>All outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-23 14:55:10 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-23 14:54:38 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Konduri-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-12 15:21:23 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2008">
<DESCRIPTION>
<P>Outcomes of all participants reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-23 14:54:23 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mercier-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-23 14:54:05 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ninos-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-12 15:30:02 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ninos-1997">
<DESCRIPTION>
<P>All participants accounted for</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-24 11:10:08 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roberts-1996">
<DESCRIPTION>
<P>Complete outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-23 14:53:54 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sadiq-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-10-17 15:17:31 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wessel-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-12-12 15:30:04 -0500" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-17 16:35:40 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barefield-1996">
<DESCRIPTION>
<P>No registered or published protocol found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-17 16:36:03 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Christou-2000">
<DESCRIPTION>
<P>No registered or published protocol found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 14:08:06 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clark-2000">
<DESCRIPTION>
<P>No registered or published protocol found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-17 16:36:35 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cornfield-1999">
<DESCRIPTION>
<P>No registered or published protocol found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-17 16:37:11 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Davidson-1997">
<DESCRIPTION>
<P>No registered or published protocol found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-17 16:37:29 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Day-1996">
<DESCRIPTION>
<P>No registered or published protocol found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 14:18:07 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gonzalez-2010">
<DESCRIPTION>
<P>No registered or published protocol found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 14:20:04 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-INNOVO-2007">
<DESCRIPTION>
<P>Protocol registered (ISRCTN 17821339). Primary outcome variables consistent with publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-17 16:37:54 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kinsella-1997">
<DESCRIPTION>
<P>No registered or published protocol found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 15:11:44 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Konduri-2004">
<DESCRIPTION>
<P>Study registered in 2000 (after start of trial but before completion); NCT00005773. Primary and secondary outcomes match registration documents.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 15:21:27 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2008">
<DESCRIPTION>
<P>No registered or published protocol found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-17 16:38:44 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mercier-1998">
<DESCRIPTION>
<P>No registered or published protocol found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 15:26:49 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ninos-1996">
<DESCRIPTION>
<P>Study registered, NCT00005776, in 2000 (after completion). Outcomes in registration documents are reported in the main publication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 15:30:04 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ninos-1997">
<DESCRIPTION>
<P>Study registered, NCT00005776, in 2000 (after completion). Outcomes as registered are reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-17 16:39:23 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roberts-1996">
<DESCRIPTION>
<P>No registered or published protocol found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-17 16:39:36 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sadiq-1998">
<DESCRIPTION>
<P>No registered or published protocol found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-17 16:39:56 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wessel-1996">
<DESCRIPTION>
<P>No registered or published protocol found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-12-12 17:20:09 -0500" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 10:47:20 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barefield-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 14:04:28 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Christou-2000">
<DESCRIPTION>
<P>Study terminated early after ad hoc committee reviewed the data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 14:08:10 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clark-2000">
<DESCRIPTION>
<P>Uncertain how sample size was determined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 11:01:08 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cornfield-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 14:11:46 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Davidson-1997">
<DESCRIPTION>
<P>Terminated early for poor enrolment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 14:16:27 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Day-1996">
<DESCRIPTION>
<P>No sample size calculation presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 10:52:39 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gonzalez-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 10:53:22 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-INNOVO-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 10:54:04 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kinsella-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 15:11:53 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Konduri-2004">
<DESCRIPTION>
<P>Early termination without examination of data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 10:55:27 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 15:23:17 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mercier-1998">
<DESCRIPTION>
<P>Terminated early for poor enrolment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 10:57:04 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ninos-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 10:57:23 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ninos-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 17:17:34 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Roberts-1996">
<DESCRIPTION>
<P>Early termination after examination of data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 17:20:09 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sadiq-1998">
<DESCRIPTION>
<P>Early termination, but not because of examination of data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 10:59:48 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wessel-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2016-12-12 17:21:28 -0500" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Funding Source(s)</NAME>
<DESCRIPTION>
<P>Funding from local funds (hospital, research centre or university), charitable foundations, government agencies, or from industry</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 10:49:14 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barefield-1996">
<DESCRIPTION>
<P>Charitable foundation (March of Dimes)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 14:04:30 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Christou-2000">
<DESCRIPTION>
<P>Supported by local and government agencies</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 14:08:17 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Clark-2000">
<DESCRIPTION>
<P>Funded "in part" by INOtherapeutics; no other sources listed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 14:09:57 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cornfield-1999">
<DESCRIPTION>
<P>Local funds and charitable sources</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 10:51:57 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Davidson-1997">
<DESCRIPTION>
<P>Industry funded (Ohmeda)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 10:52:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Day-1996">
<DESCRIPTION>
<P>Local sources</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 14:18:14 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gonzalez-2010">
<DESCRIPTION>
<P>Local (university) sources and industry (AGA, SA)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 10:53:32 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-INNOVO-2007">
<DESCRIPTION>
<P>Government agency</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 14:24:30 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-1997">
<DESCRIPTION>
<P>Local and government sources</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 15:11:55 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Konduri-2004">
<DESCRIPTION>
<P>Government agency, partial industry support</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 15:21:29 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2008">
<DESCRIPTION>
<P>Uncertain</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 15:23:19 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mercier-1998">
<DESCRIPTION>
<P>Government agency and industry support</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 15:26:57 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ninos-1996">
<DESCRIPTION>
<P>Started with government agency support, industry support after study commenced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 15:30:24 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ninos-1997">
<DESCRIPTION>
<P>Planned and commenced with government agency support; industry support provided after study commenced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 11:10:17 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roberts-1996">
<DESCRIPTION>
<P>Government agency</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 10:59:21 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sadiq-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-12 17:21:28 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wessel-1996">
<DESCRIPTION>
<P>Supported by local and charitable sources</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-12-12 18:36:59 -0500" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-12-12 18:36:59 -0500" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2016-12-12 17:32:36 -0500" MODIFIED_BY="[Empty name]">Inhaled NO compared with control for respiratory failure in infants born at or near term</TITLE>
<TABLE COLS="7" ROWS="18">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Inhaled NO compared with control for respiratory failure in infants born at or near term</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>respiratory failure in infants born at or near term<BR/>
<B>Setting: </B>neonatal intensive care units<BR/>
<B>Intervention: </B>inhaled NO<BR/>
<B>Comparison: </B>placebo or no treatment</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with control</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with inhaled NO</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Death or use of ECMO; studies that did not allow back-up use of iNO in controls</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.66<BR/>(0.57 to 0.77)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>859<BR/>(8 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>High</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>540 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>356 per 1000<BR/>(308 to 416)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Death or use of ECMO; infants with diaphragmatic hernia</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 1.09<BR/>(0.95 to 1.26)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>84<BR/>(2 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>870 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>948 per 1000<BR/>(826 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Death before hospital discharge; studies that did not allow back-up use of iNO in controls</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.89<BR/>(0.60 to 1.31)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>860<BR/>(8 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>High</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>120 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>106 per 1000<BR/>(72 to 157)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Death before hospital discharge; infants with diaphragmatic hernia</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 1.20<BR/>(0.74 to 1.96)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>84<BR/>(2 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>391 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>470 per 1000<BR/>(290 to 767)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Use of ECMO before hospital discharge; studies that did not allow back-up use of iNO in controls</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.60<BR/>(0.50 to 0.71)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>815<BR/>(7 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>High</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>514 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>308 per 1000<BR/>(257 to 365)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Use of ECMO before hospital discharge; infants with diaphragmatic hernia</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 1.27<BR/>(1.00 to 1.62)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>84<BR/>(2 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate<SUP>a,b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>674 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>856 per 1000<BR/>(674 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Neurodevelopmental disability at 18 to 24 months among survivors</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.97<BR/>(0.66 to 1.44)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>301<BR/>(2 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>Low<SUP>a,b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>265 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>257 per 1000<BR/>(175 to 382)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: confidence interval; OR: odds ratio; RR: risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence.</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to the estimate of effect.<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of effect but may be substantially different.<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of effect.<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Small numbers of participants studied.</P>
<P>
<SUP>b</SUP>Subgroup of participants from only 2 trials evaluated.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2016-12-12 17:48:26 -0500" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2016-12-12 17:41:17 -0500" MODIFIED_BY="[Empty name]">Inhaled NO at moderate compared with severe criteria for illness severity in respiratory failure among infants born at or near term</TITLE>
<TABLE COLS="7" ROWS="16">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Inhaled NO at moderate compared with severe criteria for illness severity in respiratory failure among infants born at or near term</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>infants born at or near term in respiratory failure<BR/>
<B>Setting: </B>neonatal intensive care units<BR/>
<B>Intervention: </B>inhaled NO at moderate criteria for illness severity (earlier iNO)<BR/>
<B>Comparison: </B>inhaled NO at severe criteria for illness severity (later iNO)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with inhaled NO at severe criteria for illness severity</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with Inhaled NO at moderate criteria for illness severity</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Death or requirement for ECMO</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.88<BR/>(0.62 to 1.27)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>495<BR/>(5 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>Low<SUP>a,b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>192 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>169 per 1000<BR/>(119 to 244)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Death before hospital discharge</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.69<BR/>(0.38 to 1.26)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>495<BR/>(5 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>100 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>69 per 1000<BR/>(38 to 126)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Use of ECMO before hospital discharge</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 1.01<BR/>(0.66 to 1.54)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>439<BR/>(4 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>144 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>146 per 1000<BR/>(95 to 222)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Progression to severe criteria</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.66<BR/>(0.55 to 0.79)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>512<BR/>(6 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>595 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>392 per 1000<BR/>(327 to 470)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Neurodevelopmental disability at 18 to 24 months among survivors</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 1.13<BR/>(0.74 to 1.74)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>234<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>248 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>280 per 1000<BR/>(183 to 431)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: confidence interval; OR: odds ratio; RR: risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence.</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to the estimate of effect.<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of effect but may be substantially different.<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of effect.<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Highly variable risk ratio.</P>
<P>
<SUP>b</SUP>Very wide confidence intervals.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-12-12 17:51:12 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2016-12-12 17:51:12 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-12-12 17:48:43 -0500" MODIFIED_BY="[Empty name]">Additional important outcomes</TITLE>
<TABLE COLS="5" ROWS="7">
<TR>
<TD VALIGN="TOP">
<P>Study</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Ventilator days</P>
</TD>
<TD VALIGN="TOP">
<P>Oxygen days</P>
</TD>
<TD VALIGN="TOP">
<P>Hospitalisation days</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Gonzalez</P>
</TD>
<TD VALIGN="TOP">
<P>Early iNO</P>
</TD>
<TD VALIGN="TOP">
<P>Median 6, range 3-28</P>
</TD>
<TD VALIGN="TOP">
<P>Median 11.5, range 5-90</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Late iNO</P>
</TD>
<TD VALIGN="TOP">
<P>Median 8, range 4-37</P>
</TD>
<TD VALIGN="TOP">
<P>Median 18, range 6-142</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Konduri</P>
</TD>
<TD VALIGN="TOP">
<P>Early iNO</P>
</TD>
<TD VALIGN="TOP">
<P>Median 8, IQR 6-12</P>
</TD>
<TD VALIGN="TOP">
<P>Median 13, IQR 9-19</P>
</TD>
<TD VALIGN="TOP">
<P>Median 17, IQR 12-22</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Late iNO</P>
</TD>
<TD VALIGN="TOP">
<P>Median 8, IQR 6-12</P>
</TD>
<TD VALIGN="TOP">
<P>Median 13, IQR 9-19</P>
</TD>
<TD VALIGN="TOP">
<P>Median 18, IQR 12-30</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Sadiq</P>
</TD>
<TD VALIGN="TOP">
<P>Early iNO</P>
</TD>
<TD VALIGN="TOP">
<P>Mean 8,7, SD 4</P>
</TD>
<TD VALIGN="TOP">
<P>Mean 14, SD 8</P>
</TD>
<TD VALIGN="TOP">
<P>Mean 21, SD 14</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Late iNO</P>
</TD>
<TD VALIGN="TOP">
<P>Mean 10, SD 6</P>
</TD>
<TD VALIGN="TOP">
<P>Mean 18, SD 17</P>
</TD>
<TD VALIGN="TOP">
<P>Mean 21, SD 11</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>IQR: interquartile range; SD: standard deviation.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-12-12 19:43:20 -0500" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2016-12-12 19:43:20 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Inhaled NO versus control</NAME>
<DICH_OUTCOME CHI2="40.101766580625124" CI_END="0.8296907985613504" CI_START="0.6406189455601986" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7290511947150018" ESTIMABLE="YES" EVENTS_1="203" EVENTS_2="255" I2="75.06344270421387" I2_Q="91.16902731698336" ID="CMP-001.01" LOG_CI_END="-0.08108372629553895" LOG_CI_START="-0.1934002217281078" LOG_EFFECT_SIZE="-0.13724197401182336" METHOD="MH" MODIFIED="2016-12-12 18:37:24 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.6259633128901108E-5" P_Q="1.2082260774981535E-5" P_Z="1.6690983460894911E-6" Q="22.647561846118247" RANDOM="NO" SCALE="1.2" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="561" TOTAL_2="489" WEIGHT="300.0" Z="4.789845430885052">
<NAME>Death or use of ECMO</NAME>
<GROUP_LABEL_1>iNO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors iNO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.564262086355994" CI_END="0.7717450969081998" CI_START="0.5664158526964007" DF="7" EFFECT_SIZE="0.6611570593508961" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="211" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.11252612101979295" LOG_CI_START="-0.24686460022961312" LOG_EFFECT_SIZE="-0.1796953606247031" MODIFIED="2016-12-12 18:37:10 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5914445000053941" P_Z="1.5762843432214608E-7" STUDIES="8" TAU2="0.0" TOTAL_1="468" TOTAL_2="391" WEIGHT="100.00000000000001" Z="5.243418521409155">
<NAME>Death or use of ECMO; studies that did not allow back-up use of iNO in controls</NAME>
<DICH_DATA CI_END="1.0247472601146619" CI_START="0.1828770781825883" EFFECT_SIZE="0.4329004329004329" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.010616765809057398" LOG_CI_START="-0.7378407255933461" LOG_EFFECT_SIZE="-0.36361197989214433" ORDER="160" O_E="0.0" SE="0.4396476353741065" STUDY_ID="STD-Christou-2000" TOTAL_1="21" TOTAL_2="20" VAR="0.1932900432900433" WEIGHT="5.120163263485133"/>
<DICH_DATA CI_END="0.750766196133973" CI_START="0.410479219660024" EFFECT_SIZE="0.555134148054502" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="63" LOG_CI_END="-0.12449529007704431" LOG_CI_START="-0.38670882396577755" LOG_EFFECT_SIZE="-0.2556020570214109" ORDER="161" O_E="0.0" SE="0.1540255277841682" STUDY_ID="STD-Clark-2000" TOTAL_1="113" TOTAL_2="104" VAR="0.02372386320919157" WEIGHT="29.81363602814406"/>
<DICH_DATA CI_END="1.1971510654821211" CI_START="0.4596179367259833" EFFECT_SIZE="0.7417763157894737" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="16" LOG_CI_END="0.07814895639281998" LOG_CI_START="-0.3376030311823688" LOG_EFFECT_SIZE="-0.1297270373947744" ORDER="162" O_E="0.0" SE="0.24421477550719545" STUDY_ID="STD-Davidson-1997" TOTAL_1="114" TOTAL_2="41" VAR="0.059640856576029876" WEIGHT="10.69421280537557"/>
<DICH_DATA CI_END="1.9387120432221914" CI_START="0.487111870871711" EFFECT_SIZE="0.9717868338557993" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.28751330813667314" LOG_CI_START="-0.31237128658249" LOG_EFFECT_SIZE="-0.012428989222908464" MODIFIED="2014-01-09 12:44:04 -0500" MODIFIED_BY="[Empty name]" ORDER="151" O_E="0.0" SE="0.3523751804146714" STUDY_ID="STD-INNOVO-2007" TOTAL_1="29" TOTAL_2="31" VAR="0.12416826777227222" WEIGHT="4.831646127209384"/>
<DICH_DATA CI_END="2.0955880548429615" CI_START="0.16907349190307674" EFFECT_SIZE="0.5952380952380952" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3213059142411822" LOG_CI_START="-0.7719244776929078" LOG_EFFECT_SIZE="-0.22530928172586287" MODIFIED="2016-04-28 11:55:58 -0400" MODIFIED_BY="[Empty name]" ORDER="146" O_E="0.0" SE="0.6421689437998014" STUDY_ID="STD-Liu-2008" TOTAL_1="21" TOTAL_2="25" VAR="0.4123809523809524" WEIGHT="2.4892493336311126"/>
<DICH_DATA CI_END="0.9095387143375069" CI_START="0.5608445879519225" EFFECT_SIZE="0.7142197599261311" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="76" LOG_CI_END="-0.0411788105473754" LOG_CI_START="-0.25115746663249267" LOG_EFFECT_SIZE="-0.14616813858993405" ORDER="163" O_E="0.0" SE="0.1233425019955089" STUDY_ID="STD-Ninos-1996" TOTAL_1="114" TOTAL_2="119" VAR="0.015213372798512119" WEIGHT="33.79233552771572"/>
<DICH_DATA CI_END="0.9204644263546468" CI_START="0.3406975772458291" EFFECT_SIZE="0.56" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="20" LOG_CI_END="-0.035992991229945086" LOG_CI_START="-0.46763095475765404" LOG_EFFECT_SIZE="-0.25181197299379954" ORDER="164" O_E="0.0" SE="0.253546276418555" STUDY_ID="STD-Roberts-1996" TOTAL_1="30" TOTAL_2="28" VAR="0.0642857142857143" WEIGHT="9.401105857720129"/>
<DICH_DATA CI_END="2.1484653715592366" CI_START="0.46098379913433657" EFFECT_SIZE="0.9951923076923077" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3321283582238146" LOG_CI_START="-0.33631433723550214" LOG_EFFECT_SIZE="-0.002092989505843789" MODIFIED="2016-04-28 11:55:59 -0400" MODIFIED_BY="[Empty name]" ORDER="165" O_E="0.0" SE="0.3926465481575095" STUDY_ID="STD-Wessel-1996" TOTAL_1="26" TOTAL_2="23" VAR="0.15417131178000743" WEIGHT="3.8576510567188995"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.162005775722118" CI_START="0.33558199823346074" DF="0" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.619302678557613" LOG_CI_START="-0.4742013442603895" LOG_EFFECT_SIZE="0.07255066714861175" MODIFIED="2016-12-12 18:37:24 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7948056887202715" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="52" WEIGHT="100.0" Z="0.2600753023279893">
<NAME>Death or use of ECMO; studies that allowed back-up use of iNO in controls</NAME>
<DICH_DATA CI_END="4.162005775722118" CI_START="0.33558199823346074" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.619302678557613" LOG_CI_START="-0.4742013442603895" LOG_EFFECT_SIZE="0.07255066714861175" ORDER="168" O_E="0.0" SE="0.6423296759355064" STUDY_ID="STD-Mercier-1998" TOTAL_1="55" TOTAL_2="52" VAR="0.4125874125874126" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7658021592627469" CI_END="1.2558693304820647" CI_START="0.9509560047511374" DF="1" EFFECT_SIZE="1.0928295754621167" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="40" I2="43.36851414784104" ID="CMP-001.01.03" LOG_CI_END="0.09894445468559138" LOG_CI_START="-0.021839574898324294" LOG_EFFECT_SIZE="0.03855243989363356" MODIFIED="2016-12-12 17:52:28 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.18390257123599718" P_Z="0.21086815733705722" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="46" WEIGHT="99.99999999999999" Z="1.2511818651516358">
<NAME>Death or use of ECMO; infants with diaphragmatic hernia</NAME>
<DICH_DATA CI_END="1.1852254822738986" CI_START="0.8059757493742379" EFFECT_SIZE="0.9773755656108597" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.07380098021264711" LOG_CI_START="-0.09367802528100674" LOG_EFFECT_SIZE="-0.009938522534179813" MODIFIED="2015-10-26 21:22:09 -0400" MODIFIED_BY="[Empty name]" ORDER="212" O_E="0.0" SE="0.09837799686141996" STUDY_ID="STD-Clark-2000" TOTAL_1="13" TOTAL_2="18" VAR="0.009678230266465554" WEIGHT="39.65400501049495"/>
<DICH_DATA CI_END="1.4137183005632583" CI_START="0.9661398079560983" EFFECT_SIZE="1.1686956521739131" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.15036287997078782" LOG_CI_START="-0.014960023242398262" LOG_EFFECT_SIZE="0.0677014283641948" MODIFIED="2015-10-26 21:22:05 -0400" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.09711149170899477" STUDY_ID="STD-Ninos-1997" TOTAL_1="25" TOTAL_2="28" VAR="0.00943064182194616" WEIGHT="60.34599498950504"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.410417426459356" CI_END="1.3301650304981996" CI_START="0.7253186013256588" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9822389930425571" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="69" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.1239055262215599" LOG_CI_START="-0.139471184596023" LOG_EFFECT_SIZE="-0.007782829187231517" METHOD="MH" MODIFIED="2016-12-12 18:37:55 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9269391760799761" P_Q="0.6199270447690082" P_Z="0.907783646729455" Q="0.9563070982827138" RANDOM="NO" SCALE="1.2" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="560" TOTAL_2="491" WEIGHT="300.0" Z="0.11583457669775532">
<NAME>Death before hospital discharge</NAME>
<GROUP_LABEL_1>iNO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors iNO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.145947223088476" CI_END="1.3146883670755884" CI_START="0.5993729403754714" DF="7" EFFECT_SIZE="0.8876872378554974" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="47" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.1188228201271502" LOG_CI_START="-0.2223028678483134" LOG_EFFECT_SIZE="-0.05174002386058162" MODIFIED="2016-12-12 18:37:38 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8711806228872635" P_Z="0.5521425715517503" STUDIES="8" TAU2="0.0" TOTAL_1="467" TOTAL_2="393" WEIGHT="100.0" Z="0.5945526056851932">
<NAME>Death; studies that did not allow back-up use of iNO in controls</NAME>
<DICH_DATA CI_END="19.40224594904089" CI_START="0.1869947388236024" EFFECT_SIZE="1.9047619047619047" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.287852005539399" LOG_CI_START="-0.7281706123513129" LOG_EFFECT_SIZE="0.2798406965940431" ORDER="169" O_E="0.0" SE="1.1842216652219095" STUDY_ID="STD-Christou-2000" TOTAL_1="21" TOTAL_2="20" VAR="1.4023809523809523" WEIGHT="2.1987573147962696"/>
<DICH_DATA CI_END="1.7448038694134582" CI_START="0.15852110045936219" EFFECT_SIZE="0.5259165613147914" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2417466156971052" LOG_CI_START="-0.799912921438973" LOG_EFFECT_SIZE="-0.2790831528709338" ORDER="170" O_E="0.0" SE="0.6118759684116009" STUDY_ID="STD-Clark-2000" TOTAL_1="113" TOTAL_2="104" VAR="0.3743922007196343" WEIGHT="15.64799176566992"/>
<DICH_DATA CI_END="24.98447987062036" CI_START="0.42680110255267745" EFFECT_SIZE="3.265486725663717" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.3976703126871215" LOG_CI_START="-0.36977446733584013" LOG_EFFECT_SIZE="0.5139479226756406" ORDER="171" O_E="0.0" SE="1.0382058127782507" STUDY_ID="STD-Davidson-1997" TOTAL_1="113" TOTAL_2="41" VAR="1.0778713096865482" WEIGHT="3.1499204203621267"/>
<DICH_DATA CI_END="2.252690584231217" CI_START="0.3883666725542961" EFFECT_SIZE="0.9353448275862069" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.35270154379253355" LOG_CI_START="-0.41075804587727394" LOG_EFFECT_SIZE="-0.029028251042370185" MODIFIED="2014-01-09 12:47:22 -0500" MODIFIED_BY="[Empty name]" ORDER="153" O_E="0.0" SE="0.4484599421579637" STUDY_ID="STD-INNOVO-2007" TOTAL_1="29" TOTAL_2="31" VAR="0.20111631972032415" WEIGHT="16.598872681223902"/>
<DICH_DATA CI_END="2.0955880548429615" CI_START="0.16907349190307674" EFFECT_SIZE="0.5952380952380952" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3213059142411822" LOG_CI_START="-0.7719244776929078" LOG_EFFECT_SIZE="-0.22530928172586287" MODIFIED="2016-04-28 11:56:11 -0400" MODIFIED_BY="[Empty name]" ORDER="145" O_E="0.0" SE="0.6421689437998014" STUDY_ID="STD-Liu-2008" TOTAL_1="21" TOTAL_2="25" VAR="0.4123809523809524" WEIGHT="11.758571726953965"/>
<DICH_DATA CI_END="1.5558503647304278" CI_START="0.4634183066327704" EFFECT_SIZE="0.8491228070175438" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.19196782601047935" LOG_CI_START="-0.3340268140666372" LOG_EFFECT_SIZE="-0.07102949402807894" ORDER="172" O_E="0.0" SE="0.3089718552967588" STUDY_ID="STD-Ninos-1996" TOTAL_1="114" TOTAL_2="121" VAR="0.09546360736552124" WEIGHT="41.64940907541141"/>
<DICH_DATA CI_END="6.184805150349353" CI_START="0.140846977380024" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7913260219180813" LOG_CI_START="-0.8512524686729677" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="173" O_E="0.0" SE="0.964858736267844" STUDY_ID="STD-Roberts-1996" TOTAL_1="30" TOTAL_2="28" VAR="0.930952380952381" WEIGHT="4.440839896879166"/>
<DICH_DATA CI_END="5.785450016524434" CI_START="0.1352607621642426" EFFECT_SIZE="0.8846153846153846" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7623371458447383" LOG_CI_START="-0.8688281697511885" LOG_EFFECT_SIZE="-0.053245511953225105" MODIFIED="2016-04-28 11:56:12 -0400" MODIFIED_BY="[Empty name]" ORDER="174" O_E="0.0" SE="0.9581545807795819" STUDY_ID="STD-Wessel-1996" TOTAL_1="26" TOTAL_2="23" VAR="0.9180602006688964" WEIGHT="4.555637118703253"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.162005775722118" CI_START="0.33558199823346074" DF="0" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.619302678557613" LOG_CI_START="-0.4742013442603895" LOG_EFFECT_SIZE="0.07255066714861175" MODIFIED="2016-12-12 18:37:55 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7948056887202715" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="52" WEIGHT="100.0" Z="0.2600753023279893">
<NAME>Death; studies that allowed back-up use of iNO in controls</NAME>
<DICH_DATA CI_END="4.162005775722118" CI_START="0.33558199823346074" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.619302678557613" LOG_CI_START="-0.4742013442603895" LOG_EFFECT_SIZE="0.07255066714861175" ORDER="177" O_E="0.0" SE="0.6423296759355064" STUDY_ID="STD-Mercier-1998" TOTAL_1="55" TOTAL_2="52" VAR="0.4125874125874126" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.15442119524802392" CI_END="1.9615105070437653" CI_START="0.7358778554490457" DF="1" EFFECT_SIZE="1.201429209468513" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.2925906388172788" LOG_CI_START="-0.13319426597052314" LOG_EFFECT_SIZE="0.07969818642337784" MODIFIED="2015-10-26 21:22:52 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6943457874011014" P_Z="0.46311332796598936" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="46" WEIGHT="100.0" Z="0.7337299808729842">
<NAME>Death; infants with diaphragmatic hernia</NAME>
<DICH_DATA CI_END="3.3328102123434" CI_START="0.5752382047478174" EFFECT_SIZE="1.3846153846153846" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.5228105833638695" LOG_CI_START="-0.24015227777093093" LOG_EFFECT_SIZE="0.1413291527964693" MODIFIED="2015-10-26 21:22:49 -0400" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="0.4481681613576547" STUDY_ID="STD-Clark-2000" TOTAL_1="13" TOTAL_2="18" VAR="0.20085470085470084" WEIGHT="30.772666368914695"/>
<DICH_DATA CI_END="2.0226747062846595" CI_START="0.6201689258794059" EFFECT_SIZE="1.12" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.30592604360867176" LOG_CI_START="-0.20748999826830855" LOG_EFFECT_SIZE="0.04921802267018165" MODIFIED="2015-10-26 21:22:52 -0400" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.30158312444893354" STUDY_ID="STD-Ninos-1997" TOTAL_1="25" TOTAL_2="28" VAR="0.09095238095238094" WEIGHT="69.2273336310853"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="35.353736688248226" CI_END="0.7907268380969348" CI_START="0.5868284579808696" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6811908771295406" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="220" I2="77.37155743805933" I2_Q="95.91961260177585" ID="CMP-001.03" LOG_CI_END="-0.1019735205428309" LOG_CI_START="-0.23148883340343562" LOG_EFFECT_SIZE="-0.16673117697313328" METHOD="MH" MODIFIED="2016-12-12 18:38:10 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="2.304875092262737E-5" P_Q="7.402331724248867E-7" P_Z="4.5042827995080554E-7" Q="24.507476923274965" RANDOM="NO" SCALE="1.2" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="485" TOTAL_2="414" WEIGHT="200.0" Z="5.04630834377138">
<NAME>Use of ECMO before hospital discharge</NAME>
<GROUP_LABEL_1>iNO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors iNO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.432840170833211" CI_END="0.712773813296572" CI_START="0.5028413811207386" DF="6" EFFECT_SIZE="0.5986753449948843" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="189" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.1470482642878313" LOG_CI_START="-0.29856898943299887" LOG_EFFECT_SIZE="-0.22280862686041508" MODIFIED="2016-12-12 18:38:10 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.48961095509123576" P_Z="8.205248288243521E-9" STUDIES="7" TAU2="0.0" TOTAL_1="447" TOTAL_2="368" WEIGHT="100.00000000000001" Z="5.7641868288691285">
<NAME>Use of ECMO before hospital discharge; studies that did not allow back-up use of iNO in controls</NAME>
<DICH_DATA CI_END="0.7961762867637945" CI_START="0.08473626212124644" EFFECT_SIZE="0.2597402597402597" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.09899076154342522" LOG_CI_START="-1.0719306974735763" LOG_EFFECT_SIZE="-0.5854607295085007" ORDER="178" O_E="0.0" SE="0.5715097344957272" STUDY_ID="STD-Christou-2000" TOTAL_1="21" TOTAL_2="20" VAR="0.3266233766233766" WEIGHT="5.708930574034353"/>
<DICH_DATA CI_END="0.7305276700500754" CI_START="0.39092616933943136" EFFECT_SIZE="0.5343990864972881" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="62" LOG_CI_END="-0.13636332973313817" LOG_CI_START="-0.4079052560980737" LOG_EFFECT_SIZE="-0.272134292915606" ORDER="179" O_E="0.0" SE="0.1595050717009769" STUDY_ID="STD-Clark-2000" TOTAL_1="113" TOTAL_2="104" VAR="0.025441867898333782" WEIGHT="32.71425522510966"/>
<DICH_DATA CI_END="1.1112819183983447" CI_START="0.3711570452890449" EFFECT_SIZE="0.6422305764411027" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="14" LOG_CI_END="0.04582424802569186" LOG_CI_START="-0.4304422912715669" LOG_EFFECT_SIZE="-0.19230902162293756" ORDER="180" O_E="0.0" SE="0.2797613227406015" STUDY_ID="STD-Davidson-1997" TOTAL_1="114" TOTAL_2="41" VAR="0.07826639770157101" WEIGHT="10.433447313015277"/>
<DICH_DATA CI_END="1.3666407230723236" CI_START="0.11758057229120869" EFFECT_SIZE="0.40086206896551724" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.13565435765850611" LOG_CI_START="-0.9296644303324353" LOG_EFFECT_SIZE="-0.39700503633696455" MODIFIED="2014-01-09 12:45:51 -0500" MODIFIED_BY="[Empty name]" ORDER="152" O_E="0.0" SE="0.625773529478928" STUDY_ID="STD-INNOVO-2007" TOTAL_1="29" TOTAL_2="31" VAR="0.39159251019651464" WEIGHT="3.9179904487889448"/>
<DICH_DATA CI_END="0.9390232327183917" CI_START="0.5332147842235404" EFFECT_SIZE="0.7076023391812866" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="66" LOG_CI_END="-0.027323662561814666" LOG_CI_START="-0.27309781758959273" LOG_EFFECT_SIZE="-0.15021074007570376" ORDER="181" O_E="0.0" SE="0.14436895526500537" STUDY_ID="STD-Ninos-1996" TOTAL_1="114" TOTAL_2="121" VAR="0.02084239524430912" WEIGHT="32.441995748372726"/>
<DICH_DATA CI_END="0.9204644263546468" CI_START="0.3406975772458291" EFFECT_SIZE="0.56" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="20" LOG_CI_END="-0.035992991229945086" LOG_CI_START="-0.46763095475765404" LOG_EFFECT_SIZE="-0.25181197299379954" ORDER="182" O_E="0.0" SE="0.253546276418555" STUDY_ID="STD-Roberts-1996" TOTAL_1="30" TOTAL_2="28" VAR="0.0642857142857143" WEIGHT="10.482138537188021"/>
<DICH_DATA CI_END="1.9756308747066493" CI_START="0.3960984760447321" EFFECT_SIZE="0.8846153846153846" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.2957058045972012" LOG_CI_START="-0.40219682850365135" LOG_EFFECT_SIZE="-0.053245511953225105" MODIFIED="2016-04-28 11:56:16 -0400" MODIFIED_BY="[Empty name]" ORDER="183" O_E="0.0" SE="0.40995146135719085" STUDY_ID="STD-Wessel-1996" TOTAL_1="26" TOTAL_2="23" VAR="0.16806020066889632" WEIGHT="4.30124215349103"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.708384853782077" CI_END="1.6202373358536826" CI_START="0.9985033300073455" DF="1" EFFECT_SIZE="1.2719325356527884" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="31" I2="73.03408250683238" ID="CMP-001.03.02" LOG_CI_END="0.2095786355932595" LOG_CI_START="-6.504824193143865E-4" LOG_EFFECT_SIZE="0.10446407658697257" MODIFIED="2016-12-12 17:54:00 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.054139994249237544" P_Z="0.051434697151331726" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="46" WEIGHT="100.0" Z="1.9478351022378753">
<NAME>Use of ECMO before hospital discharge; infants with diaphragmatic hernia</NAME>
<DICH_DATA CI_END="1.3024391114039124" CI_START="0.8279867806653046" EFFECT_SIZE="1.0384615384615385" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.11475742932327314" LOG_CI_START="-0.08197659694693436" LOG_EFFECT_SIZE="0.016390416188169384" MODIFIED="2015-10-26 21:23:34 -0400" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.0" SE="0.11556254088025598" STUDY_ID="STD-Clark-2000" TOTAL_1="13" TOTAL_2="18" VAR="0.013354700854700835" WEIGHT="48.67323060620778"/>
<DICH_DATA CI_END="2.2203008043417656" CI_START="1.0043884324518666" EFFECT_SIZE="1.4933333333333334" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="0.34641181625965906" LOG_CI_START="0.001901702297304077" LOG_EFFECT_SIZE="0.1741567592784816" MODIFIED="2015-10-26 21:23:36 -0400" MODIFIED_BY="[Empty name]" ORDER="217" O_E="0.0" SE="0.20236694629405502" STUDY_ID="STD-Ninos-1997" TOTAL_1="25" TOTAL_2="28" VAR="0.04095238095238095" WEIGHT="51.32676939379222"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="57" EVENTS_2="135" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-12-12 18:38:23 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.186591836653186" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="166" TOTAL_2="172" WEIGHT="0.0" Z="0.0">
<NAME>Failure to improve oxygenation (PaO<SUB>2</SUB>)</NAME>
<GROUP_LABEL_1>iNO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors iNO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="37" EVENTS_2="108" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-12-12 18:38:23 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="142" TOTAL_2="145" WEIGHT="0.0" Z="0.0">
<NAME>Failure to improve PaO<SUB>2</SUB>; studies that did not allow back-up use of iNO in controls</NAME>
<DICH_DATA CI_END="0.42977668339731107" CI_START="0.19976564199743177" EFFECT_SIZE="0.2930095818815331" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="82" LOG_CI_END="-0.36675714991151137" LOG_CI_START="-0.6994792046687763" LOG_EFFECT_SIZE="-0.5331181772901438" ORDER="1" O_E="0.0" SE="0.19544258196515096" STUDY_ID="STD-Ninos-1996" TOTAL_1="112" TOTAL_2="117" VAR="0.038197802845204756" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.74681882153996" CI_START="0.33819538273721383" EFFECT_SIZE="0.5025641025641026" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" LOG_CI_END="-0.126784745372207" LOG_CI_START="-0.47083232596783936" LOG_EFFECT_SIZE="-0.2988085356700232" ORDER="188" O_E="0.0" SE="0.20209525190486502" STUDY_ID="STD-Roberts-1996" TOTAL_1="30" TOTAL_2="28" VAR="0.04084249084249085" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="27" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-03-12 17:22:01 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Failure to improve PaO<SUB>2</SUB>; infants with diaphragmatic hernia</NAME>
<DICH_DATA CI_END="1.0099435980808311" CI_START="0.690210019061732" EFFECT_SIZE="0.8349090909090909" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="27" LOG_CI_END="0.004297120588351963" LOG_CI_START="-0.16101874079700546" LOG_EFFECT_SIZE="-0.07836081010432673" MODIFIED="2015-10-26 21:25:28 -0400" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.09710735530447062" STUDY_ID="STD-Ninos-1997" TOTAL_1="24" TOTAL_2="27" VAR="0.0094298384542287" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="14.088745406002225" CI_END="-5.64733398631077" CI_START="-11.532137620659515" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.589735803485143" ESTIMABLE="YES" I2="64.5106795820879" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2016-12-12 18:38:37 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.015055429212183502" P_Q="0.49838112026785764" P_Z="1.0545658894080862E-8" Q="0.45838206421291067" RANDOM="NO" SCALE="33.001989405845165" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="408" TOTAL_2="345" UNITS="" WEIGHT="99.99999999999999" Z="5.721710989056052">
<NAME>Oxygenation index 30 to 60 minutes after treatment</NAME>
<GROUP_LABEL_1>iNO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors INO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="13.630363341789314" CI_END="-5.4829538870322345" CI_START="-11.421405313996843" DF="4" EFFECT_SIZE="-8.452179600514539" ESTIMABLE="YES" I2="70.65375368434673" ID="CMP-001.05.01" MODIFIED="2016-12-12 18:38:37 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.008573223481763481" P_Z="2.4159758414432225E-8" STUDIES="5" TAU2="0.0" TOTAL_1="387" TOTAL_2="322" WEIGHT="98.20136724209868" Z="5.57922138847575">
<NAME>OI 30 to 60 minutes after treatment; studies that did not allow back-up use of iNO in controls</NAME>
<CONT_DATA CI_END="7.9395188573045345" CI_START="-13.739518857304535" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="15.6" MEAN_2="18.5" MODIFIED="2014-01-09 11:42:05 -0500" MODIFIED_BY="[Empty name]" ORDER="147" SD_1="22.0" SD_2="14.0" SE="5.530468387585321" STUDY_ID="STD-Liu-2008" TOTAL_1="21" TOTAL_2="26" WEIGHT="7.368582489929898"/>
<CONT_DATA CI_END="-0.12669935500523266" CI_START="-11.873300644994767" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="26.0" MEAN_2="32.0" ORDER="190" SD_1="26.0" SD_2="21.0" SE="2.9966370256405797" STUDY_ID="STD-Clark-2000" TOTAL_1="126" TOTAL_2="122" WEIGHT="25.098022002274472"/>
<CONT_DATA CI_END="-0.26276611128845495" CI_START="-9.737233888711545" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="19.0" MEAN_2="24.0" ORDER="191" SD_1="11.0" SD_2="14.0" SE="2.4170004786201384" STUDY_ID="STD-Davidson-1997" TOTAL_1="114" TOTAL_2="41" WEIGHT="38.5792966253192"/>
<CONT_DATA CI_END="-7.027452940437516" CI_START="-22.372547059562475" EFFECT_SIZE="-14.699999999999996" ESTIMABLE="YES" MEAN_1="30.6" MEAN_2="45.3" ORDER="193" SD_1="24.8" SD_2="30.6" SE="3.9146367586764614" STUDY_ID="STD-Ninos-1996" TOTAL_1="96" TOTAL_2="105" WEIGHT="14.707025265328022"/>
<CONT_DATA CI_END="-11.660413840266736" CI_START="-28.339586159733265" EFFECT_SIZE="-20.0" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="45.0" ORDER="194" SD_1="14.0" SD_2="18.0" SE="4.254969083878508" STUDY_ID="STD-Roberts-1996" TOTAL_1="30" TOTAL_2="28" WEIGHT="12.448440859247087"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.839702318585356" CI_START="-38.039702318585356" DF="0" EFFECT_SIZE="-16.1" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" MODIFIED="2015-10-26 21:43:32 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.1503548168524024" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="1.7986327579013086" Z="1.4382793208804816">
<NAME>OI 30 to 60 minutes after treatment; infants with diaphragmatic hernia</NAME>
<CONT_DATA CI_END="5.839702318585353" CI_START="-38.039702318585356" EFFECT_SIZE="-16.1" ESTIMABLE="YES" MEAN_1="43.9" MEAN_2="60.0" MODIFIED="2015-10-26 21:43:32 -0400" MODIFIED_BY="[Empty name]" ORDER="219" SD_1="25.8" SD_2="46.4" SE="11.193931363863278" STUDY_ID="STD-Ninos-1997" TOTAL_1="21" TOTAL_2="23" WEIGHT="1.7986327579013086"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="11.289483110848138" CI_END="41.667229064905705" CI_START="23.564181417191186" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="32.615705241048445" ESTIMABLE="YES" I2="64.56879415359262" I2_Q="89.21594390561279" ID="CMP-001.06" MODIFIED="2016-12-12 18:38:54 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.02349625374384312" P_Q="0.00232564058892748" P_Z="1.6363471762044075E-12" Q="9.272948798184306" RANDOM="NO" SCALE="122.82" SORT_BY="WEIGHT" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="387" TOTAL_2="320" UNITS="" WEIGHT="100.00000000000001" Z="7.062413892602195">
<NAME>PaO<SUB>2</SUB> 30 to 60 minutes after treatment</NAME>
<GROUP_LABEL_1>iNO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors iNO</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.0165343126638313" CI_END="55.51479002335229" CI_START="32.29888262010597" DF="3" EFFECT_SIZE="43.90683632172913" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" MODIFIED="2016-12-12 18:38:54 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5689820848745661" P_Z="1.2298881119107933E-13" STUDIES="4" TAU2="0.0" TOTAL_1="366" TOTAL_2="297" WEIGHT="60.80398779450927" Z="7.413521803903376">
<NAME>PaO<SUB>2</SUB> after 30 to 60 minutes; studies that did not allow back-up use of iNO in controls</NAME>
<CONT_DATA CI_END="76.26956797484168" CI_START="25.730432025158326" EFFECT_SIZE="51.0" ESTIMABLE="YES" MEAN_1="89.0" MEAN_2="38.0" ORDER="200" SD_1="70.0" SD_2="9.0" SE="12.892873631436496" STUDY_ID="STD-Roberts-1996" TOTAL_1="30" TOTAL_2="28" WEIGHT="12.8306235699979"/>
<CONT_DATA CI_END="66.05186917786111" CI_START="17.948130822138886" EFFECT_SIZE="42.0" ESTIMABLE="YES" MEAN_1="134.0" MEAN_2="92.0" ORDER="196" SD_1="103.0" SD_2="90.0" SE="12.271587318736053" STUDY_ID="STD-Clark-2000" TOTAL_1="126" TOTAL_2="122" WEIGHT="14.162689429142091"/>
<CONT_DATA CI_END="74.46372059167146" CI_START="30.136279408328548" EFFECT_SIZE="52.300000000000004" ESTIMABLE="YES" MEAN_1="115.9" MEAN_2="63.6" ORDER="199" SD_1="98.7" SD_2="52.9" SE="11.308228501388829" STUDY_ID="STD-Ninos-1996" TOTAL_1="96" TOTAL_2="106" WEIGHT="16.67854129341166"/>
<CONT_DATA CI_END="53.8683478721261" CI_START="10.131652127873899" EFFECT_SIZE="32.0" ESTIMABLE="YES" MEAN_1="109.0" MEAN_2="77.0" ORDER="197" SD_1="78.0" SD_2="54.0" SE="11.157525365068357" STUDY_ID="STD-Davidson-1997" TOTAL_1="114" TOTAL_2="41" WEIGHT="17.132133501957618"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.799026502482321E-32" CI_END="29.55775152977472" CI_START="0.6422484702252884" DF="0" EFFECT_SIZE="15.100000000000003" ESTIMABLE="YES" I2="100.0" ID="CMP-001.06.02" MODIFIED="2016-12-12 17:56:40 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.04065510475608419" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="39.196012205490746" Z="2.0470303494706688">
<NAME>PaO<SUB>2</SUB> after 30 to 60 minutes; infants with diaphragmatic hernia</NAME>
<CONT_DATA CI_END="29.557751529774716" CI_START="0.6422484702252866" EFFECT_SIZE="15.100000000000001" ESTIMABLE="YES" MEAN_1="53.4" MEAN_2="38.3" MODIFIED="2015-10-26 21:56:02 -0400" MODIFIED_BY="[Empty name]" ORDER="220" SD_1="30.1" SD_2="16.1" SE="7.37653938736406" STUDY_ID="STD-Ninos-1997" TOTAL_1="21" TOTAL_2="23" WEIGHT="39.196012205490746"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.6317094896474968" CI_END="-8.697944470444185" CI_START="-18.531867264911213" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-13.614905867677699" ESTIMABLE="YES" I2="38.7145808525001" I2_Q="38.7145808525001" ID="CMP-001.07" MODIFIED="2016-12-12 18:39:11 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.2014668262534265" P_Q="0.2014668262534265" P_Z="5.728461256774745E-8" Q="1.6317094896474968" RANDOM="NO" SCALE="20.99491861912011" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="135" TOTAL_2="142" UNITS="" WEIGHT="100.0" Z="5.427076398965685">
<NAME>Change in oxygenation index after treatment</NAME>
<GROUP_LABEL_1>iNO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors iNO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-9.680698599106961" CI_START="-20.51930140089304" DF="0" EFFECT_SIZE="-15.1" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" MODIFIED="2016-12-12 18:39:11 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="4.731396421348619E-8" STUDIES="1" TAU2="0.0" TOTAL_1="114" TOTAL_2="119" WEIGHT="82.32030794854403" Z="5.46112016609333">
<NAME>Change in OI; studies that did not allow back-up use of iNO in controls</NAME>
<CONT_DATA CI_END="-9.680698599106961" CI_START="-20.51930140089304" EFFECT_SIZE="-15.1" ESTIMABLE="YES" MEAN_1="-14.1" MEAN_2="1.0" ORDER="1" SD_1="21.0" SD_2="21.2" SE="2.765000501866257" STUDY_ID="STD-Ninos-1996" TOTAL_1="114" TOTAL_2="119" WEIGHT="82.32030794854403"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.993902018545726" CI_START="-18.393902018545727" DF="0" EFFECT_SIZE="-6.7" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" MODIFIED="2015-10-26 21:57:48 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2614554281160758" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="17.679692051455973" Z="1.1229578181510582">
<NAME>Change in OI; infants with diaphragmatic hernia</NAME>
<CONT_DATA CI_END="4.993902018545726" CI_START="-18.393902018545727" EFFECT_SIZE="-6.7" ESTIMABLE="YES" MEAN_1="-2.7" MEAN_2="4.0" MODIFIED="2015-10-26 21:57:48 -0400" MODIFIED_BY="[Empty name]" ORDER="221" SD_1="23.4" SD_2="14.8" SE="5.966386173820403" STUDY_ID="STD-Ninos-1997" TOTAL_1="21" TOTAL_2="23" WEIGHT="17.679692051455973"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="17.68179110802519" CI_END="23.357165700251024" CI_START="7.182337236691032" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="15.269751468471027" ESTIMABLE="YES" I2="94.34446434815004" I2_Q="94.34446434815004" ID="CMP-001.08" MODIFIED="2016-12-12 18:39:24 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="2.6111622354663133E-5" P_Q="2.6111622354663133E-5" P_Z="2.1510310210331004E-4" Q="17.68179110802519" RANDOM="NO" SCALE="70.91" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="135" TOTAL_2="142" UNITS="" WEIGHT="100.0" Z="3.700584893188264">
<NAME>Change in PaO<SUB>2</SUB> after treatment</NAME>
<GROUP_LABEL_1>iNO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors iNO</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="68.66275499566979" CI_START="32.13724500433021" DF="0" EFFECT_SIZE="50.4" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" MODIFIED="2016-12-12 18:39:24 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="6.33981112611298E-8" STUDIES="1" TAU2="0.0" TOTAL_1="114" TOTAL_2="119" WEIGHT="19.6104152596591" Z="5.408942125338735">
<NAME>Change in PaO<SUB>2</SUB>; studies that did not allow back-up use of iNO in controls</NAME>
<CONT_DATA CI_END="68.66275499566979" CI_START="32.13724500433021" EFFECT_SIZE="50.4" ESTIMABLE="YES" MEAN_1="59.4" MEAN_2="9.0" ORDER="1" SD_1="85.6" SD_2="51.8" SE="9.317903359308675" STUDY_ID="STD-Ninos-1996" TOTAL_1="114" TOTAL_2="119" WEIGHT="19.6104152596591"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="15.720067661744455" CI_START="-2.3200676617444564" DF="0" EFFECT_SIZE="6.699999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.02" MODIFIED="2016-03-12 17:22:41 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.14543736437224414" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="80.38958474034091" Z="1.45583815874378">
<NAME>Change in PaO<SUB>2</SUB>; infants with diaphragmatic hernia</NAME>
<CONT_DATA CI_END="15.720067661744455" CI_START="-2.3200676617444564" EFFECT_SIZE="6.699999999999999" ESTIMABLE="YES" MEAN_1="7.8" MEAN_2="1.1" MODIFIED="2015-10-26 21:58:50 -0400" MODIFIED_BY="[Empty name]" ORDER="222" SD_1="19.8" SD_2="7.6" SE="4.602159903392918" STUDY_ID="STD-Ninos-1997" TOTAL_1="21" TOTAL_2="23" WEIGHT="80.38958474034091"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.568094466991816" CI_END="1.44149856935323" CI_START="0.656929889927751" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9731204943357364" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="48" I2="36.22833183523891" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.15881421569938717" LOG_CI_START="-0.18248097753646214" LOG_EFFECT_SIZE="-0.011833380918537481" METHOD="MH" MODIFIED="2008-08-22 13:26:15 -0400" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.210484002349149" P_Q="1.0" P_Z="0.891891107113093" Q="0.0" RANDOM="NO" SCALE="4.101469199311378" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="120" TOTAL_2="181" WEIGHT="100.00000000000001" Z="0.13591167338620927">
<NAME>Neurodevelopmental disability at 18 to 24 months among survivors</NAME>
<GROUP_LABEL_1>iNO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours iNO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4865289637055483" CI_START="0.2506345221440166" EFFECT_SIZE="0.6103896103896104" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="22" LOG_CI_END="0.1721733754682698" LOG_CI_START="-0.6009591099417987" LOG_EFFECT_SIZE="-0.21439286723676443" ORDER="203" O_E="0.0" SE="0.4541418489973991" STUDY_ID="STD-Davidson-1997" TOTAL_1="35" TOTAL_2="94" VAR="0.2062448190107765" WEIGHT="31.719876416065915"/>
<DICH_DATA CI_END="1.7670936787904041" CI_START="0.7375481539551312" EFFECT_SIZE="1.141628959276018" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="26" LOG_CI_END="0.2472595733343426" LOG_CI_START="-0.1322096196694148" LOG_EFFECT_SIZE="0.057524976832463895" ORDER="204" O_E="0.0" SE="0.222902082373207" STUDY_ID="STD-Ninos-1996" TOTAL_1="85" TOTAL_2="87" VAR="0.04968533832631196" WEIGHT="68.2801235839341"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.17235938604139384" CI_END="1.6754787099432045" CI_START="0.7214030857043534" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0994068907301686" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.2241389136914752" LOG_CI_START="-0.14182200437763987" LOG_EFFECT_SIZE="0.04115845465691764" METHOD="MH" MODIFIED="2016-12-12 18:39:38 -0500" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.6780236913621046" P_Q="0.6808200131602414" P_Z="0.6593130740756841" Q="0.16920451789226781" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="83" TOTAL_2="95" WEIGHT="100.0" Z="0.4408617685872585">
<NAME>Hearing impairment in at least 1 ear among survivors</NAME>
<GROUP_LABEL_1>iNO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours iNO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.841066555686663" CI_START="0.706972467029508" DF="0" EFFECT_SIZE="1.1408695652173912" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="0.26506948880004305" LOG_CI_START="-0.15059749942798356" LOG_EFFECT_SIZE="0.057235994686029766" MODIFIED="2016-12-12 18:39:38 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5893616241894527" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="82" WEIGHT="80.46960037319235" Z="0.5397613540693508">
<NAME>Hearing impairment among survivors; studies that did not allow back-up use of iNO in controls</NAME>
<DICH_DATA CI_END="1.8410665556866628" CI_START="0.7069724670295081" EFFECT_SIZE="1.1408695652173912" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.265069488800043" LOG_CI_START="-0.15059749942798348" LOG_EFFECT_SIZE="0.057235994686029766" ORDER="205" O_E="0.0" SE="0.24416484646991882" STUDY_ID="STD-Ninos-1996" TOTAL_1="75" TOTAL_2="82" VAR="0.05961647225167903" WEIGHT="80.46960037319235"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1865346633724934" CI_START="0.39434311854414605" DF="0" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="0.3397563666532381" LOG_CI_START="-0.40412573339604063" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2016-12-12 18:02:25 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8653255300027496" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="13" WEIGHT="19.53039962680765" Z="0.16959897343300182">
<NAME>Hearing impairment among survivors; infants with diaphragmatic hernia</NAME>
<DICH_DATA CI_END="2.1865346633724934" CI_START="0.39434311854414605" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.3397563666532381" LOG_CI_START="-0.40412573339604063" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2015-10-26 21:29:28 -0400" MODIFIED_BY="[Empty name]" ORDER="223" O_E="0.0" SE="0.43696002784472854" STUDY_ID="STD-Ninos-1997" TOTAL_1="8" TOTAL_2="13" VAR="0.19093406593406592" WEIGHT="19.53039962680765"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.082864002103428" CI_END="2.450688221610295" CI_START="0.6166273409008218" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2292930331977483" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" I2="3.9783683437682833" I2_Q="46.381315308856486" ID="CMP-001.11" LOG_CI_END="0.38928806349731" LOG_CI_START="-0.2099772228156246" LOG_EFFECT_SIZE="0.08965542034084273" METHOD="MH" MODIFIED="2016-12-12 18:39:51 -0500" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.3529490578022565" P_Q="0.1720465596901677" P_Z="0.5575690492895609" Q="1.865021504649433" RANDOM="NO" SCALE="6.895977046828895" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="128" TOTAL_2="193" WEIGHT="99.99999999999999" Z="0.5864561118432291">
<NAME>Cerebral palsy among survivors</NAME>
<GROUP_LABEL_1>iNO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours iNO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.21827844324343404" CI_END="2.138407339348155" CI_START="0.48692145248072793" DF="1" EFFECT_SIZE="1.020409921389856" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="0.3300904363175673" LOG_CI_START="-0.3125410911580167" LOG_EFFECT_SIZE="0.00877467257977526" MODIFIED="2016-12-12 18:39:51 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.640354816785555" P_Z="0.9573145643040224" STUDIES="2" TAU2="0.0" TOTAL_1="120" TOTAL_2="179" WEIGHT="97.14364420299077" Z="0.05352380484676452">
<NAME>Cerebral palsy among survivors; studies that did not allow back-up use of iNO in controls</NAME>
<DICH_DATA CI_END="3.4424207572829" CI_START="0.1638473891619534" EFFECT_SIZE="0.7510204081632653" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.5368639518132406" LOG_CI_START="-0.7855604745232326" LOG_EFFECT_SIZE="-0.12434826135499599" ORDER="206" O_E="0.0" SE="0.776798654136529" STUDY_ID="STD-Davidson-1997" TOTAL_1="35" TOTAL_2="92" VAR="0.6034161490683229" WEIGHT="29.38822762277204"/>
<DICH_DATA CI_END="2.659407319319121" CI_START="0.4863296805413639" EFFECT_SIZE="1.1372549019607843" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.42478485970279284" LOG_CI_START="-0.313069224772791" LOG_EFFECT_SIZE="0.0558578174650009" ORDER="207" O_E="0.0" SE="0.43341914165758183" STUDY_ID="STD-Ninos-1996" TOTAL_1="85" TOTAL_2="87" VAR="0.18785215235519498" WEIGHT="67.75541658021874"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="154.78009043484093" CI_START="0.4486652272223542" DF="0" EFFECT_SIZE="8.333333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="2.1897150960731366" LOG_CI_START="-0.3480775881683866" LOG_EFFECT_SIZE="0.9208187539523752" MODIFIED="2015-10-26 21:31:13 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.1549345305499678" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="14" WEIGHT="2.856355797009221" Z="1.422316019147247">
<NAME>Cerebral palsy among survivors; infants with diaphragmatic hernia</NAME>
<DICH_DATA CI_END="154.78009043484093" CI_START="0.4486652272223542" EFFECT_SIZE="8.333333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.1897150960731366" LOG_CI_START="-0.3480775881683866" LOG_EFFECT_SIZE="0.9208187539523752" MODIFIED="2015-10-26 21:31:13 -0400" MODIFIED_BY="[Empty name]" ORDER="224" O_E="0.0" SE="1.4907119849998596" STUDY_ID="STD-Ninos-1997" TOTAL_1="8" TOTAL_2="14" VAR="2.222222222222222" WEIGHT="2.856355797009221"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1610093586333175" CI_END="1.1207387339036077" CI_START="0.3830756630603837" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6552310536044361" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.049504381864764246" LOG_CI_START="-0.4167154380307922" LOG_EFFECT_SIZE="-0.183605528083014" METHOD="MH" MODIFIED="2016-12-12 19:43:12 -0500" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.6882291333232977" P_Q="1.0" P_Z="0.12265223635500538" Q="0.0" RANDOM="NO" SCALE="6.53" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="173" WEIGHT="100.0" Z="1.5437362679509485">
<NAME>BSID MDI &gt; 2 SD below the mean</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7432954310518016" CI_START="0.16550404701371493" EFFECT_SIZE="0.5371428571428571" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="15" LOG_CI_END="0.2413709919311708" LOG_CI_START="-0.7811913821043623" LOG_EFFECT_SIZE="-0.2699101950865958" ORDER="208" O_E="0.0" SE="0.6006582002738587" STUDY_ID="STD-Davidson-1997" TOTAL_1="35" TOTAL_2="94" VAR="0.36079027355623094" WEIGHT="28.46580406654344"/>
<DICH_DATA CI_END="1.2768338110315158" CI_START="0.38620221764361196" EFFECT_SIZE="0.7022222222222222" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" LOG_CI_END="0.10613437443741465" LOG_CI_START="-0.4131852367512944" LOG_EFFECT_SIZE="-0.15352543115693987" ORDER="209" O_E="0.0" SE="0.30505091028578235" STUDY_ID="STD-Ninos-1996" TOTAL_1="75" TOTAL_2="79" VAR="0.09305605786618444" WEIGHT="71.53419593345656"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.398573497942326" CI_END="0.9354687115964953" CI_START="0.24763722059077456" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4813074606625052" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="-0.02897073366715764" LOG_CI_START="-0.6061840790286348" LOG_EFFECT_SIZE="-0.3175774063478962" METHOD="MH" MODIFIED="2016-12-12 19:43:20 -0500" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.5278272948277727" P_Q="1.0" P_Z="0.031028434364075843" Q="0.0" RANDOM="NO" SCALE="13.84" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="173" WEIGHT="100.0" Z="2.1567078576664516">
<NAME>BSID PDI &gt; 2 SD below the mean</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3858583674638414" CI_START="0.08132438658858376" EFFECT_SIZE="0.3357142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" LOG_CI_END="0.14171884833355944" LOG_CI_START="-1.0897792038186007" LOG_EFFECT_SIZE="-0.4740301777425206" ORDER="210" O_E="0.0" SE="0.7233880518478523" STUDY_ID="STD-Davidson-1997" TOTAL_1="35" TOTAL_2="94" VAR="0.523290273556231" WEIGHT="34.397622798795446"/>
<DICH_DATA CI_END="1.1730157539100499" CI_START="0.26510321040272994" EFFECT_SIZE="0.5576470588235294" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.0693038448437978" LOG_CI_START="-0.5765850129242132" LOG_EFFECT_SIZE="-0.2536405840402077" ORDER="211" O_E="0.0" SE="0.3793983122543394" STUDY_ID="STD-Ninos-1996" TOTAL_1="75" TOTAL_2="79" VAR="0.1439430793414412" WEIGHT="65.60237720120455"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-12-12 18:03:34 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Inhaled NO at moderate compared with severe criteria for illness severity</NAME>
<DICH_OUTCOME CHI2="0.46344238674072435" CI_END="1.266137420352785" CI_START="0.6172092187293501" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8840088732699108" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.10248084443493999" LOG_CI_START="-0.2095675958730059" LOG_EFFECT_SIZE="-0.05354337571903294" METHOD="MH" MODIFIED="2016-10-07 17:04:42 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9769608962965127" P_Q="1.0" P_Z="0.5011969218110723" Q="0.0" RANDOM="NO" SCALE="1.2" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="245" TOTAL_2="250" WEIGHT="100.0" Z="0.6726076753752566">
<NAME>Death or use of ECMO</NAME>
<GROUP_LABEL_1>Earlier iNO</GROUP_LABEL_1>
<GROUP_LABEL_2>Later iNO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours earlier iNO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours later iNO</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.637782360776234" CI_START="0.4824349533326522" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.21425618936955568" LOG_CI_START="-0.3165612342643183" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2016-03-24 12:19:38 -0400" MODIFIED_BY="[Empty name]" ORDER="166" O_E="0.0" SE="0.31180478223116176" STUDY_ID="STD-Barefield-1996" TOTAL_1="9" TOTAL_2="8" VAR="0.09722222222222221" WEIGHT="13.51019685734467"/>
<DICH_DATA CI_END="2.8192288560414775" CI_START="0.42548744586314746" EFFECT_SIZE="1.0952380952380953" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.45013033194884083" LOG_CI_START="-0.3711132493814935" LOG_EFFECT_SIZE="0.039508541283673655" MODIFIED="2016-03-24 12:19:37 -0400" MODIFIED_BY="[Empty name]" ORDER="167" O_E="0.0" SE="0.48240254489472895" STUDY_ID="STD-Cornfield-1999" TOTAL_1="15" TOTAL_2="23" VAR="0.232712215320911" WEIGHT="11.752291125906549"/>
<DICH_DATA CI_END="5.2041576126931846" CI_START="0.04803851431982733" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7163504410960008" LOG_CI_START="-1.3184104324239634" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2014-01-09 11:15:19 -0500" MODIFIED_BY="[Empty name]" ORDER="144" O_E="0.0" SE="1.1952286093343936" STUDY_ID="STD-Gonzalez-2010" TOTAL_1="28" TOTAL_2="28" VAR="1.4285714285714284" WEIGHT="4.253210121756656"/>
<DICH_DATA CI_END="1.3901082007935894" CI_START="0.5275036084727215" EFFECT_SIZE="0.8563218390804598" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="29" LOG_CI_END="0.14304860541865935" LOG_CI_START="-0.2777745651593107" LOG_EFFECT_SIZE="-0.06736297987032568" ORDER="225" O_E="0.0" SE="0.2471936135057899" STUDY_ID="STD-Konduri-2004" TOTAL_1="150" TOTAL_2="149" VAR="0.06110468255804983" WEIGHT="61.877806119202184"/>
<DICH_DATA CI_END="3.6529443336510337" CI_START="0.2611671894879745" EFFECT_SIZE="0.9767441860465116" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.562643054152134" LOG_CI_START="-0.5830813845155063" LOG_EFFECT_SIZE="-0.010219165181686082" MODIFIED="2016-03-24 12:19:27 -0400" MODIFIED_BY="[Empty name]" ORDER="226" O_E="0.0" SE="0.673004206700811" STUDY_ID="STD-Sadiq-1998" TOTAL_1="43" TOTAL_2="42" VAR="0.45293466223698786" WEIGHT="8.606495775789938"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2357401237996128" CI_END="1.258770524385951" CI_START="0.3756352012881582" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6876325467161347" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.09994656483666452" LOG_CI_START="-0.4252337161693351" LOG_EFFECT_SIZE="-0.16264357566633528" METHOD="MH" MODIFIED="2016-12-12 18:03:01 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8721799335720486" P_Q="1.0" P_Z="0.22476066033741404" Q="0.0" RANDOM="NO" SCALE="1.2" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="245" TOTAL_2="250" WEIGHT="100.0" Z="1.2139661832398108">
<NAME>Death before hospital discharge</NAME>
<GROUP_LABEL_1>Earlier iNO</GROUP_LABEL_1>
<GROUP_LABEL_2>Later iNO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours earlier iNO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours later iNO</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.099863450809426" CI_START="0.19630562935001775" EFFECT_SIZE="1.7777777777777777" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2068221926274114" LOG_CI_START="-0.7070672461942117" LOG_EFFECT_SIZE="0.2498774732165999" MODIFIED="2016-04-28 12:00:47 -0400" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="1.1242281302693367" STUDY_ID="STD-Barefield-1996" TOTAL_1="9" TOTAL_2="8" VAR="1.2638888888888888" WEIGHT="4.47824295989884"/>
<DICH_DATA CI_END="1.8316233368658879" CI_START="0.10478542928489472" EFFECT_SIZE="0.4380952380952381" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.26283616827317113" LOG_CI_START="-0.979699103049899" LOG_EFFECT_SIZE="-0.358431467388364" MODIFIED="2016-04-28 12:00:48 -0400" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="0.7298713690239609" STUDY_ID="STD-Cornfield-1999" TOTAL_1="15" TOTAL_2="23" VAR="0.532712215320911" WEIGHT="23.37328562403342"/>
<DICH_DATA CI_END="5.2041576126931846" CI_START="0.04803851431982733" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7163504410960008" LOG_CI_START="-1.3184104324239634" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2014-01-09 11:14:53 -0500" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="1.1952286093343936" STUDY_ID="STD-Gonzalez-2010" TOTAL_1="28" TOTAL_2="28" VAR="1.4285714285714284" WEIGHT="8.45890336869781"/>
<DICH_DATA CI_END="1.5465606537050471" CI_START="0.32551199015385657" EFFECT_SIZE="0.7095238095238096" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.18936695702776196" LOG_CI_START="-0.4874330096710523" LOG_EFFECT_SIZE="-0.14903302632164522" ORDER="227" O_E="0.0" SE="0.3975556506527503" STUDY_ID="STD-Konduri-2004" TOTAL_1="150" TOTAL_2="149" VAR="0.15805049536593163" WEIGHT="59.41035810791104"/>
<DICH_DATA CI_END="15.111695347702627" CI_START="0.06313184477482867" EFFECT_SIZE="0.9767441860465116" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.179313189610355" LOG_CI_START="-1.1997515199737272" LOG_EFFECT_SIZE="-0.010219165181686082" ORDER="228" O_E="0.0" SE="1.3974743869699322" STUDY_ID="STD-Sadiq-1998" TOTAL_1="43" TOTAL_2="42" VAR="1.9529346622369879" WEIGHT="4.279209939458892"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0578022427934763" CI_END="1.5419247800436722" CI_START="0.6569670011764669" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0064758808759278" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.18806318797644023" LOG_CI_START="-0.18245644408844616" LOG_EFFECT_SIZE="0.002803371943997052" METHOD="MH" MODIFIED="2016-12-12 18:03:11 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7872693140935638" P_Q="1.0" P_Z="0.9763394965453722" Q="0.0" RANDOM="NO" SCALE="1.2" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="217" TOTAL_2="222" WEIGHT="99.99999999999999" Z="0.029658390919172925">
<NAME>Use of ECMO before hospital discharge</NAME>
<GROUP_LABEL_1>Earlier iNO</GROUP_LABEL_1>
<GROUP_LABEL_2>Later iNO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours earlier iNO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours later iNO</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.637782360776234" CI_START="0.4824349533326522" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.21425618936955568" LOG_CI_START="-0.3165612342643183" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2016-04-28 11:57:59 -0400" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="0.31180478223116176" STUDY_ID="STD-Barefield-1996" TOTAL_1="9" TOTAL_2="8" VAR="0.09722222222222221" WEIGHT="20.235000507566898"/>
<DICH_DATA CI_END="4.404616312142398" CI_START="0.5337834091540961" EFFECT_SIZE="1.5333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.6439080828327717" LOG_CI_START="-0.27263492890894836" LOG_EFFECT_SIZE="0.18563657696191166" MODIFIED="2016-04-28 11:58:00 -0400" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="0.5383819020581656" STUDY_ID="STD-Cornfield-1999" TOTAL_1="15" TOTAL_2="23" VAR="0.2898550724637682" WEIGHT="12.572916982040837"/>
<DICH_DATA CI_END="1.6647130205673983" CI_START="0.46832311895933215" EFFECT_SIZE="0.882962962962963" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.22133937638518764" LOG_CI_START="-0.32945440256676456" LOG_EFFECT_SIZE="-0.054057513090788496" ORDER="229" O_E="0.0" SE="0.3235389922295545" STUDY_ID="STD-Konduri-2004" TOTAL_1="150" TOTAL_2="149" VAR="0.10467747949291573" WEIGHT="57.524248934554734"/>
<DICH_DATA CI_END="5.470880093054035" CI_START="0.31001445674345574" EFFECT_SIZE="1.302325581395349" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7380571963172899" LOG_CI_START="-0.5086180534640622" LOG_EFFECT_SIZE="0.11471957142661392" MODIFIED="2016-03-24 12:16:21 -0400" MODIFIED_BY="[Empty name]" ORDER="230" O_E="0.0" SE="0.7323032128635795" STUDY_ID="STD-Sadiq-1998" TOTAL_1="43" TOTAL_2="42" VAR="0.536267995570321" WEIGHT="9.66783357583752"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="34.48234023970178" CI_END="0.786974704519523" CI_START="0.5514600503235164" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6587754626256739" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="154" I2="85.49982406866" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.10403922680756963" LOG_CI_START="-0.25848594388105217" LOG_EFFECT_SIZE="-0.1812625853443109" METHOD="MH" MODIFIED="2016-11-02 21:23:46 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.9084479303543844E-6" P_Q="1.0" P_Z="4.214235715704592E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="253" TOTAL_2="259" WEIGHT="100.0" Z="4.600526909878415">
<NAME>Progression to severe disease criteria</NAME>
<GROUP_LABEL_1>Earlier iNO</GROUP_LABEL_1>
<GROUP_LABEL_2>Later iNO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours earlier iNO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours later iNO</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2372590834406036" CI_START="0.8082381559237963" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.0924606509040061" LOG_CI_START="-0.09246065090400613" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-04-28 11:58:13 -0400" MODIFIED_BY="[Empty name]" ORDER="186" O_E="0.0" SE="0.10862368805723334" STUDY_ID="STD-Barefield-1996" TOTAL_1="9" TOTAL_2="8" VAR="0.011799105607155136" WEIGHT="5.9251056389334105"/>
<DICH_DATA CI_END="1.2847141031086746" CI_START="0.7732027242799069" EFFECT_SIZE="0.9966666666666667" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="0.10880649166982398" LOG_CI_START="-0.11170662446028957" LOG_EFFECT_SIZE="-0.0014500663952327743" MODIFIED="2016-04-28 11:58:13 -0400" MODIFIED_BY="[Empty name]" ORDER="182" O_E="0.0" SE="0.12953049597235794" STUDY_ID="STD-Cornfield-1999" TOTAL_1="15" TOTAL_2="23" VAR="0.016778149386845034" WEIGHT="10.45606877458837"/>
<DICH_DATA CI_END="1.4452230424315222" CI_START="0.02767738876672061" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.159934877280902" LOG_CI_START="-1.5578748859529397" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2015-10-26 21:53:49 -0400" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="1.009049958219026" STUDY_ID="STD-Day-1996" TOTAL_1="11" TOTAL_2="11" VAR="1.0181818181818183" WEIGHT="3.311088445286318"/>
<DICH_DATA CI_END="0.8353176083745628" CI_START="0.20297689323263132" EFFECT_SIZE="0.4117647058823529" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="17" LOG_CI_END="-0.07814836363268365" LOG_CI_START="-0.6925533990953506" LOG_EFFECT_SIZE="-0.38535088136401713" MODIFIED="2014-01-23 18:37:10 -0500" MODIFIED_BY="[Empty name]" ORDER="183" O_E="0.0" SE="0.36090455918474645" STUDY_ID="STD-Gonzalez-2010" TOTAL_1="28" TOTAL_2="28" VAR="0.13025210084033617" WEIGHT="11.25770071397348"/>
<DICH_DATA CI_END="0.9537564254561368" CI_START="0.5867352412597001" EFFECT_SIZE="0.7480658436213992" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="81" LOG_CI_END="-0.02056252318569329" LOG_CI_START="-0.23155782583688658" LOG_EFFECT_SIZE="-0.12606017451128992" MODIFIED="2014-01-23 18:36:00 -0500" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="0.12393968522090362" STUDY_ID="STD-Konduri-2004" TOTAL_1="150" TOTAL_2="149" VAR="0.015361045572656676" WEIGHT="53.81902957890135"/>
<DICH_DATA CI_END="0.5715552258178355" CI_START="0.11906623714153639" EFFECT_SIZE="0.2608695652173913" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="23" LOG_CI_END="-0.24294180007328026" LOG_CI_START="-0.9242113711946183" LOG_EFFECT_SIZE="-0.5835765856339492" MODIFIED="2014-01-23 18:42:51 -0500" MODIFIED_BY="[Empty name]" ORDER="185" O_E="0.0" SE="0.40018111841543935" STUDY_ID="STD-Sadiq-1998" TOTAL_1="40" TOTAL_2="40" VAR="0.16014492753623188" WEIGHT="15.231006848317062"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7914373148260245" CI_END="1.5263942362035325" CI_START="0.5397966146760121" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9077127526721458" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.18366671742964336" LOG_CI_START="-0.2677698434403722" LOG_EFFECT_SIZE="-0.042051563005364404" METHOD="MH" MODIFIED="2016-10-07 17:05:06 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.40831409594887713" P_Q="1.0" P_Z="0.7150043379013098" Q="0.0" RANDOM="NO" SCALE="1.2" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="220" TOTAL_2="217" WEIGHT="100.00000000000001" Z="0.3651434382066482">
<NAME>Chronic lung disease</NAME>
<GROUP_LABEL_1>Earlier iNO</GROUP_LABEL_1>
<GROUP_LABEL_2>Later iNO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours earlier iNO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours later iNO</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6599400659009105" CI_START="0.18241084813716563" EFFECT_SIZE="0.5502645502645502" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.22009240760727705" LOG_CI_START="-0.7389493373562047" LOG_EFFECT_SIZE="-0.2594284648744638" MODIFIED="2016-03-24 12:38:06 -0400" MODIFIED_BY="[Empty name]" ORDER="285" O_E="0.0" SE="0.5633458683247508" STUDY_ID="STD-Gonzalez-2010" TOTAL_1="27" TOTAL_2="26" VAR="0.3173585673585674" WEIGHT="27.173805126983183"/>
<DICH_DATA CI_END="2.451727312313499" CI_START="0.6096367150504904" EFFECT_SIZE="1.2225641025641025" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.3894721651354651" LOG_CI_START="-0.21492888572410354" LOG_EFFECT_SIZE="0.08727163970568079" MODIFIED="2016-03-24 12:38:25 -0400" MODIFIED_BY="[Empty name]" ORDER="286" O_E="0.0" SE="0.35502816910836404" STUDY_ID="STD-Konduri-2004" TOTAL_1="150" TOTAL_2="149" VAR="0.12604500086043713" WEIGHT="49.69674505624944"/>
<DICH_DATA CI_END="2.143760390379424" CI_START="0.19778935271499137" EFFECT_SIZE="0.6511627906976745" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3311762423307585" LOG_CI_START="-0.703797090805493" LOG_EFFECT_SIZE="-0.18631042423736727" MODIFIED="2016-03-24 12:42:13 -0400" MODIFIED_BY="[Empty name]" ORDER="287" O_E="0.0" SE="0.6079484590848591" STUDY_ID="STD-Sadiq-1998" TOTAL_1="43" TOTAL_2="42" VAR="0.3696013289036545" WEIGHT="23.129449816767387"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7423132583242202" CI_START="0.7380770072394047" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1340023612750885" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.24112624144701347" LOG_CI_START="-0.13189832371300245" LOG_EFFECT_SIZE="0.05461395886700551" METHOD="MH" MODIFIED="2016-10-07 17:05:15 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.5660282428474959" Q="0.0" RANDOM="YES" SCALE="1.2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="121" TOTAL_2="113" WEIGHT="100.0" Z="0.5739106880886804">
<NAME>Neurodevelopmental disability at 18 to 24 months among survivors</NAME>
<GROUP_LABEL_1>Earlier iNO</GROUP_LABEL_1>
<GROUP_LABEL_2>Later iNO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours earlier iNO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours later iNO</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7423132583242202" CI_START="0.7380770072394047" EFFECT_SIZE="1.1340023612750885" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="28" LOG_CI_END="0.24112624144701347" LOG_CI_START="-0.13189832371300245" LOG_EFFECT_SIZE="0.05461395886700551" MODIFIED="2015-10-02 10:18:38 -0400" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.21911647607637086" STUDY_ID="STD-Konduri-2004" TOTAL_1="121" TOTAL_2="113" VAR="0.04801203008812681" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9493507394406255" CI_START="0.03285619100626076" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.31129476584022037" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.4697264223130815" LOG_CI_START="-1.4833827854184671" LOG_EFFECT_SIZE="-0.5068281815526928" METHOD="MH" MODIFIED="2016-12-12 18:03:25 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.3090516673535417" Q="0.0" RANDOM="NO" SCALE="1.2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="121" TOTAL_2="113" WEIGHT="100.0" Z="1.0172139665932516">
<NAME>Hearing impairment among survivors</NAME>
<GROUP_LABEL_1>Earlier iNO</GROUP_LABEL_1>
<GROUP_LABEL_2>Later iNO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours earlier iNO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours later iNO</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9493507394406255" CI_START="0.03285619100626076" EFFECT_SIZE="0.31129476584022037" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4697264223130815" LOG_CI_START="-1.4833827854184671" LOG_EFFECT_SIZE="-0.5068281815526928" MODIFIED="2015-10-02 10:19:13 -0400" MODIFIED_BY="[Empty name]" ORDER="86" O_E="0.0" SE="1.1472660166680142" STUDY_ID="STD-Konduri-2004" TOTAL_1="121" TOTAL_2="113" VAR="1.316219313001292" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.3854904285998026" CI_START="0.5257369193677124" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.334120425029516" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.5296215903053039" LOG_CI_START="-0.2792315239998782" LOG_EFFECT_SIZE="0.12519503315271283" METHOD="MH" MODIFIED="2016-12-12 18:03:34 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.5440300619370606" Q="0.0" RANDOM="NO" SCALE="1.2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="121" TOTAL_2="113" WEIGHT="100.0" Z="0.6067300766552619">
<NAME>Cerebral palsy among survivors</NAME>
<GROUP_LABEL_1>Earlier iNO</GROUP_LABEL_1>
<GROUP_LABEL_2>Later iNO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours earlier iNO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours later iNO</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3854904285998026" CI_START="0.5257369193677124" EFFECT_SIZE="1.334120425029516" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5296215903053039" LOG_CI_START="-0.2792315239998782" LOG_EFFECT_SIZE="0.12519503315271283" MODIFIED="2015-10-02 10:19:43 -0400" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="0.4751243232303537" STUDY_ID="STD-Konduri-2004" TOTAL_1="121" TOTAL_2="113" VAR="0.2257431225251016" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-12-12 18:13:32 -0500" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-12-12 18:13:32 -0500" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram: review update.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAoIAAAMxCAYAAAB/2dJ6AABiV0lEQVR42uzdD4RWef8//g9ZSbJu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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-12-12 17:21:29 -0500" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAT4AAAMYCAIAAADdMBxlAAApGElEQVR42u3dva4cxdbG8S0hIQIH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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-12-12 17:21:29 -0500" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAAEACAMAAABWJIaGAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAZP0lEQVR42u1da2wbV3Y+sjgzHFKvGUobK14YtiXkjxNg68Cx5UTZ
gHZ2IySt06CLBmiDjf1DgbtOimKBIimwbbc/asNAfmQ3G9RGUW+bzWKDBi7sbWI3thnElFNEbg0U
ibdFIFmq04jKSpqhZEkkZyix9zFPvkRRlETJ59NjZu7ce8/l5Tf3nhnejwcAgSiPBlCwExDloG/B
PkAsAeQIAjmCQI4gkCMI5AgCOYJAjiA2OwLYBUWgYxd4nq0iR+pseF03ywv+wxzONQj0RxDIEQRy
BIEcQSBHagZtzQsiynEkSiDKg8XyRdergdtK2FbDS7Tw/uIFo8VzN6WQC5WNI7FYbFz8dl01sIe0
qtgo8QdfLlHwQPGC9ivNO76j4LhT8VyjjiwAtMtiUCEXW1tQjAOYYZE+dDNDUoh0ZPS0eFCNSxK/
8FRJDJI9LSSFNZblbJRfpOTPbBLDJtlr7RNJFrNPPOukser6FZJpMCyGBrkp1akn2iaRNgikDVH2
A4OW7Tbb7q4WldqWXdvg1NVB7VkFSds9baDokJk98iJfkiTyulKi0BcH9fguJEPF/kg3SZrTjNA8
2c+NXT0IEBHH6XugSJngdrLtH//XzDOJZCvLPRcyQuS93T6duUT6OxJMvOzWFNENKUJ33rnaQor/
sPUYSxMj/Kxwkta690tj6hDZLo41zTn1wHsJ0gaTtCHGr/ioZXvRtps9zGzLrm1a10fG1F7yrv/7
XJtdMCIY5wNOGygyX4X2sp3ZP84kicnWD8xzTwIcNpEMFXGE+iOZa6SXZdAeJccjau9jpFeH1Rv0
bRmGoSzZ3lDlfSOq/BgrETDVIXKBZgXolUnOIdXzUUdGAC3Da+kFMPZMpFmanuFnR1jeoAqyQbaj
KrVo1QN7VKcNnBLEtslyWXaN3fm2aV2PgEz2zNtCxmnDbdgTdNpAMaVOBtlOuhdoZYGDqRRp2G7k
SCn41sVHYxB/92/okL9zIXsgRo/pn5RhG3okGnYi+yM5v5l98V8m2OwyYNDTdk66IYniJecoZvuK
A5QTTl6yGze9RQa4DbcNhbYBnrpEbS9837Xtrws8BUn73YL0f/8ZujE7fvxqT4zWkmud4O2xoePn
NTmlZGf0Pryd3UyI13y3kXRWuE42vQXuy/z4P8+Qc8TbJX3coMGge+c5QBIvOTkHmM8wwDOCk7eB
JLiX8HXntL8NBbZjg9R2wmPbrWvA436SfS3na3EHaP/EdlpyLTPsFSROk+0gjhcV0/YIkHFk8X+G
DrlJ0i422AgydH+an11OqQ30nAlnySgvdQEtNxDXdtCh34QrISeneNMMsjSFp0k74dAAwJVBUGUn
k1UPBWnDXodap/Jtiw8R26ptO8VnD6sucZcpEeow5mW64WbG1+IUPMC914XJw9QzIrU8T1j0kIhk
qHhok/dpEDra6TkxZTLXMxYRUwV3kx+qwlySnGsVj83QnCItNx3tbKTl2oTX3acY8utNOkvbz9Om
shLNqz8hpWbc4YHXQxE+2kmZKW5ld8ARMe2zLdxHbKeEOVJXrE1U7vJRkdelp5uuED+jiTkyGeFw
1v/6+lLcZzrd3Ekp9uE+sZVkvQ9XSVTkj9QE0VjFWa89NV/1U9TOhFrTx7m++tAf8fojteeI1/cr
h9yhuJAUqjZz9uXZWrY6/OYRQI6sFUc2A3Ctometoo6zcNn+QQCuDUAgRxDIEQRyBLH+QJ8V72uW
8tuRI5t4eF3Jq8jiXINAfwSBHEEgRxDIEcQ9z5FVFCJo69+EewyNIFd183wgmQaIjtDfYngjW+pM
RShX9if8rkwJGOXL/KR4E6y0/FM5Ne05Sjdsijd3Ja9i0eFFuspxxPz0hbLnywugVoQePkrs15fO
twwNVnY/jju1nWs048u/c/rUDItNJtkEJRWgPSj2O8ops0ngAqigEOdZWR4tJMqaI7uy0sIiFVkl
ZDF4hV/oiiip7UxyZZ3j+aNchtl1XYCUKAbbHZkVawmzZ8qS0wS/Ld4G1ibHVlygtQjXu5AMNeVI
d0YVnD6NiEYgAtAmN88DzF42ehzlVCRgivRBbm4sdpBl5XkUyZCZoIrJrqy0pPFvCsBRzZCftng4
nkwbTHJFz+2w81tVGyJAa5PRNEusJA3pNd6SJFt5q0jN++18flssZewSF4FRW88QtjQbl+8CiBkk
Q005Yqhw3hE8ZIbhdobKpCbTTNh0xFFOPX8bhl8Cqpzq5copnifoCKqY7IqlyVxIdVEG3Squq/J+
Lrmi51yZljU3fAEg/FX8Cy7r0n7K7ZG956kGa/Kinc9vi+KO2vs826G2DtC1lfHdpPlfLCAZSro1
Vay50raSd25gXC3QR5H3pyPbm4mVE0BBnqDK1WbFTdB2vHjGEV55hVkemRbLL9A5pc3s/a/JPA3W
9UyBBssn3nLbZNkitTQ0T9aNBqteblqzyso6o1uIxWJit3U04Ei0CFpzF//ByXddy7sD5XlockN+
GpdPbdvyi7sF5q77ZFrWyyelhLnx12a9si6aMWPX6DbB796bdpssW6QWmdSiNeCAUUuqTVG9knDU
OnqlG3YFAQLdHeR/dnL3684bn+6GLu8tpZWHirmEvLQ0F18tCkOFn0SnXWEWHVGYoi5wi8wjKVVa
9Eq9pAQTeAW62vvsfH5bFC1wS+J3d9xWMK4myDxzCz8BrylHXhom/4bftK7HExnBnAJIzt8l7890
c+ffk7RTnWy8yoiGbyDhee5ExPSdvDS9VaLiq/Dsq4WyGd0VZlEiMNdG/BygWREPXmWyrt/lsq6R
bjFNmpb83t1zdr47Eclji2Lm+FNTbMey1fSuSDWdn6NOr6b+SB1A+6MLQi3rM3/vnfrQYNWhP7Jh
9TVKbR2IXMQ74CFHvBzZsLOwXlsfs8HvXC9uCo7U6FWgp1Z0kMIuqNFwhECOIBDIEQRyBIE+66rd
NGEXoAZrPYfX3IboAYyDhUB/BIEcQSBHEMgRBHJkHaAtcYyoBUdo1IlgB1tb6g8TFS0Ri+psU5HE
lFjVzV2J+FRlM/v2tuXl2basOFjhs8iFisaRWGxc5stJC9RLRWNRHSuW2tq0kk/tq1du9RQeL0OD
9eUxHHcqnGtUfdEZORQemYoKmngCl1KZYamNX4Vd4iMQTTEBlB3NSglGH/sWjUxlRa2iUqqgFTWr
Qxap2sqql0uvrHIUHSFWxslnRbkiiLOIWK59R03F93gdVHFlRcQiFZx142DlycBK2FFFjINVqT/i
iQHBZUvvyglbeZIbm6FRsYTECX5sfE3+nRmnca32Jnk0Kxij2qftUib4Njm4kAD423E9nUkk2wD+
MGyE55x635JH5z3lAH77f6HtbMfKNxsyNP48+DssIpZtPyCO8/WoELk4TrW/vA5q993pzCSNfvbr
1mOODOy8yeNusbJl7HyNMY4q4ghxSL51yjkaYbKl94ZU6y2xglBlbqsPW9fxZ3RIV4eprEoAmQrd
htklvm8Yhi6Q7YPk6GFV3r9HlUlNb07awbXo5sJwp6ccQVad3Md2rHyCyeJTgRuVi9sP8qhcBJkH
1VHw1vFnZO+QHXGLI70HaPvACdxVys5nyJFS8K5npfKkjpmMR71E/tzQVv6oWADOHpU0Qb5MKi9i
Fos7ZS72xIpKr8ArzLLyDT6xALNsXbO2MykfKG3fte2JolU2DlZRO5JHzKnj5zVl4mBN5L+CLfk6
KnAScppz5JdJFQqfmDObm/TcB/mkVxTtdhkr3yPzidAP+B1KQ+RaMfvAI2m5dVgRsQbyNFj+l1TC
jpbDAaNCf0RpzL+V7YIdvgQaFWuA7QlUqbcDuiQmk/J4MqcKhE9skJ9MeS7VQFeiz1cuBQ+kvflo
hK2fc8fov31RuW7aDSJ7NN2qg7DhFN8Tb1JVlyUD+xy6gv4XVNyOjPqaCv0RMf1xXoYbhnTOlzBl
imf4HlPqNYrGFJNQpdxBoiBqFcN08/c81j5K7fjUVy7UN3/Dmy/8nDA3zZ9dHN3qjcp1WHrD2ntW
oowmdczPENJthZ42cf5jGnFrRmfHlAh9rH0elLDzI1wlUYk/UjEUg31Pg3b/mBqNbY5+MJvH1kqD
teH8keVzpMnMBcIT/EY5M1dp1Kt6R9OE9zu/kCMYB2sp4FpFjINVcf8gANcGIJAjCOQIAjmCWH+g
z4r3NUv57cgRHF6LYhE7A4EXDAI5gkCOIJAjCORIHrSqTi23iOY9hVqIWqGaz30rXjPiZrRUEMXA
lrwvr7ag7wvGFXPWTbcMkbyk3mINtdLyTzWJm/D7WVd076usdWf0lD61f/m1HfANHm5ErAOOoRir
dxkaLD2F406N55poW79IrljzuHQNHMmV0i+pcZYeTUky73PtDTGscYFUmOUCNz+th/0kZKrRmgr3
M7nUFak/FQ/2sxQxzBcamuF+yut2WbKibHUcZwIq4BGxnHRWX1u/VS+Pg8XlYKxdrKogrTNKK+un
8rKUKB6PgzCPcbBq7Y8snpymEap+0XwCYHswI1FZk3YymX6apUMw8RYfq5QeY1JhgiglmfnZDpZm
57cu6BickFraAFThDIua9VyiR31mrIdUcyJpSFzvFRBPUiXY7IeZHh4K6+6vjDCfYoz3PelMedVw
0qqX2vqZwWzx9rKqxi7tZDt7tTNhMs+1ho2HnwToMJAMNeYI10PxiFPmEAxT8YIbuQqy6mG+9i/4
CMh8TxbgCH8f7PwOTt+eyAC8dBuGadSQKfVIz4h6hFTzUyfC1UvDTG5Fo2xxKVV6EjQrttZubzrF
sGdlqnmY2xp1NFg31F6+PP8il3aJfx0/TPybL7JIhtr6rH4hVYHkim6EPFlUMbmVRygF+XIptzA4
ciuzI5vlaiyzw3w840bEctJ9bSsVB4snDD65kLXiYI128nrQZ629z1osrpV146nxmq/7glSZ4M9v
+YkDTjXf99XS7RS2hFctuQkrLm9rbvKCNRJq3vQiLcxrWwdoL7Kdbzd8YMXBep9MPhrSYnWej/CI
U8J56MqTXO2Abh5sKj3IZFEDpiealZV/QNV2cIKIXR0Sj5p12ldLiwlKH9uTdjHh1cJkikXZMiF7
ORWx2iB70wcG7cKceIVtmwO5he0sCEFahRVN6zx+Ar46HEmmaMSpOz8QM/5YU3BOyozygeoJkQqk
hCY70hU4+ZvmOun7It4Hevr3r7CoWabfKTjRJqT/g+1NZSWa9yqPskVqm36805KGUUWYmy46bgmp
l9vKi4M1HWz/C7YTnu2lEi4rmtaLqNOrpT9Sw6dsNUBtImKtoQZrw/kjq8MRaS0DKqtTNQh3lFO9
a8+QI16OrM4svKYxt2sSNK3BvzxxERCu14ldUASowaqdz4pAjiAQyBEEcgSBPuvqADVYqMGq8fC6
GQfjLM41CPRHEMgRBHIEgRxBIEdKQVuDEisrh8hHzdcGmK0LueCUs6IjfyWJnFru4pJgungJZYnP
e0uUK6XBWsn3s27Ke99V1GC1SIlxiJQ83bPsUFcHSgThSmerKmch/9QdBcedNbsEFodVdSbtjXBl
Racy+5zoVH0mObLT6UXdFnQiaZ0VQ3ShuxNJy9JSkSw8KlfQCsJ1XhCqKgemzPIDtAclrsES+uKg
Hsc4WGvGEWGnYoIBsPcjY2ovS9k+nblE3ovAD53oVNe/Ad/4xE6nSIw5+V8ev0BGIUXKBKl06r2E
paWyomcp0pi1/Oe4WF05iHwV4u2avZxJklNtH5jnngQ4jPqaNePInQUjLLd7xVdZAXrJnuRGp3rf
AFOw0ylSqpNfV/dkSJlhGKJCiz3OItNRFj1Lvm1H5TK/qK4cTKmTPFhJuheoLqvxIIuDtRt1emvm
s9LJZaeRKhudSuvMUI8SbIUVU0g5+eGpS8VlWm5ULuCSqWrKufIws+PHr/bEQPvm47HWiRXFwUKf
dXmQNFCnFwj5ykSnUoW2gFeexchq5R8E7SMuneotRmkNLDndFq26clSDxeM4tSy2UC2HOv/L02Q7
iHGw1uwSSO8ytVbiK1xxIlwJXHzljU4l7plw0i3Y+Q/BTYmck6H7U35iwCsNTndBhMdgDdyqrhzM
wwNcSrMwdZjef8mq+jzhx0Oor1kzjuh609asziNccclVrFU8xqNTXSZvIotO9fX1lJNul7PyNwrP
jpJzETFl3Z4K3mDkNzLSOd5ksa+6chDqS42ynavNnTTpw31iK8l6H66SWEt/ZCVY+gGbmmZffKTd
/1WkmnKlfKhXT1avwdrk/ki9cWSJuFo5qaFxmj/EVY3ZqsoVR/jNI4Ac2RgcqQ/gWkWMg1Vx/yAA
1wYgkCMI5AgCOYJYf6DPivc1S/ntyJGKhtdVHG4Xyp5tq4PLBOcaBPojCOQIAjmCQI4gkCPrCJRD
IEdKQZVFFg/rL/ly1wJEfRvEPciR9t/50NCe6QD4Tfl8MXz771mOpG/2gvyfv+UiLCUoxGkcLZHF
2GrlC2jNIDsCSMhi8ApAXBCD7UiGe4gj5jD5d1vigq+FsdhBgEjSkF4jqY1fsRzK2CW+0PGoZshP
E7Y0G5fvIhlKYDM+i3+UrkxVeWwUGFXpWteMFVFriC9avaNC/xm6c1EGnclv4rszSIZ7aBxhMWxs
vQwnxaPRaDTnHNHNP/I7n5ZXqGgvmTvYiXPNvcQR8bvk33d848KAT+8Fpn1bvG3LL6xYWPIskuEe
4kgwlYJ4esArw3rFBCXs5miBW3wqWhSG6GwbjKu/XkAylEAjyJvuNc3fVbf8UnubvPWBhZ0jAOTv
47YjN8PzdI9i52/+dOhyIz2abZwY6RyBtgb1f695pBXp/K+/aVi91pbXkAbX7eZQ9nQGrgEvhI7r
R/Q1jyWPwHvfzYbFJY7X7nJGjtQpcP7d7Pc1COQIAjmCQI4g8L5m4wM1WKjB2jjD67o9vMvhXINA
fwSBHEEgRxDIEQRyBIEcWWNEKYqeKC6lMkOS2GIuXa/6hrXzxlnkwkYfR2IEpU4VSWsuH43Lhjb3
grX3wp+g8HNzzDVRa+Ro7RO5sEq1EpS8aFc5OxpXSJQHveXADEqqE6Vr18sqqBIVfqoCxsHaZP7I
O1ffBohcHLeDVy2waFfvOtGuTu28xqNxBY3gXrdY4zvwltyyj6QnjalDhGWHAeZChqwAfI1xsDY6
R/zuyIjaOwSQeVAdtRJ4tKv3nGhXLyz0hftoNK4hGPYsGx5S4c+HJy6SdAHkDOHIboCAqQ6REecz
jINVChtkzbMn4qob3IpGrioR7QrsaFxO1CtPNnCiZ9EC2rZFmBX8UQl0/Lwmt4HXPGu+/UF/h2r2
aTsa1yckZYuvHA+y9IkVPYscqKlEqAm/q2TT+CPXU5pn2JNuwiHf6dQu2MmjXUk0GhcZHFK3oCvt
K3eqK0EmnxSPniXKNCq1StUzMsbB2hwcSbZu/bl7NPWs1Og7fcOQGvgLGqXRuJIA2e9Khu4r15Pa
EWLRs+ZniC9yH0D4OWGO5PwRrpLY4P5IxSgf7apg4uqctdR5ZvNY9XGwNrk/sqk40pJu2DIjLKfE
2ZctKXjThFfTihzZtBypGXCtIsbBqrh/EICf+yKQIwjkCAI5gkCOIJAjCOQIAjmCQCBHikFf5/L1
VQFyBIHjCAI5glht4Oe+qzKbbwLg576VdlCVHFvphVcHFeBcg0B/BIEcQaDPiqgfBx591pIum8I2
SuX+n1OGbZdV1PUTlepsu36mUnEL+Cm31aWMIkdKdh/5Y78VU8TuXcU6qryo73aqGttucR0qbYGe
90pLGkV/pNb3y9XfdepKzchdU2s4jtT8ndOrpoue/2Bm+baVilugVPyCkSNlhwad/uoV+/X2VEO2
yy0KTskqbRfUU1ULipVBjiw9wyvLup6VqosqK7a90hYUL4P+SA2nGn2FM8XKpzll5R5OYRnkSK3p
VP3ngbX6JLHWn0jiM7Ty7qNuP2dY1tOJ5RYteMBSbQXKchpf7PlIkTKoCUcsSTycaxBLATmCQI4g
kCMI5AgCOYKodwTy7u8RCAtKEY7gkxIEFBsycK5BoD+CQI4gkCMI5AhiA937lrkLrtc7HmzounEk
f3RZ3CjNr9+YeA3+wxzONQj0RxDIkYqm1BJnC/Lpupu6Fs/79aKW9PprvNPQUvbrpFNrpZ1YSlVa
167aejdeqe9OXf5co+sW8x0m6+zHOuO9QnhOPY/5VjY39+oNKLYlb9PtjV4/jecVg6+xddSpyx5H
iglKdcV/xntsK4wdYY9fhLy6JFHc30LLbsPqoPG0Up+lOurUKucaRbd+8gY7pWAgLBgQlbUbJJWi
hhT/dh0br+f1aWFr6qJTa6jlVDzfv7F0zyj62nsnZXy8dWl8BZqteujUQG0vW8r2JRSmuudLVNaY
JIqvARuj8XXQri1VDxoK5H2ZSaU3xx5vd3V6VS8YmvUlbozrovH6Sp44rGanBpb5GpTSw5l7hpPH
n1PRnZP8zOrNNXlVey3TPasB9dX4oo2qk071aDndSy9fvbdYtx+V5X9eU7cNzf+8Rlnqocf6N1kp
0cmI9XpHoH4/C0aO1Afqea1AcY4sbpSuzW6UhuY2MH8DG43U2NA1B64NQCBHEMgRBHIEgRxBIEcQ
Gx3ee1/8cgnEEhzBr5ZA4FyDQI4gkCMI5AgCOYJAjiCQIwgEAlEE/w98Fzrs+DXAHAAAAABJRU5E
rkJggg==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-12-12 18:14:14 -0500" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2016-12-12 18:14:14 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-12-12 18:14:14 -0500" MODIFIED_BY="[Empty name]">Search strategy 2016</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-19 11:08:39 -0500" MODIFIED_BY="[Empty name]">
<P>(Nitric OR Nitrix Oxide) with database specific terms:</P>
<P>PubMed: ((infant, newborn[MeSH] OR newborn OR neonate OR neonatal OR premature OR low birth weight OR VLBW OR LBW or infan* or neonat*) AND (randomized controlled trial [pt] OR controlled clinical trial [pt] OR Clinical Trial[ptyp] OR randomized [tiab] OR placebo [tiab] OR clinical trials as topic [mesh: noexp] OR randomly [tiab] OR trial [ti]) NOT (animals [mh] NOT humans [mh]))<BR/>
<BR/>Embase: (infant, newborn or newborn or neonate or neonatal or premature or very low birth weight or low birth weight or VLBW or LBW or Newborn or infan* or neonat*) AND (human not animal) AND (randomized controlled trial or controlled clinical trial or randomized or placebo or clinical trials as topic or randomly or trial or clinical trial)<BR/>
<BR/>CINAHL: (infant, newborn OR newborn OR neonate OR neonatal OR premature OR low birth weight OR VLBW OR LBW or Newborn or infan* or neonat*) AND (randomized controlled trial OR controlled clinical trial OR randomized OR placebo OR clinical trials as topic OR randomly OR trial OR PT clinical trial)<BR/>
<BR/>Cochrane Library: (infant or newborn or neonate or neonatal or premature or very low birth weight or low birth weight or VLBW or LBW)</P>
<P>Clinicaltrials.gov: (infant)</P>
<P>Controlled-trials.com: (infant)</P>
<P>WHO Trials database: (infant OR neonate)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;16 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;17 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="125">
<FLOWCHARTBOX TEXT="&lt;p&gt;14 studies included in previous version of review&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;3 NEW studies included&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;652 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;652 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;588 records identified through database searching (2008-2016)&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;64 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;649 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;0 full-text articles excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>